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Acetaminophen-induced liver injury (AILI) is the leading cause of acute liver 
failure (ALF) in Western Europe and USA. In ALF patients the intrinsic 
regenerative capacity of the liver is overwhelmed by massive hepatocellular 
death. Current treatment for AILI is limited to N-Acetylcysteine (NAC), the 
therapeutic potential of NAC decreases dramatically during the later stages of 
AILI and liver transplantation becomes the sole option. More potent therapies 
which promote liver regeneration which negates the need for transplantation 
is urgently required. Previous studies in both humans and animal models have 
highlighted monocytes and macrophages are key regulators of liver 
regeneration following AILI, due to their dynamic nature during AILI their 
therapeutic manipulation has proven to be challenging. In this thesis, using a 
murine model of AILI, I show specific hepatic leucocytes populated the liver at 
distinct phases of AILI, at the time of maximal liver regeneration macrophages 
represented the most dominant subset in the liver. Phenotypic characterisation 
of the three distinct macrophages populations: Kupffer cells (KCs), Ly6CHi 
monocytes and Ly6CLo monocyte derived macrophages (MDMs) indicated 
injury induced heterogeneity, particularly in the Ly6CLo MDMs.  
 
Droplet-based single cell RNA sequencing (scRNA-seq) was employed to 
interrogate monocyte and macrophage heterogeneity during liver 
regeneration, in an unbiased manner. Unsupervised clustering of mononuclear 
phagocytes from uninjured and post-AILI livers generated four distinct injury 
specific monocyte/MDM clusters. Gene ontology enrichment analysis 
indicated distinct functional roles for each cluster. Using newly identified 
marker genes, the heterogeneity within the Ly6CLo MDMs was validated in wild 
type and macrophage reporter mice. During maximal liver regeneration two 
distinct Ly6CLo MDMs populated the liver, they were defined as: CD63+ 
MHCII- and CD63- MHCII- MDMs. Identification of CD63+ MHCII- and CD63- 
MHCII- MDMs in the liver following CCl4 but not partial hepatectomy suggested 
it is an inflammation-induced phenotype. Experiments in CCR2 deficient mice 
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indicated both macrophage subsets are a progeny of bone-marrow derived 
circulating monocytes. Localization of CD63+ macrophages to areas of 
resolving liver necrosis, adjacent to proliferating hepatocytes and their 
increased phagocytic capacity suggested a pro-repair role for CD63+ MHCII- 
MDMs.  
 
Additionally, scRNA-seq of circulating monocytes indicated AILI resulted in 
transcriptional pre-programming of circulating monocytes into an inflammatory 
phenotype, prior to their entry into the liver. These results support the notion 
that both circulating and hepatic monocytes and macrophages are highly 
dynamic and utilization of scRNA-seq in combination with traditional 
techniques such as flow cytometry and immunohistochemistry has facilitated 
the delineation of macrophage heterogeneity during liver regeneration. Further 
studies in mouse models and in humans are required to investigate the 





The liver has an exceptional capacity to regenerate after various different 
injuries such as alcohol, drugs, and viruses. However, following overwhelming 
injury the regenerative capacity of the liver is diminished resulting in liver failure 
and if left untreated this can cause death. This is often seen in the case of 
acetaminophen (APAP) poisoning. APAP is an over the counter drug, 
commonly taken as a pain killer and in western countries like the UK, APAP 
poisoning is the commonest cause of acute (sudden and unexpected) liver 
failure. Past research in the field has shown macrophages can promote both 
liver regeneration and liver failure after APAP poisoning. However, we have 
not been able to identify which specific type of macrophage can help the liver 
regenerate and which type contribute to liver failure. This is because 
macrophages are like chameleons, their appearance (phenotype) and function 
are influenced by their environment. The aim of my research is to pinpoint the 
macrophage subset that drive live regeneration and understand the 
mechanism behind this process in order to manipulate these cells as a 
treatment for patients suffering from APAP poisoning.  
 
By the time patients are admitted to the hospital from APAP poisoning, their 
liver has already began shutting down and the high degree of cell death makes 
it difficult to study macrophages in humans. For this reason, I used a mouse 
model, where I controlled the timing and dose of APAP and took out 
macrophages from the liver when there is less death and more repair to study 
their genetic-make up. Genes make proteins and proteins defines what a 
macrophage looks like, where they go, and what they do. To do this, I used a 
method called single cell RNA sequencing (scRNA-seq), this allowed me to 
study the hundreds and thousands of genes a single macrophage is 
expressing and then do this for thousands of macrophages. By doing this I was 
able to find a specific type of macrophage, that populated the liver at the time 
of repair, with the ability to eat dead cells. Using genetically modified mice, 
with fluorescent macrophages, I saw that these macrophages were infiltrating 
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the liver from the blood stream, to localise specifically to the areas of death, 
neighbouring regenerating liver cells.  
 
To summarise, a specific type of macrophage involved in clearing up dead 
cells was found in the liver at the time of repair. Future studies are needed to 
see how important these cells are and whether they help the liver repair by 
clearing up dead liver cells, paving the way for new liver cells to grow. These 
findings will allow us to develop macrophage-based cell treatments for patients 
suffering from liver failure.  
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1.1 Liver disease - a global clinical burden  
 
Worldwide, liver disease accounts for approximately two million deaths a year 
(Asrani et al., 2019). While we have made massive strides in lowering mortality 
from many life-threatening conditions, mortality associated with liver diseases 
has continued to rise inexorably since the 1970s (Figure 1.1) (Williams and 
Horton, 2013). In the UK, liver disease is estimated to overtake ischemic heart 
disease as the leading cause of years of working life lost (Williams et al., 2018). 
 
Acute liver failure (ALF) is a clinical syndrome initiated via hepatocyte death 
overwhelming the regenerative capacity of liver, leading to the rapid 
development of hepatic encephalopathy, coagulopathy and jaundice, and 
culminating in multi-organ failure and death (Bernal and Wendon, 2013). In 
contrast to chronic liver disease, where damage culminates overtime to cause 
liver failure, acute liver failure (ALF) is characterized by rapid deterioration of 
hepatic function, without any pre-existing liver disease. Though not as major a 
global concern as chronic liver disease, the mortality and morbidity rates 
associated with ALF are significant. The aetiologies of ALF vary 
demographically, with viral infections the predominant cause in developing 
countries (Figure 1.2): hepatitis A and E, typically transmitted by ingestion of 
contaminated food or water, and hepatitis B transmitted through infected bodily 
fluids (Bernal, Lee, et al., 2015). The most common cause of ALF in the 
developed world is drug-induced liver injury, primarily via acetaminophen 
(APAP) overdose (Figure 1.2). APAP-induced liver injury (AILI) accounts for 
60% of ALF cases in the UK and 50% of the cases in USA (Bernal and 
Wendon, 2013; Bernal, Lee, et al., 2015). Rarer cases of ALF may be caused 
by idiosyncratic drug reaction, hepatic ischemic insults, autoimmune hepatitis, 
hypoxia-induced liver injury, acute Budd-Chiari syndrome, or Wilson disease 
(Bernal and Wendon, 2013). Additionally, liver failure may also be caused by 
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acute-on-chronic liver failure (ACLF), where ALF occurs in patients with 
underlying liver disease or undiagnosed cirrhosis. The mortality rates 
associated with ACLF are higher than those seen with chronic liver disease 
(Bernal, Jalan, et al., 2015; Sarin and Choudhury, 2016)  
 
Implementation of vaccination policies and improved sanitation have reduced 
the incidence of viral-induced ALF in developed countries, whereas the 
incidence of drug-induced ALF, particularly from APAP overdose, has 
increased (Bernal, Lee, et al., 2015). This can be attributed to ease of 
accessibility: APAP is readily purchased over the counter. Many cases occur 
after intentional ingestion of large doses from suicide attempts; accidental 
overdose from “therapeutic misadventure” is also common, when APAP is not 
taken as directed (Zimmerman and Maddrey, 1995). Regardless of the nature 
of liver injury (acute, chronic or acute-on-chronic) the regenerative capacity of 
the liver is severely compromised, and if left untreated this may result in death. 
The only current therapeutic remedy for AILI is N-acetylcysteine (NAC) 
administration, which has the potential to reduced hepatotoxicity by 30% (El-
Serafi et al., 2018), but as NAC targets the initial stages of AILI it is most 
effective when given within 8-10 hours after APAP overdose. Unfortunately, 
many patients are late-presenting; in these instances, there are no alternative 
strategies available to prevent APAP-induced ALF (Nelson and Kowdley, 
2010; Hu et al., 2015). 
 
Curative treatment for end-stage liver disease and liver failure are limited to 
liver transplantation. Ever-increasing demand for donor livers outweighs the 
availability of donor-matched organs; coupled with life-long dependency on 
immunosuppression medications, this is far from ideal (Asrani et al., 2019). 
This has put an emphasis on the development of potent therapies that promote 








Figure 1.1 Standardised UK under-65 mortality rates (1970-2010). Reprinted from 












Figure 1.2 Worldwide aetiologies of Acute Liver Failure (ALF). (HAV) Hepatitis 
A Virus, (HEV) Hepatitis E Virus, (HBV) Hepatitis B Virus and (NT) not tested.  




1.2 Liver architecture 
 
The liver is the largest internal organ in the body, responsible for a myriad of 
functions including metabolic homeostasis of carbohydrates, lipids and 
proteins, storage of nutrients, bile secretion, metabolism and detoxification of 
harmful toxins and immunoregulation (Trefts, Gannon and Wasserman, 2017). 
It is segmented into two major lobes (right and left) and two minor lobes 
(caudate and quadrate). The lobes are further divided into hexagonal 
microscopic lobules, centred on branches of the hepatic vein (central vein) and 
bordered on the periphery by the “portal triad”, composed of branches of the 
hepatic artery, hepatic portal vein and bile duct (Stanger, 2015). 
 
The primary liver parenchymal cells are hepatocytes, responsible for executing 
liver function and contributing up to 80% of liver mass; the remaining 20% is 
contributed to by non-parenchymal cells (NPC). Hepatocytes are arranged as 
cords that radiate from central vein to lobule perimeter. Cords of hepatocytes 
are separated by small capillaries called sinusoids, and the space between 
hepatocytes and adjacent sinusoids is called the Space of Disse. The Space 
of Disse is characterized by extra cellular matrix (ECM) components and 
contains blood plasma and hepatic stellate cells (HSCs) (Stanger, 2015). 
HSCs are NPCs that have a role in vitamin A and fat storage during 
homeostasis; during liver pathogenesis they are activated and transform into 
ECM-secreting cells called myofibroblasts, which contribute to fibrosis (Trefts, 
Gannon and Wasserman, 2017). The remaining NPCs are located in the 
sinusoids and includes Liver Sinusoidal Endothelial Cells (LSECs) lining the 
insides of sinusoids, Kupffer cells (KCs) and  a wide spectrum of other immune 
cells such as Natural Killer (NK) Cells, Dendritic Cells (DCs) and T cells that 
circulate in the sinusoidal lumen (Gao, 2016).  
 
The liver lobule receives blood flow from two independent sources. The 
hepatic portal vein supplies the lobule with two-thirds of its blood flow, enriched 
with nutrients drained from the gastrointestinal tract and spleen. The remaining 
oxygenated blood flow comes from the hepatic artery (Jenne and Kubes, 
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2013). Arterial and venule blood disseminate through the liver via a meshwork 
of sinusoids before draining into the central vein and Inferior Vena Cava (IVC). 
Fenestrated LSECs facilitate efficient exchange of oxygen and nutrients 
between the sinusoids and hepatocytes. 
 
The biliary network transports bile produced primarily by hepatocytes, to the 
bile canaliculi and then to bile ductules within the portal triad via the canals of 
Hering, for storage in the gall bladder before draining into the duodenum. Bile 
ducts are lined with liver parenchymal cells called cholangiocytes, which are 
epithelial cells that modulate bile secretion (Bloomston and Misih, 2010). 
 
The liver lobule represents the structural unit of the liver, but the functional unit 
of the liver is known as the hepatic acinus, visualized by the porto-central axis 
which runs from the portal triad to the central vein (Kietzmann, 2017). 
Hepatocyte distribution along the porto-central axis shows functional 
specialization, a phenomenon known as metabolic zonation (Kietzmann, 
2017). Zone 1 contains hepatocytes closer to the portal ducts (periportal) 
specialized for functions such as gluconeogenesis, urea production and 
cholesterol synthesis; as they are surrounded by oxygen-rich blood, periportal 
hepatocytes are generally more resistant to damage (Kietzmann, 2017). 
Hepatocytes closer to the central vein (zone 3; pericentral), are responsible for 
glycolysis, lipogenesis, and cytochrome P-450-based drug detoxification. The 
intermediary zone (zone 2) contains hepatocytes that lie in between zone 1 
and 3 (Macaulay et al., 2016). Zonation has been shown to be dynamic, 
controlled by a combination of hemodynamic factors including oxygen 
gradient, reactive oxygen species and Wnt/β-catenin signaling. Metabolic 
zonation can influence liver injury patterns seen during liver pathologies 






1.3 Liver regeneration  
 
Mechanisms of cellular regeneration vary across tissues of the body. Epithelial 
tissues such as the intestine and the skin possess distinct stem cell pools, 
which contributes to high cellular turnover in these tissues during homeostasis. 
Conversely, tissues such as the heart and the brain show minimal turnover. 
Regeneration in the liver is context-dependent; in mammals during steady-
state there is minimal cellular turnover (roughly 1-2% of hepatocytes in cell 
cycle), and cells have an average life span of 200-300 days (MacDonald, 
1961). Following injury the liver exhibits a remarkable regenerative capacity, a 
potential evolutionary adaptation brought about by its anatomical location and 
function where it is frequently exposed to ingested toxins from the GI tract 
(Stanger, 2015). This regenerative capacity is not limited to toxin-induced 
injuries, for example following the removal of tissue the liver can fully 
regenerate to its original mass in the span of a week in rodents and within 60 
days in humans (Nagasue et al., 1987; Michalopoulos, 2017). When the 
proliferative ability of mature hepatocytes is blocked (senescence), either 
experimentally or during chronic liver diseases, hepatic progenitor cells 
(HPCs) located in the canals of Hering have been shown to give rise to 
hepatocytes and ductular cells (Lu et al., 2015; Stanger, 2015). However the 
most common mechanism of liver regeneration, and the focus of this body of 
work, is proliferation of fully-differentiated hepatocytes (Stanger, 2015). Liver 
regeneration is a complex process, and injury initiation to cellular regeneration 
encompasses a multitude of events including involvement from different cell 
types, growth factors and cytokines. We rely on animal models to study this 
phenomenon in vivo.  
 
1.4 Models of acute liver injury and regeneration 
 
Pre-clinical rodent models represent an ideal system to study the cellular and 
molecular mechanisms at play during liver injury, regeneration and 
progression of liver failure. Reliable and highly reproducible models of liver 
regeneration have been developed, where liver injury can be induced in a 
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timely manner via chemical or surgical methods (Forbes and Newsome, 2016). 
Recent advancements in transgenic technology, such as the development of 
fluorescent reporter mice, has allowed the interrogation of specific cells, 
molecules or pathways involved in liver injury and regeneration (Greenhalgh, 
Conroy and Henderson, 2015).  
 
1.4.1 Partial hepatectomy (PHx) 
 
One of the most widely used and well-described models of liver regeneration 
is partial hepatectomy (PHx), whereby two-thirds or 70% of the liver is 
surgically resected (Mitchell and Willenbring, 2008) (Figure 1.3a). PHx was 
developed by Higgins and Anderson in 1931 and has become a standardized 
procedure in rodents for the study of liver regeneration, popular for two main 
reasons. First, the process of liver regeneration post-PHx is mediated by 
crosstalk between the hepatic parenchymal and non-parenchymal cells with 
minimal involvement from any necrotic or acute inflammatory processes 
(Figure 1.3b). Second, the multilobular structure of the rodent liver makes a 
“clean” removal feasible, with regeneration initiated immediately after the 
resection and completed approximately within 7-10 days in mice. Liver 
regeneration following PHx is achieved through compensatory hyperplasia, in 
which remnant lobes enlarge through parenchymal and NPC proliferation until 
the original mass of the liver is reached (Figure 1.3). 
 
The series of events which are involved in this process can be broadly 
categorized into three distinct phases: (1) initiation or priming of hepatocytes, 
(2) proliferation of hepatocytes, (3) termination of hepatocyte proliferation. 
Initiation events involve rapid upregulation of more than 100 genes, promoting 
production of growth factors and mitogenic signalling pathways required for 
hepatocytes to switch from their homeostatic, quiescent state to a proliferative 
state (Michalopoulos, 2007). The proliferation phase consists of both 
parenchymal (hepatocytes and cholangiocytes) and NPC proliferation, where 
the former precedes the latter (Taub, 2004). In mice, four continuous waves of 
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hepatocyte replication are required to restore lost hepatocytes and 
reconstitute liver mass. Hepatocyte proliferation starts in the periportal areas 
of the liver and proceeds to the pericentral areas, peaking 36-48h post-
PHx  (Zou et al., 2012). Paracrine signalling between hepatocytes and NPCs 
is crucial in orchestrating liver regeneration following PHx (Taub, 2004); during 
the early stages of liver regeneration, NPCs secrete many growth factors 
needed for hepatocyte priming and proliferation. NPCs then proliferate during 
the later stages of regeneration, around 48-72hrs post-PHx, when additional 
growth factors such as vascular endothelial growth factor (VEGF) are required 
to promote endothelial proliferation and vascular sprouting, so as to establish 
normal liver architecture (Michalopoulos, 2017).  
 
To avoid carcinogenesis, hepatocyte proliferation needs to be terminated once 
the liver has re-gained structural and functional capacity. A small wave of 
hepatocyte apoptosis is seen at the end of DNA synthesis, highlighting the 
intrinsic capacity in the liver, termed as the “hepatostat”, to sense and prevent 
over-shooting of the regenerative response (Sakamoto et al., 1999). As in the 
initiation phase, termination of liver regeneration following PHx is mediated by 
numerous factors, but these are not well-characterized. Nevertheless, key 
factors and signalling pathways have been highlighted, such as transforming 
growth factor β (TGF-β). TGF-β signalling can significantly suppress liver 
regeneration following PHx by inhibiting cell cycle genes in hepatocytes, 
promoting apoptosis of hepatocytes and inactivating hepatocyte mitogens 
(Michalopoulos, 2007, 2017) 
 
Studying liver regeneration in the context of PHx has highlighted the major 
growth factors, signalling pathways and molecules necessary for liver growth. 
Importantly, PHx does not reflect hepatic and extrahepatic manifestations such 
as necrosis, inflammation and fibrosis evident in human acute liver injury, 
where liver regeneration may be compromised. To address this, liver injury 




Figure 1.3 Liver regeneration following partial hepatectomy (PHx). (a) 70% 
PHx model of regeneration is established via removal of median (M) and left lateral 
(LL) lobes, the remnant right lateral (RL) and caudate (C) lobes enlarge via 
compensatory hyperplasia, until the original liver mass is reached. Reprinted from 
Goss, (1992). (b) Tissue injury activates hepatic NPCs (Kupffer cells, stellate cells) 
via upregulation of lipopolysaccharides (LPS). NPCs release pro-mitogenic factors: 
interleukin-6 (IL-6), tumour necrosis factor a (TNF-a), hepatocyte growth factor 
(HGF), and various factors from other cells and tissues are also released: epidermal 
growth factor (EGF), insulin, norepinephrine, triodothronine (T3). The released 
factors stimulate hepatocyte proliferation by promoting cell cycle entry (G0àG1), 
once the original mass is reached hepatocyte proliferation halts via transforming 
growth factor b (TGFb) mediated signalling, restoring a quiescent state in 







1.4.2 Hepatotoxins to model liver regeneration and failure 
 
Researchers have relied on hepatotoxins for experimental models of ALF, 
each with individual advantages and disadvantages. A wide range of 
hepatotoxins such as thioacetamide, galactosamine and carbon tetrachloride 
(CCl4) have been used to induce massive hepatocyte death, either directly or 
indirectly. However, the murine model of acetaminophen-induced liver injury 
(AILI) represents the most widely used system to study liver regeneration in 
the context of acute liver injury.  
 
Administrating a single dose of APAP can initiate hepatocyte necrosis and 
elevation in liver enzyme levels (AST, aspartate aminotransferase; ALT, 
alanine aminotransferase) similar to that seen in humans. Moderate doses of 
APAP (200-400mg/kg) can be administered to recapitulate a regenerative 
response, whereas severe doses of APAP (600mg/kg and above) can inhibit 
liver regeneration and can be used to model ALF (Bhushan et al., 2014). One 
main disadvantage of the AILI model is lack of reproducibility, as injury extent 
and temporal dynamics of cellular and molecular events can vary between 
mice. Some of this variation has been attributed to factors such as genetic 
background, sex and age of the mice, fasting period, and routes of 
administration and dose of APAP (Mossanen and Tacke, 2015). Mice bred on 
different genetic backgrounds show differences in the extent of liver injury; for 
example, C57BL/6 mice exhibit enhanced liver injury in comparison to BALB/c 
mice, and even within C57BL/6 mice sub-strains display differential 
susceptibility to APAP (Mossanen and Tacke, 2015; Duana et al., 2016). 
Female mice are more resistant to APAP hepatotoxicity, irrespective of their 
genetic background; therefore most studies use male mice (Mohar et al., 2014; 
Mossanen and Tacke, 2015). These factors must be controlled to identify 






1.4.3 Mechanisms of AILI 
 
In therapeutic doses, APAP is mainly metabolized through sulfation and 
glucuronidation. A small proportion is metabolized by cytochrome P450 
isoform 2E1 (CYP2E1), which leads to the formation of toxic metabolite N-
acetyl-p-benzoquinoneimine (NAPQI). NAPQI is quenched by endogenous 
glutathione, preventing hepatotoxicity (Yan et al., 2018). During APAP 
overdose, sulfation and glucuronidation pathways are saturated, and as a 
result the P450 cytochrome oxidase enzyme system is relied upon for APAP 
metabolism. Consequently, the rate of NAPQI production exceeds glutathione 
production, leading to glutathione depletion and accumulation of NAPQI in 
hepatocytes. Covalent binding of NAPQI to cellular and mitochondrial proteins 
results in mitochondrial dysfunction, oxidative stress, peroxynitrite formation 
and initiation of stress signalling pathways leading to hepatocyte necrosis. 
AILI-induced necrosis occurs primarily in pericentral hepatocytes (Zone 3) due 
to their high expression of CYP2E1 enzymes (Jaeschke, Xie and Mcgill, 2014). 
 
AILI is bi-phasic, where the primary stage is characterized by a series of necro-
inflammatory events (Figure 1.5). Dying hepatocytes release damage 
associated molecular patterns (DAMPs) such as high-mobility group box 1 
(HMGB1) and heat shock protein-70. DAMPs activate NPCs such as KCs via 
toll-like receptors (TLRs), which release various inflammatory cytokines and 
chemokines to recruit peripheral leucocytes (immune cells) into the liver. 
Additionally, release of proteolytic enzymes like calpains from necrotic 
hepatocytes creates a milieu that promotes further death and inflammation 
(Limaye et al., 2003).   
 
This primary stage is followed by a repair phase, in which hepatocytes close 
to necrotic zones proliferate and replace dead cells; additionally, proliferation 
in NPCs and other recruited cells is also seen (Figure 1.6) (Jaeschke, Xie and 
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Mcgill, 2014; Zigmond et al., 2014). The cellular and molecular mechanisms 
underpinning liver regeneration following AILI is wildly different to that in PHx, 
perhaps unsurprising considering the differences in mode of injury. In AILI, 
hepatocyte proliferation depends on other events such as attenuation of liver 
injury via resolution of inflammation and clearance of necrotic and apoptotic 
debris (Triantafyllou et al., 2017). Therefore, unlike in PHx, the term “liver 
regeneration” in the context of AILI extends beyond hepatocyte proliferation. 
Nevertheless, following efficient repair, liver architecture and function is 
restored in rodent models of AILI within 7 days. 
 
In circumstances where liver regeneration fails, AILI progresses to ALF. Of 
note, NAC (the current therapy for AILI) replenishes glutathione; while this 
prevents further hepatocyte damage from occurring, it has very little effect on 
pre-established hepatocyte necrosis and hepatic and systemic events that 
precede ALF. These events include heightened liver injury, systemic and 
hepatic inflammation and inhibition of hepatocyte proliferation, which 
accumulates to hepatic encephalopathy, multi-organ failure and death 
(Bernsmeier, Antoniades and Wendon, 2014).   
 
Mechanisms of CCl4 induced liver injury  
 
CCl4 is a solvent primarily used in generating an experimental model of liver 
fibrosis. Like APAP, CCl4 is metabolized in the liver by the cytochrome P450 
system, to form trichloromethyl peroxy free radicals. These free radicals react 
with nucleic acids, protein and lipids in hepatocytes, leading to lipid 
peroxidation, mitochondrial dysfunction, membrane dysfunction, all of which 
ultimately lead to hepatocyte death (Scholten et al., 2015). The subsequent 
events that follow hepatocyte death are analogous to those seen in AILI, 
whereby DAMPs released by dying hepatocytes, such as HMGBI, activate 
NPCs which initiate a hepatic and systemic inflammatory response resulting in 
the recruitment of immune cells into the liver (Dai et al., 2018). Repeated 
occurrence of these events can lead to fibrosis, which is established via 
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chronic iterative administration of CCl4 (Ramachandran et al., 2012; Scholten 
et al., 2015). Since most studies use CCl4 in the context of establishing fibrosis 
to reflect a chronic liver injury scenario, from herein this literature review will 
focus on AILI.  
 
1.5 Factors influencing liver regeneration  
 
1.5.1 Growth factors and cytokines  
 
Growth factors driving liver regeneration can either directly induce or indirectly 
promote hepatocyte proliferation. The primary hepatocyte mitogens are 
hepatocyte growth factor (HGF) and epidermal growth factor (EGF). HGF 
receptor cMET and EGF receptor EGFR on hepatocytes are activated within 
30 minutes to an hour post-PHx (Stolz et al., 1999); combined elimination of 
cMET and EGFR signalling completely abolishes liver regeneration, prevents 
restoration of liver mass and leads to liver decompensation (Paranjpe et al., 
2016). EGFR and cMET are activated following AILI within 15 minutes and 3 
hours respectively (Bhushan et al., 2014, 2017); abolishment of EGFR alone 
results in complete inhibition of compensatory hepatocyte proliferation, 
progression of liver injury and decreased survival in mice (Bhushan et al., 
2017).  
 
Cytokines such as interleukin(IL)-6, tumour necrosis factor α (TNFα) and IL-4 
have been identified to act as hepatocyte mitogens (Selzner et al., 2003). 
These cytokines do not have the ability to directly induce hepatocyte 
proliferation, like HGF and EGF, however they promote hepatocyte 
proliferation indirectly and their inhibition can impair regenerative response. IL-
6 and TNFa regulate liver regeneration following PHx by promoting hepatocyte 
entry from G0 into G1, via STAT3 and NF-kB signalling respectively 
(Michalopoulos, 2007). IL-6 deficient mice display increased necrosis and 
mortality rate following PHx, and IL-6 injections have been shown to rescue 
this phenotype (Cressman et al., 1996). TNF-α mediated NF-κB signalling 
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occurs mainly through TNF-receptor1 (TNFR1) on hepatocytes; TNFR1 
knockout (KO) mice exhibit a regenerative defect rescued by IL-6 injection. 
This suggests a redundancy in cytokine mediated signalling during liver 
regeneration (Yamada et al., 1997).  
 
Cytokines have also been shown to promote liver regeneration following AILI. 
TNF-R1 KO mice following AILI show extensive necrosis and decreased liver 
regeneration, with reduced expression of cell cycle genes like cyclin D and A 
and STAT3 signalling. However, it is unclear whether TNF-R1 KO mice are 
more susceptible to APAP, which could explain the increase in liver injury. 
Similar to PHx, IL-6 has also been heavily implicated in liver regeneration 
following AILI, with elevated serum levels. IL-6 KO mice show attenuated 
regenerative capacity, without differences in initial liver necrosis and serum 
ALT levels. IL-6 administration in these mice prior to APAP overdose was able 
to restore efficient regenerative response (James et al., 2003). While there is 
evidence to suggest IL-6 signalling is pro-mitogenic, IL-6 signalling alone does 
not promote liver regeneration. A study in which incremental doses of APAP 
was used to identify the key pathways active during AILI highlighted the IL-
6/STAT3 pathway to be significantly elevated in mice which received moderate 
doses (300mg/kg) and also which in mice which received severe doses 
(600mg/kg) of APAP (Bhushan et al., 2014). Similar to PHx there is crosstalk 
between IL-6/STAT3 and TNF-α/NF-κB pathways during AILI, which was 
highlighted in TNFR1 KO mice where inhibition of TNF-a signalling also 
resulted in delayed STAT 3 activation (Chiu et al., 2003). Bhushan et al. (2014) 
highlighted the NF-κB pathway to be downregulated in animals receiving 
severe doses of APAP (600mg/kg) where liver regeneration was inhibited, 
whereas in mice in which successful regeneration took place, the NF-κB 
pathway was active (Bhushan et al., 2014).  
 
Several signalling pathways observed during development are also 
upregulated during liver regeneration. Following PHx there is rapid induction 
of both Wnt/β-catenin and Notch pathways within 15mins-3hrs post-PHx 
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(Michalopoulos, 2007). Wnt/ β-catenin signaling promotes upregulation of key 
cell cycle genes such as Cyclin D1, involved in G1 to S phase transition during 
cell cycle. In the absence of β-catenin, hepatocyte proliferation following PHx 
is delayed but not abolished, again indicating redundancy during liver 
regeneration (Tan et al., 2006; Sekine et al., 2007). Inducible deletion of Notch-
1 in hepatocytes causes delayed hepatocyte proliferation following PHx; notch 
signalling is also important for endothelial regeneration (Wang et al., 2009). 
The Wnt/β-catenin pathway has been associated with promoting liver 
regeneration during AILI, with the downstream targets of β-catenin signalling 
(cyclin-D1) downregulated following administration of severe doses of APAP 
where liver regeneration was inhibited (Bhushan et al., 2014).  Studies in β-
catenin KO mice in the context of AILI have been challenging due to 
differences in APAP metabolism resulting in reduced liver injury. However, β-
catenin KO mice receiving equitoxic dose of APAP show deficient liver 
regeneration (Apte et al., 2009). In line with this, β-catenin activation correlated 
with increased levels of spontaneous liver regeneration in APAP-induced ALF 
patients (Apte et al., 2009). 
 
In a very recent study, Bird et al (2018) demonstrated that TGF-b-driven 
hepatocyte senescence (permanent cell cycle arrest) inhibits liver 
regeneration following AILI. Administration of TGFb receptor 1 inhibitor in mice 
receiving a lethal dose of APAP showed striking improvement in their clinical 
symptoms. Additionally, they also showed inhibition of hepatocyte senescence 
and increased hepatocyte proliferation in the peri-necrotic area (Bird et al., 
2018). This has highlighted the therapeutic potential of inhibiting TGF-b 
signalling for liver pathologies where regeneration is inhibited. However, 
considering the role that TGF-b signalling has in preventing tumorigenesis, this 







1.5.2 Inflammation and Immune dysfunction 
 
Sterile inflammation is a key feature of AILI, and a response required to combat 
overwhelming parenchymal death and initiate the repair process. Crucially, the 
resolution of inflammation is also key for successful liver repair. Persistent 
hepatic and systemic inflammation are features of many acute and chronic 
liver pathologies. There is strong evidence to suggest that mortality from ALF 
correlates with the presence of systemic inflammatory response syndrome 
(SIRS), a condition sharing striking similarities to sepsis, featuring systemic 
inflammation, immune dysfunction and extra-hepatic organ failure (Bernsmeier 
et al., 2015; Triantafyllou et al., 2018). Numerous targets have been identified 
to promote inflammation during AILI.  
 
AILI triggers local inflammation through the release of DAMPs from necrotic 
hepatocytes, which overrides hepatic tolerogenic mechanisms. DAMPs such 
as high mobility group box 1 (HMGB1), adenosine triphosphate (ATP), heat 
shock protein 70, mitochondrial DNA (mitDNA) are detected by KCs and other 
NPCs via various TLRs (2, 4, 9) and the receptor for advanced glycation end 
products (RAGE) recognition receptor, initiating pro-inflammatory signalling 
(Scaffidi, Misteli and Bianchi, 2002; Martin-Murphy, Holt and Ju, 2010). 
Genomic DNA (gDNA) and mitDNA from necrotic-release have been detected 
in systemic circulation of ALF patients and in experimental models of AILI, 
suggesting a role for DAMPs in promoting SIRS and multiorgan dysfunction 
(Marques et al., 2012). DNA release from necrotic hepatocytes have the 
capacity to guide neutrophils to the areas of injury via the TLR9/NF-κB 
pathway, where they promoted inflammation. Blocking this interaction via DNA 
removal or through ablation of TLR9 significantly reduced systemic 
inflammation, neutrophil recruitment and liver injury (Marques et al., 2015). 
 
Similarly, mice lacking HMGB1 were protected from a lethal dose of APAP, 
and humanized antibodies to HMGB1 attenuated AILI in mice more effectively 
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than NAC (Lundbäck et al., 2016). DAMP recognition by immune cells via 
TLR9 and TLR4 pathway can activate molecular complexes called 
inflammasomes. The NACHT, LRR and PYD domains-containing protein 3 
(Nalp3) inflammasome has been implicated in promoting hepatotoxicity during 
AILI by promoting the activation and secretion of potent pro-inflammatory 
mediators IL-1β and IL-18 (Imaeda et al., 2009; Woolbright and Jaeschke, 
2017b; Bachmann, Pfeilschifter and Mühl, 2018). Blocking inflammasome 
formation, either via TLR9 antagonism or blocking IL-18 activity, was shown to 
ameliorate hepatotoxicity during AILI (Imaeda et al., 2009; Bachmann, 
Pfeilschifter and Mühl, 2018).   
 
Activated NPCs also release a range of chemotactic factors, called 
chemokines, which guide and recruit circulatory leucocytes to necrotic areas. 
KCs are the major producer of C-X-C ligand 2 (CXCL2) and C-C ligand 2 
(CCL2), involved in the recruitment of neutrophils and monocytes respectively 
(Ishida et al., 2006; Zimmermann, Trautwein and Tacke, 2012). CXCL2 
binding to its receptor CXCR2 inhibited neutrophil accumulation in the liver 
following AILI, which in turn dampened liver injury and inflammation (Marques 
et al., 2012). Similarly, inhibiting CCL2 interaction with CC receptor 2 (CCR2) 
led to reduced monocyte infiltration and attenuation of liver injury and 
inflammation (Mossanen et al., 2016). ALF patients often show increased 
levels of chemokine ligands (namely CCL2) in their serum, and this has been 
attributed to poor prognosis (discussed further in sections below) (Antoniades 
et al., 2012; Mossanen et al., 2016). As a result, blocking chemokine ligand-
receptor interaction and or inhibiting chemokine release has become a 
therapeutic target for the treatment of AILI (Mota et al., 2017).  
 
There is a wealth of evidence implicating inflammation in the progression of 
liver injury, but crucially it is also needed for driving liver repair through 
chemokine-mediated recruitment of various leucocytes into the liver. 
Leucocytes regulate liver injury and regeneration and their dysfunction can 
drive mortality and morbidity in ALF patients. For instance, circulating 
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neutrophils and monocytes have significantly impaired capacity to respond to 
pathogens during  ALF, a feature often seen in patients with worst outcomes 
from APAP poisoning (Antoniades et al., 2008; Taylor et al., 2013; Bernsmeier 
et al., 2015; Moore et al., 2017). The role of leucocytes in regenerating liver 
has been studied both in the context of PHx and AILI; the majority of existing 
data is on myeloid cells, especially macrophages, however lymphocytes have 
also been shown to be modulators of liver regeneration. 
 
1.6 Liver as an immunological organ  
 
The liver is a highly immunological organ, harbouring a rich reservoir of innate 
and adaptive immune cells essential for immunoregulatory functions (Jenne 
and Kubes, 2013). Portal blood flow supplied by the hepatic vein contains a 
spectrum of gut contents including pathogens, non-self-antigens from nutrients 
and gut microbiota. The immune network in the liver forms a “firewall” between 
these gut contents and systemic circulation (Balmer et al., 2014). The hepatic 
immune network includes KCs, dendritic cells, NK cells, NKT cells, T cells; 
during steady-state conditions they function to maintain tolerance against 
harmless non-self-antigens whilst rapidly removing harmful pathogens (Figure 
1.4) (Jenne and Kubes, 2013; Heymann and Tacke, 2016).  
 
KCs are strategically positioned in the liver sinusoids and are equipped with 
various pattern-recognition receptors (PRRs), complement receptors required 
to recognize and capture non-self-antigens (Heymann and Tacke, 2016). 
Following binding, KCs are activated and pathogens are phagocytosed and 
eliminated in the phagolysosomes, thus preventing their dissemination 
(Surewaard and Kubes, 2017). Activated KCs can release various pro-
inflammatory cytokines to activate NK cells and promote cytotoxic responses 
towards bacterial and viral pathogens (Salazar-Mather, Orange and Biron, 
1998; Lauwerys et al., 2000). Most importantly, during homeostasis these 
events are tightly controlled to avoid evoking a systemic immune response 
(Heymann and Tacke, 2016). KC response to lipopolysaccharide (LPS), a 
common bacterial PAMP often found on non-pathogenic commensal bacteria, 
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is a perfect example of this. In response to physiological concentrations of 
LPS, KCs readily produce interleukin (IL)-10 which suppresses T cell activation 
via downregulation of MHC class II expression on LSECs and DCs  (Knoll et 













Figure 1.4 Regulatory role of immune cells in the liver during homeostasis. 
APCs such as KCs, DCs, and LSECs flank the sinusoids, capturing and removing 
circulating non-self-antigens and commensal bacteria. They modulate T cell 
responses via releasing immunosuppressive mediators (IL-10, TGFb and PGE2) 
to promote and tolerogenic state in the liver. Microbial pathogens detected via KCs 
are eliminated by NK cell derived TRAIL/IFN-g mechanisms. Abbreviations: APCs, 
Antigen presenting cells; CTL, cytotoxic T cells; DC, dendritic cells; HSC, hepatic 
stellate cells; IFN-g, interferon-gamma, IL, interleukin; KC, Kupffer cells; LSEC, 
liver sinusoidal endothelial cells; NK, natural killer cells; PGE2, prostaglandin E2; 
TGF-b, transforming growth factor-b; TRAIL, Tumour necrosis factor-related 
apoptosis inducing ligand. Reprinted from Markose et al (2018). 
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1.7 Role of immune cells during acute liver injury  
 
1.7.1 Lymphocytes  
 
Lymphocytes constitute approximately 25% of hepatic NPCs, including both 
innate and adaptive lymphocytes. Innate lymphocytes in the liver can be 
broadly categorised into NK cells and NKT cells. Hepatic NK cells are 
phenotypically and functionally different from conventional NK cells found in 
circulation; in fact they resemble innate lymphoid cells (ILCs); a subset of cells 
with an immunoregulatory phenotype, found on mucosal surfaces (Heymann 
and Tacke, 2016). During homeostasis NK cell activity is suppressed, partly 
via KC-derived IL-10, but following infection or injury they are activated. 
Through the release of cytolytic enzymes like perforin, granzyme and 
interferon gamma (IFN-γ) mediated signalling, NK-cells can eliminate non-self-
antigens and viral infected and tumour-transformed cells (Heymann and 
Tacke, 2016). 
 
NKT cells on the other hand are cells which share phenotypical similarities with 
both NK cells and T cells. In the context of PHx NK/NKT cells interact with KCs 
to release pro-mitogenic cytokines TNF-a, IL-6, HGF and IL-4 and also directly 
secrete IL-22 to promote liver regeneration (Hosoya et al., 2013). Thus far 
none of the existing studies in the field has been able to faithfully and precisely 
investigate the role of NK and NKT cells in promoting injury and regeneration 
the context of AILI.  A hepatoprotective role for NK/NKT cells during AILI in 
early studies has been attributed to DMSO, a widely used solvent for APAP. 
While there is no evidence to show that NK/NKT directly influence liver injury 
and regeneration following AILI, IFN-g released by activated NK cells is a 
promoter of tissue injury and inflammation following AILI (Ishida et al., 2002). 
Following hepatic focal sterile injury, invariant NKT cells were shown to have 
a wound healing phenotype via IL-4 secretion, which polarised macrophages 
to a pro-reparative phenotype and promoted hepatocyte proliferation (Liew, 
Lee and Kubes, 2017).  
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Adaptive lymphocytes (T and B cells) perform immunoregulatory functions in 
the liver during homeostasis, and following injury or infection they have the 
capacity to initiate inflammatory responses (Zhang et al., 2013). Hepatic T cells 
may be localised to the portal tracts and parenchyma of the liver, and are 
distinct from circulating T cells (Collins et al., 1996). Of the two major T cell 
subtypes, CD4+ T (T helper) cells are responsible for modulating pro-
inflammatory and inflammatory responses and CD8+ T (cytotoxic T) cells 
perform MHC-I mediated effector functions against intracellular pathogens 
(Heymann and Tacke, 2016). CD4+ T cells interact with MHCII on antigen 
presenting cells (APCs) and shape immune responses, and are subdivided 
into four different subtypes (TH1, TH2, TH17 and regulatory TReg cells) based 
on their activation states (Heymann and Tacke, 2016). Recently a small 
population of non-classical T cells were identified in the liver, termed γδ-T cells. 
Increased mortality, observed in RAG1 deficient (T and B cell deficient) mice 
following PHx, highlights the requirement for adaptive lymphocytes in 
promoting liver regeneration. T cell-derived lymphotoxin (LT) (also known as 
TNFSF1; a member of the TNF super-family) was shown to promote 
hepatocyte proliferation directly and via the IL-6 pathway in the context of PHx; 
this response was seen in both CD4+ and CD8+ T cells but not in γδ-T cells, 
indicating functional heterogeneity within T cell populations during liver 
regeneration (Tumanov et al., 2009).  
 
During AILI, CD4+ T (TH1) cells contribute towards liver injury via IFNg 
production; conversely, TReg subsets were shown to promote an anti-
inflammatory phenotype in the liver. Depletion of TReg cells amplified 
inflammation, which was reversed following adoptive transfer of TReg cells. TH1 
and TH2 balance is crucial during AILI (Wang et al., 2015), demonstrated by 
increase hepatoxicity in TH1-dominant C57B/6 mice in comparison to TH2-
dominant BALB/c mice (Masubuchi, Sugiyama and Horie, 2009). Expression 
of proinflammatory cytokines TNF-a and IL-6 was elevated in TH1-dominant 
mice, whilst mitogenic cytokine IL-6 was upregulated in TH2-dominant mice. 
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TH17 cells have also been implicated in the progression of inflammation during 
AILI via IL-17 signalling, which results in the release of pro-inflammatory 
cytokines and neutrophil-mobilizing chemokines (Zhu and Uetrecht, 2013). 
Collectively, these results indicate T cell subsets show functional difference 




One of the early responders to liver injury are neutrophils; necrosis-derived 
DAMPs, pro-inflammatory mediators such as TNF-β and IL-1β released from 
KCs and CXCL2-CXCR2 interaction can all recruit neutrophils to necrotic sites 
(Wang et al., 2013; Marques et al., 2015). Recently, TLR2 and calprotectin 
proteins S100A8 and S100A9 were identified as key regulators of hepatic 
chemokine CXCL-2 and neutrophil recruitment during AILI (Moles et al., 2014). 
Neutrophils populate the liver during the early stages of AILI and have a dual 
role. Neutrophil infiltration can exacerbate inflammation and liver injury during 
the early necroinflammatory phase, through release of tissue-damaging 
molecules like nitric oxide (NO), reactive oxygen species (ROS), proteolytic 
enzymes and through driving inflammatory pathways TLR9/NF-κB and IL-
33/ST2 (Ishida et al., 2006; Liu et al., 2006; Marques et al., 2015; Yang et al., 
2019). Therefore, depleting neutrophil recruitment and function during the 
early stages phase of AILI can dampen liver injury (Marques et al., 2012). 
Crucially, neutrophils also drive liver repair, as depleting neutrophils during the 
later stages of AILI reduces liver regenerative capacity (Yang et al., 2019). 
Neutrophils are professional phagocytes, capable of removing necrotic debris; 
their timely recruitment to the liver when hepatocyte necrosis is extensive 
suggests they may have a role in promoting clearance of debris. Interactions 
between neutrophils and other leucocytes also influence liver repair: during 
AILI, clearance of apoptotic neutrophils can induce a pro-repair phenotype in 
macrophages, and recently neutrophil-derived ROS has also been suggested 
to drive this polarisation (Graubardt et al., 2017; Yang et al., 2019). 
Furthermore, ALF patients show impaired bactericidal function in their 
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circulating neutrophils, whereby complement activity, ROS production and the 
ability to phagocytose is significantly compromised (Wyke et al., 1982; Altin et 
al., 1983; Taylor et al., 2013). The role of cytokines in promoting hepatocyte 
proliferation during acute liver injury was highlighted in previous sections. 
Neutrophil interaction with ICAM-1 has been shown to promote the release of 
pro-mitogenic cytokines TNF-α and IL-6 by KCs, following PHx. Goh et al. 
(2013) demonstrated that recruited eosinophils are a major source of IL-4, and 
that IL4-IL4r signalling promoted hepatocyte proliferation during CCl4 induced 
acute liver injury and following PHx. Eosinophil-deficient mice display ~50% 
reduction in their regenerative capacity following PHx and acute CCl4 injury 
(Goh et al., 2013). In keeping with this, eosinophilia was associated with 
favourable outcomes in patients suffering from drug-induced liver injury 
(Bjornsson, Kalaitzakis and Olsson, 2007). 
 
Currently there is no known role for basophils in the context of liver injury and 
liver regeneration. Mast cells have been implicated in a wide range of biliary 
injuries such as primary biliary cholangitis and bile duct obstruction; perhaps 
not surprising as they are localised mainly to the portal tract in the liver (Jarido 
et al., 2017).  
 
1.7.3 Mononuclear phagocyte system  
 
The mononuclear phagocyte system (MPS) was formed in 1969 to collectively 
classify cells with shared ability to phagocytose and a common ontogeny from 
bone-marrow derived precursors (Hume, 2006). The MPS comprises of 
macrophages, monocytes and dendritic cells (DCs) and perhaps the most 
studies cells in the MPS during tissue repair are macrophages. Macrophages 
were initially identified by Elie Metchnikoff in 1883 as phagocytes with the 
ability to capture and engulf dead cells and harmful pathogens, thus giving rise 
to the concept of cellular immunity (Guilliams, Mildner and Yona, 2018). Since 
then, distinct macrophage populations have been identified in different tissues 
of the body (tissue resident macrophages; TRMs) with specialised roles. For 
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example, alveolar macrophages in the lung are responsible for removing 
inhaled particles and pathogens, osteoclasts reside in the bone and have a 
role in bone resorption, and microglia in the brain function to eliminate dead 
neurons, microbes, and protein aggregates which may endanger the central 
nervous system (Colonna and Butovsky, 2017). Kupffer cells represent the 
largest population of TRMs, with a range of functions extending beyond 
providing innate immunity, including iron and lipid metabolism (Scott and 
Guilliams, 2018). Given their key roles in tissue development, homeostasis 
and inflammation macrophages have been termed as a “cell for all seasons”. 
Their involvement in a wide range of inflammatory and malignant pathologies 
have identified them as key therapeutic targets (Ginhoux et al., 2016). In order 
to fully understand their therapeutic potential, you need to appreciate the 
complex biology of macrophages, which includes their origin, activation states 
and functions.  
 
1.7.3.1 Origin and maintenance of tissue resident macrophages 
 
For a long time it was believed that all macrophages originated from circulating 
monocytes from common myeloid precursor (CMP) cells in foetal liver and 
bone marrow during embryonic and adult haematopoiesis (Ginhoux and Jung, 
2014). Bone marrow (BM) haematopoietic stem cells differentiate into CMPs, 
which diverge into either GMP (granulocyte-monocyte precursor) for the 
neutrophil differentiation pathway or MDP (monocyte-macrophage DC 
precursor). The MDP population is believed to make a binary decision to either 
differentiate into DC-restricted CDP (common DC precursor), giving rise to 
tissue DCs, or monocyte-restricted progenitor cMoP (common monocyte 
precursor) giving rise to circulating monocyte precursors (Hettinger et al., 
2013; Ginhoux and Jung, 2014).   
 
Circulating monocyte precursors were thought to continuously replenish all 
TRMs in various tissues across the body, but this concept was challenged by 
a series of studies in the early 20th century, which redefined macrophage 
ontogeny and indicated heterogeneity within the MPS. Studies showed 
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replenishment of various TRMs following their depletion occurring 
independently of bone marrow-derived circulating monocytes (Merad et al., 
2002; Ajami et al., 2007; Ginhoux et al., 2010). Additionally, parabiosis and 
BM-chimera experiments which can trace circulating monocyte mixing and 
differentiation to macrophages suggested tissue-dependent bone-marrow 
contribution to TRM maintenance (Guilliams et al., 2013; Hashimoto et al., 
2013; Tamoutounour et al., 2013; Bain et al., 2014; Epelman et al., 2014). 
TRMs such as microglia, Langerhans cells, and alveolar macrophages self-
maintain independent of circulating precursors (Ginhoux et al., 2010; Yona et 
al., 2013; Gomez Perdiguero et al., 2015). Conversely, TRM populations in the 
gut and dermis show contribution from BM-derived circulating precursors 
(Hashimoto et al., 2013; Bain et al., 2014). Yona et al. (2013) took advantage 
of the broad expression of CX3CR1 by cells in the MPS and performed fate 
mapping of MPs using a conditional CX3CR1 promoter driven Cre 
recombinase system. Their findings showed that Kupffer cells (KCs), in 
addition to lung alveolar macrophage, microglia and splenic macrophages, are 
established during embryogenesis prior to the generation of HSCs and self-
maintain with no contribution from circulating blood monocytes during 
adulthood (Yona et al., 2013). Although circulatory monocytes have the 
capacity to give rise to macrophages in tissues such as the liver, brain, and 
lungs during inflammation, these macrophages are usually ephemeral (Yona 
et al., 2013).   
 
Despite differences in origin, TRMs and their MPS counterparts share several 
common characteristics in addition to their phagocytic capacity. The 
development of MPS cells is regulated by PU.1, which in turn is regulated by 
RUNX1 (Ginhoux et al., 2010). PU.1 regulates the early stages of myeloid cell 
development, where high concentration of PU.1 levels were shown to promote 
macrophage and DC development whereas low levels of PU.1 are needed for 
B cell development (DeKoter and Singh, 2000; Carotta et al., 2010). The 
proliferation and differentiation of MPs (monocytes, DCs and macrophages) 
are regulated by colony stimulating factor 1 (CSF1) and interleukin (IL)-34, 
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signalling via a common receptor, CSF1R (Hume and MacDonald, 2012; Gow 
et al., 2014). Indeed, CSF1R is one of the major target genes of PU.1. 
Osteopetrotic (op/op) mice which show constitutive deficiency for Csf1 show 
significant reduction in circulating monocytes, macrophage populations. The 
severe phenotypical defects including loss of teeth, male and female infertility, 
and increased bone mass in these mice highlights the trophic functions of 
macrophages (Dai et al., 2002; Pollard, 2009). Similar phenotypes are 
observed in CSF1R knock out (KO) mice, which rarely live beyond a few weeks 
of age and show complete loss of Langerhans cells and microglia (Pollard, 
2009).   
 
Creation of MacGreen mice in which the expression of enhanced green 
fluorescent protein (eGFP) is under control of the Csf1r promoter allows the 
visualisation of MPs, especially macrophages, across different tissues 
(Sasmono et al., 2003). Modification to the Csf1r promoter enables selective 
interrogation of macrophages without neutrophil labelling, and MacBlue mice 
have been developed where certain TRMs such as KCs are not labelled 
(Sauter et al., 2014). Additional core macrophage genes and proteins include 
CX3CR1, Fc receptors (CD64), Adgre1 (F4/80). These are expressed by the 
majority of macrophage populations, and expression of these proteins is used 
in the identification of macrophages across various tissue (T’Jonck, Guilliams 
and Bonnardel, 2018). 
 
TRMs including KCs also acquire tissue-specific identities to perform specific 
functions, and this adaptation is controlled by many transcriptional factors. ID3 
has been identified as a regulator of KC development (Mass et al., 2016); 
similarly PPAR-γ and GATA6 are important to the development and 
maintenance of alveolar macrophages (Schneider et al., 2014) and peritoneal 
macrophages (Okabe and Medzhitov, 2014), respectively. Tissue-specific 
programming of macrophages gives rise to a unique transcriptional profile, and 
TRM-specific markers such as TIMD4 have been identified to selectively study 
these cells (Thornley et al., 2014; Fujiyama et al., 2018; Shaw et al., 2018). 
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CLEC4F has recently been identified as a KC-specific marker (Scott et al., 
2016). Scott et al. (2016) demonstrate the niche-dependent capacity of 
circulating monocytes to acquire TRM identity, selectively depleting KCs and 
showing that circulating monocytes gave rise to macrophages with a similar 
gene expression profile to KCs and the capacity to self-maintain for as long as 
four months. A similar phenotype was observed in Zeb2-/- mice, in which KCs 
are absent due to their dependency on Zeb2; BM-derived circulating 
monocytes gave rise to KCs in these mice, supporting niche competition (Scott 
et al., 2018). 
 
1.7.3.2 Circulating monocytes as precursors to macrophages 
 
The capacity of circulating monocytes to infiltrate the liver and differentiate into 
macrophages is a common feature seen during liver injury and inflammation, 
and this process does not require niche availability. The chemokine signals 
derived from the inflammatory response to tissue injury are detected by 
circulating monocytes, resulting in transmigration of specific subsets of 
monocytes to the site of injury. Circulating monocytes were thought to be a 
homogenous population, however, phenotypic characterization of monocytes 
using multi-parametric flow cytometry identified heterogeneity within the both 
human and murine monocyte populations. In humans CD14 and CD16 
expression is used to identify monocytes, with CD14+ CD16- monocytes 
(classical monocytes) accounting for 80-90% of the total monocyte pool and 
the remainder comprised of CD14+ CD16+ monocytes (intermediate) and 
CD14Lo CD16+ (non-classical) monocytes (Patel et al., 2017). Murine 
monocytes are broadly identified by flow cytometry, firstly based on their 
expression of CD115 (CSF1R), CD11b and lymphocyte antigen 6C (Ly6C). In 
depth-characterisation of murine monocyte populations was made possible by 
the generation of a CX3CR1GFP reporter mouse, in which fluorescent protein 
expression (GFP) was driven by the CX3CR1 locus. Two main subsets of 
monocytes have been identified and characterized: classical monocytes 
defined as Ly6CHi (CX3CR1Int CCR2+ CD62L+ CD43Lo) and non-classical 
monocytes as Ly6CLo (CX3CR1Hi CCR2Lo CD62L- CD43+). A third intermediary 
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subset (Ly6CInt) has been described based on CD11b expression; 
transcriptomic analysis revealed Ly6CHi and Ly6CLo monocytes to be 
homogenous, whereas Ly6CInt monocytes are heterogeneous (Mildner et al., 
2017).  
 
Ly6CHi monocytes are short lived (18 hours), with their primary function to 
respond to chemokines released following inflammation, namely CCL2 
(monocytes chemotactic protein-1; MCP-1), and to migrate to sites of injury 
and inflammation (Serbina and Pamer, 2006). Ly6CHi monocytes are often 
called inflammatory monocytes, based on their capacity to readily release pro-
inflammatory cytokines in the site of injury. At the site of inflammation Ly6CHi 
monocytes are highly plastic and depending on micro-environmental cues act 
as precursors of inflammatory and restorative monocyte-derived macrophages 
(MDMs). 
 
Ly6CLo circulating monocytes on the other hand are long lived (~2 days in mice 
and 7 days in humans) (Patel et al., 2017; Guilliams, Mildner and Yona, 2018). 
Intravital imaging studies of CX3CR1GFP/+ mice revealed Ly6CLo monocytes as 
custodians of the vasculature in the steady state, where they crawl along the 
luminal side of the endothelium (Auffray et al., 2017), carry out effector 
functions such as scavenging micro particles and maintain endothelial cell 
integrity (Carlin et al., 2013). Ly6CLo monocytes were also shown to have an 
active role during tissue injury; for example, injury induced by irritants, aseptic 
wounding and peritoneal infection with Listeria monocytogenes (Lm) resulted 
in rapid extravasation (within 1 hour) of Ly6CLo monocytes. During Lm 
infection, Ly6CLo monocytes were shown to initiate an inflammatory response, 
producing cytokines such as TNF-α. They also upregulated various TLRs, 
scavenger receptors and chemokines involved in the recruitment of other 
immune cells, and exhibited a TF profile that specified macrophage 
differentiation (Auffray, Sieweke and Geissmann, 2009). This response was 
transient, with Ly6CLo monocytes shortly replaced by Ly6CHi monocytes. 
Studies have shown a role for Ly6CLo monocytes in tissue injury and repair, 
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with Nahrendorf et al. 2007 demonstrating that during myocardial injury there 
is an initial recruitment of Ly6CHi monocytes with phagocytic, proteolytic and 
inflammatory functions, followed by infiltration of Ly6CLo monocytes which 
promoted tissue restoration through matrix remodelling and angiogenesis 
(Nahrendorf et al., 2007). A similar phenomenon was seen in the context of 
muscle regeneration following necrosis, whereby inflammatory Ly6CHi 
monocytes populated the areas of injury in the initial phase, which was 
followed by an increase in Ly6CLo monocytes with an anti-inflammatory 
phenotype. The authors of this study postulated that instead of a secondary 
infiltration, Ly6CHi monocytes differentiated into Ly6CLo monocytes (Arnold et 
al., 2007). These studies collectively show that Ly6CLo monocytes have the 
capacity to respond to tissue injury, differentiate into macrophages and 
participate in tissue repair process. However, the temporal dynamics of Ly6CLo 
infiltration, their origin and phenotype are injury dependent.  
 
As with TRM a set of transcription factors (TFs) and growth factors determine 
commitment towards monocyte lineage. The role of PU.1 and CSF1R has 
been discussed previously; additionally IRF8, GATA2 and KLF4 have been 
identified as critical in myeloid lineage differentiation, with deletion of these 
TFs resulting in reduced peripheral monocyte numbers (Guilliams, Mildner and 
Yona, 2018). Recent studies have highlighted that the canonical MDP-cMoP-
monocyte developmental pathways can be bypassed during inflammation, and 
that GMPs (granulocyte-monocyte precursors) can give rise to monocytes 
(Yáñez et al., 2017). Ly6CHi monocytes derived from GMPs during LPS-
induced inflammation exhibit a distinct gene expression signature showing 
upregulation of neutrophil-related genes (Yáñez et al., 2017). Similarly, a 
distinct monocyte subset derived from granulocyte precursors, named 
segregated nucleus-containing atypical (SatM) Ly6CLo monocytes, were 
shown to populate the lung during inflammation and identified as driving 





1.7.3.3 DCs and Macrophages- a complex relationship 
 
When dendritic cells (DCs) were first identified they were characterized as cells 
with a stellate morphology, lacking capacity for phagocytosis but with a unique 
ability to present antigens to naïve T cells. However, increasing evidence 
demonstrating their phagocytic capacity, in addition to other shared similarities 
to macrophages and monocytes, led to their inclusion in the MPS (Hume, 
2006). DCs are a heterogeneous group of cells, and assessment of surface 
markers facilitates the characterization and identification of different DC 
subsets including classical or conventional DCs (cDCs) and plasmacytoid DCs 
(pDCs); murine cDCs are further divided into two major lineages, cDC1 and 
cDC2 (Guilliams, Mildner and Yona, 2018). cDCs are short lived cells 
specialized to carry out innate immune responses, enabled via high phagocytic 
and cytokine-producing activity. They are also efficient in antigen processing 
and presenting and in regulating T cell responses. In comparison, pDCs are 
long lived, present in the BM and in all peripheral organs, and are specialized 
to rapidly secrete type 1 interferons (IFN I) in response to viral infections 
resulting in T cell priming (Patricia Fitzgerald-Bocarsly, Dai and Singh, 2008). 
pDCs can also act as APCs and can modulate T cell responses (Geissmann 
et al., 2010).  
 
Currently it is a challenge to distinguish between DCs and macrophages, due 
to overlapping expression of surface molecules. Both cDCs and pDCs are 
derived from distinct precursors in the bone marrow (CDPs), independent of 
monocyte precursors (cMoP) (Paul et al., 2015; Guilliams, Mildner and Yona, 
2018). DCs show dependency on growth factor Flt3 (Auffray, Sieweke and 
Geissmann, 2009), and therefore Flt3 expression has been used to define 
DCs. Notably, DCs also depend on CSF1, a monocyte/macrophage 
differentiation factor, and CS1FR KO mice exhibit deficiency in DC numbers. 
Recent studies have revealed that monocytes have the capacity to differentiate 
into DCs (Mildner et al., 2017) during steady state condition and inflammation 
(Menezes et al., 2016). Two independent studies report that a subset of Ly6CHi 
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monocytes can give rise to monocyte-derived DCs (m-DCs), expressing  DC-
related genes Cd209a and MHCII in steady state conditions (Menezes et al., 
2016; Mildner et al., 2017). In one of the studies these monocyte precursors 
were defined as Ly6CInt monocytes (Mildner et al., 2017). Following 
inflammatory stimuli Ly6CHi monocytes have also been shown to give rise to 
DCs, expressing TNF-α, iNOS, and reactive oxygen species; these cells have 
been termed TipDCs (Serbina, Shi and Pamer, 2012). To add complexity, in 
the context of inflammation monocyte-derived macrophages (MDMs) can 
upregulate CD11c and MHCII, classic DC markers, in addition to classical 
macrophage markers like F4/80, CD64 and MerTK (Guilliams, Mildner and 
Yona, 2018). Monocyte-derived DC populations are distinct to cDC and pDC 
subsets, and their development and maintenance is independent of CDPs and 
FLT3 (Serbina, Shi and Pamer, 2012; Menezes et al., 2016; Mildner et al., 
2017) However, it remains unclear whether m-DCs and MDMs represent 
ontogenically distinct entities, regulated by a distinct TF or gene program, or 
highly dynamic cells with the capacity to acquire a multitude of phenotypical 
and functional characteristics in response to their micro environmental signals 
(Guilliams, 2014).  
 
1.7.3.4 Macrophage activation states  
 
While the MPS framework has facilitated our understanding of tissue 
phagocyte biology, it promotes the assumption that all phagocytes are 
homogenous regarding their origin and function. Previous sections have 
highlighted heterogeneity within monocytes and DCs; here I will focus on the 
plasticity exhibited by the macrophages. 
 
The ability of macrophages to change their phenotype in response to their 
environment was demonstrated in the early 1990s, when researchers 
observed differences in macrophage phenotype in response to IL-4 versus 
interferon gamma (IFN-γ) and/or LPS. Following this, the M1 (classically 
activated) and M2 (alternatively activated) model was introduced by Mills et 
al., (2000) to define the two different macrophages responses. In vitro 
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polarization of macrophages to M1 and M2 phenotypes highlighted their 
potential to regulate their phenotype and thus function in response to 
environmental stimuli (Mills et al., 2000). M1 macrophages activated by IFN-γ 
and or LPS release various pro-inflammatory mediators such as nitric oxide, 
TNF-α and IL-1, and exhibit the necessary phenotype for pathogen killing, 
whereas M2 macrophages display a wound healing phenotype upregulating 
MHCII molecules, arginase-1 and scavenger receptors in response to IL-4 and 
IL-13. Importantly, these dichotomous states represent the extremes of a 
continuum which is not representative of in vivo macrophage responses. In 
depth transcriptomic analyses of human macrophages cultured with an array 
of stimuli including various cytokines, fatty acids and TLR ligands revealed a 
spectrum of macrophage activation states, extending beyond the M1 and M2 
polarization model (Xue et al., 2014). Tumour-associated macrophages 
(TAMs) show bidirectional transformation between anti-inflammatory and 
immunosuppressive phenotypes in vivo (Mantovani et al., 2002; Watkins et al., 
2007). In the context of tissue injury, macrophages are educated by 
endogenous stimuli, such as DAMPs from dying cells, chemokine and 
cytokines released from neighbouring cells, and are also capable of self-
regulating based on autocrine signals. As a result, macrophages show an 
incredible level of plasticity, changing their phenotype and thus their function 
depending on ever-changing microenvironmental cues. One such activation 
state exhibited by macrophages promoting tissue repair is phagocytosis.  
 
1.7.3.5 Phagocytic properties of macrophages 
 
MPs are unified by their ability to phagocytose; phagocytosis is defined as the 
cellular uptake of particulates >5 µM in size within a plasma-membrane 
envelope (Hochreiter-Hufford and Ravichandran, 2013). The mechanisms in 
place for internalization of particles <0.5 µM in size is referred to as 
endocytosis or pinocytosis. Phagocytosis is an integral part of the innate 
immune system, required to remove microbial pathogens, non-self-antigens 
and dead cells (Ravichandran and Lorenz, 2007). It begins with internalization 
of particulates, which are then processed within a membrane-bound vesicle 
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referred to as the phagosome. Phagosomal fusion to acidic lysosome 
structures results in the degradation of the particulates (Kinchen and 
Ravichandran, 2008). Phagocytosis can be further defined by their target: 
bacteria and yeasts are internalized through scavenger receptors present on 
macrophages, while complement or Fc receptors can facilitate the removal of 
microorganisms (Hochreiter-Hufford and Ravichandran, 2013). The uptake of 
apoptotic or necrotic material is referred to as efferocytosis and is a complex 
process requiring a specific set of secreted factors and cell surface receptors. 
Efferocytosis is a critical mechanism during homeostasis for the removal of 
necrotic and apoptotic debris, with around 200 billion cells being turned over a 
day and also during tissue injury, to clear apoptotic and necrotic bodies 
(Hochreiter-Hufford and Ravichandran, 2013).  
  
Efferocytosis is initiated through the release of soluble factors called “find-me” 
signals by the dying cell. These signals establish a chemotactic gradient which 
guides phagocytes towards the dying cell (Ravichandran and Lorenz, 2007). 
There have been several different “find-me” signals reported, which are 
recognized by specific receptors on the phagocytes: lysophosphatidyl-choline 
(LPC), sphingosine 1-phosphate (S1P), fractalkine (CX3CL1), and the 
nucleotides ATP and UTP, sensed by receptors G2A, S1P1-5, CX3CR1 and 
P2Y2, respectively (Koizumi et al., 2007; Hochreiter-Hufford and 
Ravichandran, 2013). Once the phagocytes are near the dying cell, “eat me” 
signals presented by the apoptotic cells facilitate their phagocytic uptake, 
whilst avoiding ‘friendly fire’ of live cells in the vicinity. A range of “eat me” 
signals have been described in the literature, including phosphatidylserine 
(PtdSer), oxidized low-density lipoprotein (LDL)-like moiety, ICAM3, bound 
opsonins such as thrombospondin and complement C1q. Phagocytes possess 
numerous receptors capable of recognizing these “eat me” signals (Table 1.1), 
and can also secrete bridging molecules such as MFG-E8, growth-arrest-
specific 6 (Gas6) and proteins S which can facilitate phagocytosis via binding 




Table 1.1 Ligands and receptors involved in efferocytosis (Hochreiter-Hufford 
and Ravichandran, 2013) 
Phagocytic Receptors “Eat me” Targets 
CD36  Thrombospondin 
LRP1/CD91 C1q complement  
CD14 ICAM3 
Scavenger receptors  Oxidized LDL 
Tyro-3-Axl-Mer family, e.g. MerTK  PtdSer (via bridging molecules) 





The interaction of phagocytes and apoptotic target leads to cytoskeletal 
rearrangements in the phagocytes resulting in internalization of the corpse in 
a membrane envelope called phagosome. For efferocytosis to be complete the 
internalized particles need to be trafficked into a series of increasingly acidified 
membrane-bound structures culminating in particle degradation; a process 
called phagosomal maturation. Acidification of the phagosome can be used as 
a readout for successful phagosome maturation (Kinchen and Ravichandran, 
2008). Defects in phagosomal maturation can have consequences during 
tissue injury: in a model of kidney ischemia reperfusion injury, defects in 
glycoprotein nonmetastatic melanoma B (GPNMB), a phagocytic protein that 
regulates phagosomal trafficking and degradation, led to an increase in 
apoptotic cellular debris and increased mortality in mice compared to wild type 
counterparts (Li, Castano, Hudson, Nowlin, S. L. Lin, et al., 2010). In 
concordance, Campana et al. (2017) demonstrated that following AILI, 
GPNMB-deficient mice had extended necrotic areas compared to wildtype 
mice; IL-6 treatment improved phagocytosis in these mice via the IL6-STAT3 
pathway. The authors also showed that successful efferocytosis promoted the 
differentiation of Ly6CHi inflammatory monocytes to Ly6CLo MDMs (Campana 
et al., 2018). 
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1.7.4 Role of MPs during acute liver injury and regeneration  
 
1.7.4.1 DCs  
 
DCs have been shown to promote liver regeneration following PHx. 
Administration of Flt3l in the context of PHx promotes expansion of DCs and 
significantly increased liver regeneration (Castellaneta et al., 2006). 
Modulation of  T cell responses by DCs during PHx to promote anti-
inflammatory milieu that facilitates liver regeneration (Castellaneta et al., 
2006). During AILI, DC depletion via diphtheria toxin (CD11c-DTR) promoted 
hepatotoxicity and increased mortality in mice in mice (Connolly et al., 2011). 
The mechanisms by which DCs suppress injury and promote repair in this 
setting has not be fully elucidated. It was shown that rather than numerical 
changes, AILI induced phenotypical changes in DCs, which resulted in 
increased production of IL-6, TNF-a and CCL2 (Connolly et al., 2011). Another 
presumed mechanism by which they exert a pro-reparative phenotype is by 
negatively regulating NK activation and promoting neutrophil apoptosis. 
Furthermore, Flt3l treatment caused expansion of hepatic DCs and reduced 
hepatotoxicity following AILI (Connolly et al., 2011). The main drawback to 
these studies is the lack of DC specific markers, conventional markers such 
as MHCII and CD11c are also expressed on macrophages, especially during 
inflammation (Guilliams, Mildner and Yona, 2018). The Flt3l experiments 
would suggest that DCs are important in modulating liver regeneration, but 
currently it remains challenging to draw specific conclusions on their specific 
role.  
 
1.7.4.2 Monocytes and macrophages  
 
Kupffer cells (KCs) represent the predominant tissue resident macrophage 
(TRM) population in the liver during homeostasis, accounting for 20% of the 
NPC population (Heymann and Tacke, 2016). KCs have been identified based 
on their expression of core macrophage receptors such as F4/80 and CD64, 
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in addition to TRM-specific receptors including CLEC4F and TIMD4, but do not 
express CX3CR1, expressed by most other MPs (Scott et al., 2016). They are 
derived embryonically and self-maintain with minimal contribution from the 
bone marrow. During homeostasis KCs function as sentinels, capturing and 
destroying food antigens and microbial pathogens. They also have a role in 
lipid and cholesterol metabolism (Scott and Guilliams, 2018). The remaining 
TRM population in the liver are liver capsular macrophages (LCMs), 
expressing macrophage markers, CD64, CSF1R, F4/80 but not KC marker 
TIMD4, which indicates that these cells are distinct from KCs (Sierro et al., 
2017). Unlike KCs, LCMs rely on circulating monocytes for replenishment; they 
reside in the liver capsule and combat bacterial load from the peritoneum by 
promoting neutrophil recruitment (Sierro et al., 2017).   
 
Both KCs and recruited macrophages have been shown to drive liver 
regeneration. Following PHx, KCs promote hepatocyte proliferation via IL-6 
and TNF-a release; inhibiting or depleting KCs resulted in significantly reduced 
numbers of proliferating hepatocytes (Selzner et al., 2003). Liver regeneration 
is also impaired in the absence of CCR2+ circulating monocytes, suggesting 
these cells might have a distinct role during PHx (Nishiyama et al., 2015; Wyler 
et al., 2016). The main caveat to these studies is they have not used KC-
specific markers to delineate the TRM from infiltrating macrophages 
((Nishiyama et al., 2015; Wyler et al., 2016).  
 
Three distinct macrophage subsets have been identified to populate the liver 
during AILI, based on a combination of cell surface markers expression:  
 
• KCs (TIMD4+ CLEC4F+ F4/80Hi CD11bLo CX3CR1Lo CCR2Lo)  
• Ly6CHi monocytes (TIMD4- CLEC4F- F4/80Lo CD11bHi CX3CR1Int 
CCR2Hi)  
• Ly6CLo MDMs1 (TIMD4- CLEC4F- F4/80Hi CD11bInt CX3CR1Hi CCR2Int) 
 
1 Ly6CLo MDMs are also referred to as Ly6CLo MoMFs. These terms are used 
interchangeably in the literature.  
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These subsets of macrophages behave dynamically during AILI (Figure 1.5, 
1.6). During the necroinflammatory phase of AILI various DAMPs released by 
necrotic hepatocytes are recognized by KCs via DAMP-sensing receptors 
(TLR4, TLR9, RAGE, P2X7), which initiates a range of signalling cascades. 
KCs secrete pro-inflammatory mediators such as TNF-α, reactive oxygen 
species and various chemokines (CCL2, CXCL2), which amplifies the 
inflammatory signal and results in the recruitment of bone-marrow derived 
immune cells into the liver. KCs were linked to promoting inflammation during 
AILI through the release of pro-inflammatory mediators such as IL-6, IL1β, and 
TNFα, and their ablation resulted in reduced liver necrosis and improved 
survival rate (Fisher et al., 2013). On the other hand, KCs have also been 
associated with promoting tissue repair following AILI through the release of 
IL-6 IL-10, IL-18 and various complement molecules, and their complete 
elimination increased hepatocyte necrosis (Ju et al., 2002). Both studies relied 
on clodronate liposomes or gadolinium chloride to deplete or inhibit KCs 
respectively, and both mechanisms are not specific to KCs and can target 
other phagocytic cells. This also indicates that KCs behave dynamically during 
AILI, promoting inflammation during the necroinflammatory phase whilst 
mediating liver repair in the later stages (Figure 1.5, 1.6). 
 
Zigmond et al. (2014) report that KC numbers are depleted during the early 
stages of AILI (~24-48hrs post-APAP), but that at 72hrs post-APAP their 
numbers are re-established via local proliferation without any BM-derived 
monocyte contribution. The significance of “KC disappearance” is currently 
unknown; it could be a result of cell death, of migration, or of macrophage 
plasticity following AILI. Transcriptomic profiling of KCs during the later stages 
of AILI (72hrs post-APAP) revealed that KCs express a wide array of 
scavenger receptor genes that can promote phagocytosis and extracellular 
matrix remodelling genes. They have also been identified as major producers 




BM-derived circulating Ly6CHi monocytes play a crucial role following AILI, with 
recruitment into the liver heavily dependent on the CCR2/CCL2 axis. CCR2 
deficient mice (CCR2-/-) show marked reduction in hepatic Ly6CHi monocytes 
(Mossanen et al., 2016; Yang et al., 2019). Circulating monocyte Ly6CHi 
monocyte (CCR2+) infiltration occurs as early as 6hrs post-AILI (Zigmond et 
al., 2014), and once in the liver they form dense cellular clusters around 
necrotic areas (Mossanen et al., 2016). Ly6CHi monocytes show increased 
expression of a wide range of proinflammatory genes including Nos1, Ptgs2, 
TLRs (Tlr2, Tlr4, Tlr5, Tlr8, Tlr9), LPS receptor Cd14, chemokines (Ccl2, Ccl3, 
Ccl6) and neutrophil recruitment genes (S100A8/9, LCN). During later phases, 
Ly6CHi monocytes acquire a pro-reparative phenotype and differentiate into 
ephemeral Ly6CLo MDMs, exhibiting a gene profile associated with 
phagocytosis (Celc4d, Clec4e, Clec5a, CD93) and ECM remodelling (MMP8, 
ADAM8) (Zigmond et al., 2014). BM-derived Ly6CLo MDMs exhibit some 
phenotypical similarity to KCs such as the expression of markers including 
F4/80 and CD64, however the pro-restorative molecular signature displayed 
by KCs and Ly6CLo MDMs are very distinct (Zigmond et al., 2014). Of note, a 
population of peritoneal macrophages marked by GATA6 was shown to 
infiltrate the liver during thermal and CCl4-induced acute liver injury. GATA6+ 
macrophages migrated via the liver visceral endothelium rather than the 
vasculature and promoted wound healing and liver regeneration (Wang and 
Kubes, 2016). The contribution of these cells to AILI is currently unknown.  
 
Ly6CHi monocytes have been shown to be drivers of both liver injury and repair 
during AILI (Figure 1.5, 1.6). Mossanen et al. (2016) demonstrated that during 
the necroinflammatory phase (6hrs-12hrs) CCR2-/- mice lacking Ly6CHi 
monocytes and Ly6CLo MDMs show attenuated liver injury, where ALT levels 
and hepatocyte necrosis is markedly reduced in CCR2-/- mice in comparison 
to wild type mice. The authors further show via adoptive transfer experiments 
that early infiltration of Ly6CHi monocytes can aggravate liver injury (Mossanen 
et al., 2016). In the clinical setting, monocytopenia coupled with high levels of 
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serum CCL2 confers a poor prognosis in ALF patients, suggesting that 
increased monocyte infiltration is a feature of worsened outcome (Antoniades 
et al., 2012). In line with this, patients show increased levels of hepatic CCR2+ 
monocytes in the necrotic areas of the liver, expressing S100A9, indicating a 
proinflammatory phenotype (Antoniades et al., 2012; Mossanen et al., 2016). 
Based on this, inhibitors of CCR2 have been suggested as a potential 
therapeutic intervention for patients suffering from acute liver injury (Mossanen 
et al., 2016).  
 
Conversely, there is evidence to show that Ly6CHi monocytes can promote 
liver repair. In addition to pro-inflammatory genes, Ly6CHi monocytes also 
display a gene signature associated with wound healing (Agr1, Chil3l3, IL4ra, 
TNFSF14), angiogenesis (Vegfa, Sema4d, Hif1a, Plaur) and extracellular 
matrix remodeling (ECM) genes (MMP18, ADAM8) (Zigmond et al., 2014; 
Graubardt et al., 2017). Several studies report liver injury is higher in CCR2-/- 
mice in comparison to wildtype mice, where this observation is made during 
the repair phase of AILI (24hrs-48hrs) (Yang et al., 2019). At this time CCR2-
/- mice exhibit increased ALT levels, extensive hepatocyte necrosis, increased 
number of apoptotic cells around the necrotic areas and more importantly, 
marked reduction in proliferating hepatocytes (Hogaboam et al., 2000; 
Zigmond et al., 2014; Yang et al., 2019). This highlights that temporal cues 
can influence macrophage phenotype during AILI. For example, there is an 
interplay between neutrophils, Ly6CHi monocytes and LyC6Lo MDMs during 
AILI that regulates macrophage phenotype and promotes liver repair. 
Neutrophil-derived reactive oxygen species provide cues for Ly6CHi 
monocytes differentiation to Ly6CLo MDMs (Yang et al., 2019). There is 
evidence to show that Ly6CHi monocytes regulate neutrophil activity and 
promote their apoptosis, and apoptotic-neutrophil clearance is carried out by 
Ly6CLo MDMs. Transcriptomic analysis of Ly6CLo MDMs during the repair 
phase of AILI (72hrs post-APAP) show expression of a unique set of apoptotic 
cell bridge molecules and receptors required for efferocytosis (Graubardt et 
al., 2017). Based on these data, infiltrating monocytes and their progeny are 
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highly dynamic, exhibiting potential to both promote and inhibit liver repair 
following AILI.  
 
Investigating the precise mechanisms by which macrophages promote liver 
injury and repair can facilitate the discovery of specific targets. An example of 
this is the recent discovery of MerTK+ macrophages populating the liver during 
the repair phase of ALF in both humans and mice. In this study, secretory 
leucocyte protease inhibitor (SLPI) induced MerTK expression on both KCs 
and Ly6CLo MDMs, which was shown to drive liver repair by promoting 
neutrophil apoptosis and subsequent clearance (Triantafyllou et al., 2017). 
Interestingly, ALF patients showed elevated numbers of both hepatic and 
systemic MerTK+ HLA-DRHi cells, characterised by supressed innate and 
enhanced efferocytic/phagocytic responses (Bernsmeier et al., 2015; 
Triantafyllou et al., 2017). The immunoregulatory phenotype exhibited by 
circulating MerTK+ HLA-DRHi monocytes supresses the innate immune 
response, which increases susceptibility to infections in these patients. In this 
context, blocking the activity of MerTK+ HLA-DRHi monocytes was reported to 
be beneficial (Bernsmeier et al., 2015). Clearly, the balance between 
immunoregulatory and pro-inflammatory macrophages and monocyte 
phenotype influences disease progression in ALF patients (Antoniades et al., 
2006; Bernsmeier, Antoniades and Wendon, 2014; Bernsmeier et al., 2015; 
Triantafyllou et al., 2017). Whilst an immunoregulatory phenotype is 
favourable in the liver to promote efferocytosis and drive liver repair, an 
inflammatory phenotype is needed in the systemic circulation to combat 
infections (Bernsmeier et al., 2015; Triantafyllou et al., 2018).  
 
Overall these data highlight that embryonically-derived KCs, BM-derived 
monocyte precursors (Ly6CHi monocytes) and their progeny (Ly6CLo MDMs) 
are key regulators of liver regeneration following AILI (Figure 1.5, 1.6). Given 
the recent developments in macrophage ontogeny and activation states, we 
need to rethink our strategy for identifying macrophage-based therapeutic 
targets (Figure 1.7). Previous studies in the context of AILI and other types of 
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acute liver injury have heavily relied on known biology and broadly classified 
macrophages into KCs, Ly6CHi monocytes and Ly6CLo MDMs for subsequent 
gene expression and functional studies (Zigmond et al., 2014; Ju and Tacke, 
2016; Mossanen et al., 2016; Graubardt et al., 2017). While this has given us 
some insights into their role during AILI, their capacity to promote both liver 























Figure 1.5 Leucocyte involvement in the necroinflammatory phase of AILI. 
Early stages of AILI is characterised by significant hepatocyte necrosis. DAMPs 
(HMGB1, Hsp70) released from necrotic materials activates liver resident 
leucocytes (KCs, DCs, gd T cells) which causes pro-inflammatory cytokine (IL6, 
TNF-a, IL-1b) and chemokine (CCL2, CXCL1, CXCL2, IL-17) release. Chemokine-
mediated leucocyte infiltration one of the key characteristics during this phase. 
Liver injury can be exacerbated by Ly6CHi monocytes (IL-1b TNF-a mediated 
mechanisms), neutrophils (ROS and NO mediated mechanisms), NKT and NK 
cells (IFN-g, Fas and Perforin mediated mechanisms). Liver repair responses are 
initiated via necrotic clearance, proliferation and differentiation of pro-inflammatory 
Ly6CHi monocytes to pro-reparative Ly6CLo MDMs (MoMFs). Adapted from 



















Figure 1.6 Leucocyte involvement in the repair phase of AILI. Inflammation is 
dampened via Ly6CHi monocyte mediated neutrophil apoptosis. Mediators such as 
SLPI drives the reprogramming macrophages to an efferocytic phenotype.  Various 
efferocytic receptors such as MerTK, expressed by Ly6CLo MDMs (MoMFs) and 
KCs facilitates apoptotic neutrophil clearance.  Cytokines released via leucocytes 
promote an anti-inflammatory milieu and drives hepatocyte proliferation. Ly6CHi 
monocytes and Ly6CLo MDMs promote angiogenesis and ECM remodelling and 
collectively these events result in restoration of normal liver architecture.  Adapted 



































Figure 1.7 Old dogmas versus new insights on macrophages during murine 
models of liver injury. Cell identification: hepatic macrophages have gone from 
broad F4/80 classification to CLECF4 and TIMD4 expression delineating yolk sac 
derived KCs from bone marrow derived Ly6CLo MDMs (MoMFs). Polarisation: rather 
than a dichotomous M1 (pro-inflammatory) M2 (anti-inflammatory) phenotype 
macrophages during liver injury are heterogenous exhibiting spectrum of activation 
states. Therapeutic implications: broad immunodepleting approaches will lead to 
loss of pro-reparative macrophages shifting focus to immunomodulating 
approaches for identifying therapeutic target to treat liver diseases. Reprinted from 
Guillot and Tacke, (2019). 
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1.8 Single-cell RNA sequencing  
 
Gene expression studies guide researchers to gain insight into the 
transcriptome of cells, from which they may infer protein expression, 
phenotype and cellular function. The advent of Next Generation Sequencing 
(NGS) enabled RNA analysis via sequencing of complementary 
Deoxyribonucleic Acid DNA (cDNA), a method referred to as Ribonucleic Acid 
(RNA) sequencing. RNA sequencing (RNA-seq) eliminates limitations posed 
by hybridization-based microarrays and Sanger sequencing-based 
approaches (Kukurba and Montgomery, 2015); for example DNA is 
simultaneously sequenced and detected base-by-base, in real time, with low 
background signal and with no requirement of prior sequence knowledge. 
 
Conventional bulk population RNA-seq analyses expression of RNA from an 
ensemble of many cells, providing genomic measures for a sample that may 
mask heterogeneity within cell populations. Conversely, single-cell RNA 
sequencing (scRNA-Seq) allows interrogation of RNA expression in individual 
cells. This facilitates the identification of rare subtypes and vital cell-to-cell 
variability in heterogeneous cell populations, which would otherwise be 
masked in population-averaged measurements generated through bulk RNA-
seq. ScRNA-seq is a multistep process, following the same basic principles of  
RNA-seq, whereby cells are isolated and lysed, messenger RNA (mRNA) is 
captured which is then reverse transcribed into cDNA, followed by cDNA 
amplification and library generation for sequencing.  
 
1.8.1 Cell capture and mRNA extraction  
 
Cells of interest can be captured via both low-throughout and high-throughput 
methods. Techniques such as micro pipetting and laser capture 
microdissection give precise control over specific cells and areas of tissue 
isolated for sequencing, however these methods are labour-intensive and limit 
the number of cells that may be isolated at a given time (Hwang, Lee and 
Bang, 2018). Therefore, high-throughput techniques such as fluorescence-
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activated cell sorting (FACS), microfluidic and droplet-based systems are 
current preferred methods for scRNA-seq (Figure 1.8). 
 
FACS allows rapid and accurate isolation of hundreds of thousands of cells in 
a matter of minutes. Cells of interest can be selected based on size, 
granularity, fluorescent-tagged cell surface markers and or transgenic 
reporters. One of the main drawbacks of FACS is that it can induce cell stress 
and reduce cell viability as cells are passed through pressured streams to 
generate single cell suspensions (Haimon et al., 2018). To combat this, 
systems have been developed to isolate cells from peripheral blood based on 
magnet-conjugated antibodies, without the use of FACS, however these are 
not feasible for cell isolation from tissues (Hwang, Lee and Bang, 2018). 
 
Droplet-based techniques such as DropSeq, InDrop and 10X Genomics 
Chromium rely on capturing cells in oil droplets, enabling capture and 
sequencing of thousands to millions of cells. Currently, this method has the 
highest throughput of all single-cell platforms, and is usually preferred for 
detecting rare cell types and investigating heterogeneity (Figure 1.8) (Nguyen 
et al., 2018; Chen, Ye and Guo, 2019). Additionally, combining FACS with 
droplet-based systems enables enrichment for populations of interest. 
Following cell isolation, cells are lysed to capture mRNA, usually via poly(A)+ 
selection using poly(dT) primers.  
 
1.8.2 cDNA amplification and library preparation  
 
Once mRNA is extracted it is reverse transcribed into cDNA, followed by an 
amplification step which is crucial as only picograms of mRNA may be 
captured from an individual cell. There are numerous methods for generating 
cDNA libraries; for example, methods such as SMART-seq are designed to 
generate full-length cDNA, while droplet-based methods generate cDNAs with 
either a 5’ or 3’ bias, which consequently reduces the read depth (See et al., 
2018). On the other hand these methods allow cDNA tagging with unique 
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molecular identifiers (UMIs), specifically marking individual mRNA in a cell, to 
assist in downstream analysis by removing amplification bias. Droplet-based 
systems such as 10X Genomics Chromium further tag the cDNA with cellular 
barcodes to map sequence reads with the cell of origin (See et al., 2018). 
During the library preparation process, cDNA is fragmented and ligated with 
primers and adapters for sequencing.   
 
1.8.3 Sequencing  
 
Illumina sequencing represents the most widely used NGS method that relies 
on Sequencing by Synthesis. Illumina flow cell immobilises cDNA strands via 
oligonucleotides complement to the ligated adapter oligonucleotides. The flow-
cell bound single stranded DNA fragments are amplified through bridge 
amplification to generate double stranded bridge which is subsequently 
denatured leaving two single-stranded templates tethered to the Illumina flow 
cell. Bridge amplification occurs simultaneously for millions of clusters, 
resulting in massively parallel clonal amplification of all the fragments in the 
sample. Sequencing occurs through the addition of fluorescently tagged 
nucleotides and DNA polymerase. The wavelength and fluorescent signal 
emitted following nucleotide binding to complementary bases in the DNA 
fragments is used to determine the sequenced base. A library of millions of 
base sequences is generated in this manner, which may then be aligned to a 
reference genome to obtain gene expression data in the form of a counts 
matrix. 
 
1.8.4 Data Analysis  
 
Conventional RNA-seq methods are not suitable for the analysis of scRNA-
seq data, due to particular challenges associated with scRNA-seq such as the 
inherent biological variation between individual cells. Additionally, the degree 
of “drop-out” events (the presence of zero-inflated counts) is high, owing to the 
low amount of starting RNA and the inefficiency of RT and amplification 
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reactions, and this can be further increased by 3’ or 5’ end bias. While some 
cells may contain no expression or low expression of certain genes due to 
biological reasons, in many cases this is a result of technical artefacts (See et 
al., 2018). Therefore, single-cell computational tools for the analysis of scRNA-
seq datasets rely heavily on quality control and normalisation steps to account 
for technical and biological variability (discussed further in Chapters 2 and 5). 
These tools also allow for the incorporation of UMIs and cellular barcodes to 
generate reads, quantify gene expression and map to individual cells. Further 
algorithms may be used to cluster the cells based on their gene profile, 
following which differentially-expressed (DE) gene analysis can identify genes 
to define and annotate clusters. Marker gene identification also facilitates 
further validation studies (Choi and Kim, 2019). Further downstream analyses 
such as pseudotime (Haghverdi et al., 2016) and RNA velocity (Manno et al., 
2018; Zywitza et al., 2018) can be applied to datasets containing cells on a 
continuum, and are often used to investigate differentiation trajectories within 
populations.  
 
1.8.5 Novel findings using scRNA-seq  
 
Since its introduction in 2009, scRNA-seq has revolutionised immunology by 
allowing the study of immune cells at an unprecedented resolution. This 
technology has been applied to cell lineages from different tissues and blood 
during development, homeostasis and disease states in both humans and 
animal models, which has led to many discoveries (Chen, Ye and Guo, 2019). 
For instance, using different scRNA-seq platforms, two independent studies 
identified precursors of dendritic cells (pre-DC) in human peripheral blood (A. 
Villani et al., 2017; See et al., 2017). In both studies, newly identified marker 
genes guided the researchers to validate their in-silico findings at protein level. 
 
Use of scRNA-seq in pathological conditions can aid the identification of 
molecular and cellular therapeutic targets in disease. Based on scRNA-seq 
data a novel disease-associated microglia (DAMs) population was identified in 
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Alzheimer’s disease, and further analysis localised the DAMs in tissue and 
uncovered the pathways by which they promote disease (Keren-Shaul et al., 
2017). 
 
scRNA-seq has also facilitated the creation of cell atlases, mapping the 
transcriptomes of multiple cell lineages in a given organ. For example, two very 
recent studies analysing parenchymal and NPCs from human liver using 
scRNA-seq (MacParland et al., 2018; Aizarani et al., 2019) have generated a 
human liver cell atlas. Using marker genes identified through scRNA-seq, both 
studies recapitulate known zonation of hepatocytes, but also highlight zonation 
of endothelial cells in the liver. Furthermore, these studies have revealed 
heterogeneity within what was believed to be a homogenous population and 
identified novel cell types. MacParland et al (2018) identified two 
transcriptionally distinct KC populations showing functional differences, one 
enriched for pathways relating to tolerance whilst the second was enriched for 
pathways relating to inflammation. A novel discovery of bipotent epithelial 
progenitor populations in the adult human liver was made by Aizarani et al. 
(2019). Efforts are already underway to combine these studies and others to 
establish a “human cell atlas”, identifying all cell types in the human body, and 
no doubt this will have a significant impact in the field of biomedicine (Regev 
et al., 2017). 
 
Two studies recently revealed novel findings in monocytes and macrophage 
dynamics in the context of non-alcoholic fatty liver disease (NAFLD) (Krenkel 
et al., 2019; Xiong et al., 2019). scRNA-seq of NPCs from healthy and non-
alcoholic steatohepatitis (NASH; a form of NAFLD) mouse livers revealed the 
emergence of NASH-associated macrophages, which the authors defined as 
TREM2+ macrophages, conserved in human disease as well. In concordance, 
unpublished data from the Henderson lab has also identified a subpopulation 
of scar associated macrophages, defined as TREM2+ CD9+, showing a pro-
fibrogenic phenotype in cirrhotic human livers (Ramachandran et al. in press). 
Krenkel et al. (2019) utilised a murine model of NAFLD and scRNA-seq to 
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show transcriptional re-programming of monocytes to a unique inflammatory 
phenotype (NAFLD myeloid phenotype) in the bone marrow, characterised by 
downregulation of calprotectin genes. This NAFLD monocyte phenotype was 
shown to be stable; following adoptive transfer they dampened AILI in recipient 
mice (Krenkel et al., 2019). These studies highlight the power of scRNA-seq 
in identifying novel, injury-specific signatures and cell types during chronic liver 
injury, that can be therapeutically manipulated. To date, however, no studies 
have looked at the transcriptional changes in monocytes and macrophages 
during acute liver injury at single-cell resolution. 
 
1.8.6 Choice of single-cell RNA sequencing method to study 
heterogeneity  
 
There are a wide range of methods and platforms available to investigate the 
transcriptome of cells at a single-cell level (Figure 1.8). The variety of methods 
can be technically categorised into two groups: full-length methods (SMART-
seq and Fluidigm C1) and molecular tag-based methods (MARS-seq and 10X 
Genomics Chromium). Full-length methods allow the whole transcriptome to 
be sequenced, providing an increased number of mappable reads (~400-7000 
genes/cell), and facilitating allelic gene expression analysis and isoform 
discovery. On the other hand, they restrict the digital quantification of 
transcripts, as they do not incorporate UMIs and restrict the number of cells 
sequenced per run (~96-384). Molecular tag-based methods preferentially 
sequence either the 3’ or 5’ end of the transcript, incorporating UMIs to 
facilitate multiplexing of the sample and thereby improving throughput and 
precise gene expression quantification. The main caveat of tag-based 
methods is the 3’ or 5’ bias impacting overall sensitivity (~500-1500 
genes/cell), and a high rate of “dropout events”. Nonetheless, given that the 
number of cells sequenced per run can range to the tens of thousands using 
droplet-based systems such as the 10X Chromium Genomics platform, it is 
often more suitable for the identification of rare cell-types. 
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To reliably dissect the heterogeneity of monocytes and macrophages I felt it 
necessary to sequence a large number of cells. Therefore, I utilised a droplet-










Figure 1.8 Characteristics of common single cell RNA sequencing methods. 
Reprinted from Nguyen et al, (2018).  
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1.9 Hypothesis  
 
Unidentified monocyte and macrophage subpopulations exist during acute 
liver injury, that are key regulators of liver repair 
  
1.10 Aims and objectives  
 
The overall aim of this body of work is to employ scRNA-seq in an unbiased 
manner to investigate heterogeneity in circulating and hepatic monocyte and 
macrophage populations during homeostasis and following AILI 
 
My experimental objectives to test this hypothesis are as follows:  
 
• Characterise the systemic and hepatic leucocyte response following 
acute liver injury  
 
• Perform scRNA-seq of systemic and hepatic monocytes and 
macrophages in an unbiased manner to study their dynamics and 
heterogeneity during AILI  
 
• Validate scRNA-seq findings at protein level and in vivo to identify 




2 Materials and Methods 
 
 
2.1 Mice  
 
Wild-type C57BL/6J mice (CD45.2+) were purchased from Charles River. 
MacGreenGFP, CX3CR1GFP and CCR2-/- mice were obtained from Prof. Jeffery 
Pollard (Secondary supervisor). All mice were maintained on a C57BL/6J 
background and bred under specific pathogen-free conditions at the University 
of Edinburgh. All experiments were done on male mice, aged between 8-14 
weeks, following approval by the University of Edinburgh Veterinary Scientific 
Services and were conducted under UK Home Office Legislation, following 
ethical guidelines.  
 
2.2 Genotyping of genetically modified mice  
 
Genotyping of MacGreenGFP and CX3CR1GFP lines were performed by flow 
cytometry. Blood samples (40µl) were obtained from the tail vein of the 
animals, then resuspended in 1mL of PBS, followed by centrifugation at 300g 
for 5mins at 4°C, before resuspending in 400µl of phosphate-buffered saline 
(PBS). GFP protein fluorescence were detected on Attune NxT flow cytometer 
(Thermo Fisher Scientific). CCR2-/- genotyping was performed by Sheila 
Webb, lab manager to Prof. Pollard, via polymerase chain reaction (PCR), the 















Table 2.1 Primer sequences used for genotyping of CCR2-/- mice  
 Primer Sequences PCR Product 
(bp) 
CCR2 wild type Fw CCACAGAATCAAAGGAAATGG 494 
CCR2 wild type Rw CACAGCATGAACAATAGCCAAG 





2.3 Murine models of liver regeneration  
 
Three models of liver regeneration were used throughout the course of this 
project. Acetaminophen Induced Liver injury (AILI), Carbon tetrachloride (CCl4) 
induced liver injury and Partial Hepatectomy (PHx). Following the induction of 
injury, all animals were assessed twice daily until the end of the experiment, 
any animals showing signs exceeding the severity limit were humanely killed.  
 
2.3.1 AILI 
Acetaminophen (APAP; Sigma-Aldrich, A7085) was dissolved at 10mg/mL of 
sterile PBS (Gibco; 14190250). Mice were fasted for 12 hours prior to 
intraperitoneal administration APAP at a dose of 300mg/kg. Animals had 
access to water throughout the experiment, food was returned with APAP 
administration. To avoid hypothermia animals were housed in a heated cabinet 
at 27°C for the first 24 hours. Aged-matched uninjured littermate controls were 
used for all experiments. Animals were humanely killed by CO2 induction at 
stated timepoints after APAP administration.  
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2.3.2 CCl4  
 
For the CCL4 acute inflammatory model, mice were once injected 
intraperitoneally with carbon tetrachloride (CCl4, 1µl/g; Sigma; 289116) diluted 
1:3 in olive oil (Sigma; O1514). Control animals received pure olive oil and 
standard checks were performed twice daily until the end of the experiment. 
Animals were humanely killed by CO2 induction stated timepoints after CCl4 
administration.  
 
2.3.3 PHx  
All surgeries were performed by me with assistance from Dr. Kylie Conroy. 
Mice were kept under anesthetised by inhalation of 2% isoflurane (Abbott) 
mixed with 2L/min oxygen flow and kept on a heated mat during surgery and 
recovery. Eye lubricant was applied (Viscotears Liquid Gel, Alcon Laboratories 
(UK) Ltd). Warmed, sterile 0.9% saline (25mL/kg, Braun, Sodium Chloride 
0.9% w/v Intravenous Infusion BP) and buprenorphine (0.1mg/kg, Ceva, 
Vetergesic), diluted to 0.03mg/mL in sterile water for injection was 
administered subcutaneously pre-operatively and post-operatively.  
Two-thirds partial hepatectomy (PHx) was performed as previously described 
in Mitchell and Willenbring, 2014. A midline abdominal skin and muscle 
incision was made, the median and left lateral lobes were exteriorised, ligated 
with 1.5M braided silk (SMI, 8015) individually and then excised. Followed by 
exteriorisation, ligation and excision of left lateral lobe. The abdominal incision 
was closed via a continuous suture of 1.5M polyglactin 910 (Ethicon, Vicryl, 
W9067). Surgical clips (Biochrom, 9mm Autoclips, 52-3748) were used to 
close the skin. Animals were humanely killed by CO2 induction stated 






2.4 5-Ethynyl-2’-deoxyuridine (EdU) administration  
 
To label proliferating cells, 5-Ethynyl-2’-deoxyuridine powder (EdU, Sigma-
Aldrich, 900584) dissolved in sterile PBS (Thermo Fisher Scientific, 14190-
250) at 2.5mg/mL, was injected intra-peritoneally at 50mg/kg, 3 hours prior to 
humane killing.  
 
2.5 Serum biochemistry  
 
Whole blood was collected from the inferior vena cava (IVC), immediately after 
post-mortem and allowed to clot at room temperature for 30 minutes. Serum 
was obtained by twice centrifuging the blood at 10000g for 5 minutes. Samples 
were frozen at -20°C until analysis. Serum alanine transaminase (ALT), 
aspartate aminotransferase (AST), glutamate dehydrogenase (GLDH) and 
albumin measurements were analysed at the Shared University Research 
Facilities within the Queen’s Medical Research Institute, according to a 
standard protocol. This was performed using commercial kits (Alpha 
Laboratories Ltd) and Cobas Fara centrifugal automated chemistry analyser 
(Roche Diagnostics).  
 
2.6 Hepatic non-parenchymal cell (NPC) isolation  
 
Mouse livers were perfused in situ with ice cold PBS via the Inferior Vena Cava 
(IVC), portal vein was cut to allow the release of perfusion PBS, until the liver 
was blanched. The liver was excised while and weighed. The right lobe and 
the caudate lobes were dissected and weighed and immediately placed in ice 
cold PBS for flow cytometric analysis, while the remaining lobes were 
processed accordingly for immunohistochemistry. The livers were 
mechanically chopped into small fragments with a razor blade, and then two 
different digestion protocols were followed for isolation of NPCs. Falcon, 
polypropylene conical centrifuge tubes (Corning) were used for centrifugation 
of the samples, despite the protocol. All samples were kept on ice unless 
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stated otherwise, centrifugation for protocol 1 was performed at 4°C, 300g for 
5 minutes and protocol 2 at 4°C, 400g for 7 minutes.  
 
Protocol 1 (adapted from Lynch et al., 2018)  
 
NPCs were isolated for all flow cytometry experiments in chapter 3 and chapter 
5 and specified experiments in chapter 4 following a protocol described in 
Lynch et al., 2018, with slight modifications. Following mechanical chopping, 
liver tissue was enzymatically digested in Roswell Park Memorial Institute 
(RPMI, Gibco, 21875034) 1640 medium, containing a cocktail of: 0.8mg/mL 
collagenase V (Sigma, C9263-1G), 0.625mg/mL collagenase D (Roche, 
11088882001), 1mg/ml dispase (Gibco, 17105-041), and 30µg/mL DNase 
(Roche, 101104159001). Enzymatic digestion was performed at 37°C for 18 
minutes with agitation (240 r.p.m).  
 
Following digestion the cell suspension was strained through a 100µm filter 
(EASYstrainer Greiner Bio-One, 542000), along with RPMI, and centrifuged. 
The resultant supernatant was removed, and cell pellet was resuspended in 
RPMI and centrifuged again. Following this, resultant supernatant was 
removed, and the cell pellet was lysed for erythrocytes by 3 minutes incubation 
with 10% RBC lysis buffer (Biolegend, 420301) in dH2O. Cells were 
resuspended in 3mL of PEB buffer, containing PBS (Thermo Fisher Scientific, 
14190-094), 2% Foetal Bovine Serum (Thermo Fisher Scientific, 10500-064), 
and 2mM EDTA (Sigma-Aldrich, E5134) and centrifuged. After the supernatant 
was discarded, the resultant cell pellet was resuspended in PEB buffer, filtered 
through a 35µm nylon mesh (Corning, 352235) 5mL tube. A 6µL aliquot was 
taken for cell counting, cells/mL count was obtained on a TC-20 cell counter 
(Bio-Rad), using trypan blue as a live dead marker, and the rest of the sample 
was centrifuged to obtain a pellet. Based on the cell count, the sample was 
resuspended in appropriate volume of PEB buffer to plate 2 million cells in a 
96-well plate. The cells were blocked in 10% mouse serum (Sigma-Aldrich, 
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M5905) and 1% CD16/32 (Biolegend, 101302), for 10 minutes at 4°C prior to 
antibody staining.  
 
Protocol 2 (adapted from Mederacke et al., 2015)  
 
NPCs were isolated to generate single cell suspensions for single cell RNA 
sequencing by following protocol. After mechanical mincing, the liver was 
enzymatically digested in Hank’s Balanced Salt Solution (HBSS, Gibco, 
14170112) containing 0.53 Wunsch Units/mL collagenase B (Roche, 
11088807001), 10mg/mL Pronase (Sigma, P5147) and 0.25mg/mL DNase 1 
(Roche, 10104159001) at 37°C for 15 minutes with agitation (240 r.p.m). 
Following this, strained through 120µm nybolt mesh, along with PEB buffer, 
containing PBS, Thermo Fisher Scientific, 14190-094), 2% low endotoxin 
Foetal Bovine Serum (Thermo Fisher Scientific, 10082139), and 2mM EDTA 
(Sigma-Aldrich, E5134) and DNase (0.02mg/ml). A syringe plunger was used 
to gently push through any undigested tissue. Then centrifuged, resultant 
supernatant was removed, cell pellet was lysed for erythrocytes by 3 minutes 
incubation with 10% RBC lysis buffer (Biolegend, 420301) in dH2O. Following 
this, cells were resuspended in PEB buffer with DNase and centrifuged, 
supernatant was discarded, and cell pellet was resuspended in 2mL of PEB 
buffer and passes through a 35µm nylon mesh (Corning, 352235). The 
samples for relevant controls was decanted, cells were centrifuged, and the 
supernatant was discarded. The cells were blocked in 10% mouse serum 
(Sigma-Aldrich, M5905) and 1% CD16/32 (Biolegend, 101302) for 10 minutes 
at 4°C prior to antibody staining.  
 
2.7 Systemic leucocyte isolation and generation of single cell 
suspension 
 
At the time of harvest, whole blood (100-200µL) was collected from the IVC, 
into 0.5mM EDTA solution, on ice. Erythrocytes were lysed by incubation with 
10% Red Blood Cell (RBC) lysis buffer (Biolegend, 420301) in dH2O for 5 
minutes, resuspended in PEB buffer (same composition as for hepatic NPC 
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isolation, low endotoxin FBS was used for scRNA-seq experiments), followed 
by centrifugation at 4°C, 300g for 5 minutes. The supernatant was removed, 
and cell pellet was lysed again by resuspending in 10% RBC lysis buffer in 
dH2O for 5 minutes, followed by centrifugation at 4°C, 300g for 5 minutes, 
before resuspending in PEB buffer and centrifuging the cell suspension. After 
the resulting supernatant was removed, the cell pellets were resuspended in 
1mL of PEB buffer and filtered through 35µm nylon mesh (Corning, 352235). 
Followed by a wash by centrifugation, the residual supernatant was removed, 
and the cells were incubated with live/dead stain (Zombie UV, Biolegend, 
423107), at a concentration of 1:100 in PBS, for 15 minutes at room 
temperature. Cells were washed in PEB buffer, then blocked in 10% mouse 
serum (Sigma-Aldrich, M5905) and 1% CD16/32 (Biolegend, 101302) for 10 
minutes at 4°C and labelled with antibodies for 20 minutes at 4°C. Followed 
by two washes in PEB buffer, before overnight fixation in 100µl of fixation and 
permeabilization buffer (1:3 to diluent, eBioscience, 00-5523), at 4°C. After 
fixation, cells were washed twice with perm/wash buffer (eBioscience, 00-
5523) and resuspended in PEB buffer for acquisition on the flow cytometer.  
 
2.8 In vivo phagocytosis assay  
 
In vivo labelling of phagocytic cells using PKH26 red fluorescent cell linker 
(PKH, Sigma-Aldrich, PKH26PCL) was performed as previous described in 
Campana et al., 2018. PKH26 was dissolved in diluent solution provided in the 
commercial kit, at a 1 in 100 dilution. To label phagocytic cells 100µL of 
dissolved PKH solution was injected intravenously, 16hrs prior to humane 
killing. The fluorescence was detected in cells of interest via flow cytometry.  
 
2.9 Ex vivo PhagoGreen assay  
 
Ex vivo labelling of phagocytic cells was performed using pH sensing smart 
fluorescent probes: PhagoGreen and PhagoRed (Vázquez-Romero et al., 
2013; Fernández and Vendrell, 2016). Both fluorescent probes were acquired 
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from Dr. Marc Vendrell. Cells were incubated with 100µL of PhagoGreen (at 
concentrations of: 50nM, 100nM, 150nM, 200nM) and PhagoRed (at 
concentrations of: 150nM, 200nM, 250nM, 300nM) for 30 minutes at 4°C. Cell 
labelling with PhagoGreen, and PhagoRed was done after live/dead staining, 
prior to blocking and surface antibody staining.  
 
2.10 Flow cytometry and fluorescence-activated cell sorting  
 
For flow cytometry or fluorescence-activated cell sorting (FACS), cells were 
isolated and following blocking, they were incubated with primary antibodies 
for 20 minutes at 4°C. Antibodies and fluorophore combinations varied 
depending on the staining combination, all antibodies and conjugates and their 
catalogue numbers are shown in Table 2.2. Flow cytometry compensations 
were set up using single stained beads (UltraComp eBeads, Thermo Fisher 
Scientific, 01-2222-42). Compensations for PKH, PhagoGreen, PhagoRed 
and intrinsic fluorescent reports (GFP) was set up using single stained cells. 
Controls for gating included ‘fluorescence-minus-one’ samples. Cell viability 
was assessed using the following live/dead stains: DAPI (1:100 dilution, 
Invitrogen, D3571), which was added immediately prior to cytometry or sorting, 
Zombie UV (Biolegend, 423107) and Zombie NIR (Biolegend, 423105), added 
prior to blocking, at a concentration of 1:100 in PBS and incubated with cells 
for 15 minutes at room temperature, in the dark. Cell sorting for scRNA-seq 
was performed on FACSAria II (BD Biosciences). Flow cytometry acquisition 
was performed on LSRFortessa (BD Biosciences) and Aurora (Cytek 
Biosciences) and data was analysed using FlowJo 10.0.8rl software.  
 
2.10.1 Gating strategy  
 
Gating strategy for the detection of different hepatic leucocytes and circulating 
leucocytes varied depending on the combination of antibodies used in 
experiments but followed the same initial steps to detect cells, single cells and 
live cells. The nonparenchymal cell (NPC) population was isolated on forwards 
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(FSC-A) against side (SSC-A) scatter, following the removal of doublets via 
FSC-A vs FSC-H. Live cells were isolated based on negative staining of one 
of the three live dead stains: DAPI, Zombie UV, Zombie NIR. Leucocytes were 
identified on the positive expression of CD45 in both liver and blood, along with 
endothelial lineage markers (CD31, ICAM2) in the liver.   
 
For the identification of specific hepatic leucocytes, the following strategy was 
followed. Cells not belonging to the of the mononuclear phagocyte 
(conventional dendritic cells, cDC; monocytes, monocyte derived 
macrophage, MDMs; Kupffer cells, KCs) compartment were identified first. B 
cells were identified as: CD45+ B220+, T cells as: CD45+ CD11b- CD3+, NK 
cells as: CD45+ NK1.1+, eosinophils as: CD45+ CD11b+ SiglecF+, 
Neutrophils as: CD45+ Ly6C+ Ly6G+, plasmacytoid DCs (pDCs) as: CD45+ 
F4/80- CD11B- B220+ CD11C+. After the removal of lymphocytes and 
eosinophils, neutrophils and pDCs the different types of MPs were isolated. In 
chapter 3, cDCs were generally identified as: CD45+ F4/80- CD11b- MHCIIHi 
CD11cHi in chapter 3, however following scRNA-seq cDCs were defined 
further into cDC1 and cDC2 in chapter 5.  
 
For the identification of mononuclear phagocytes (MPs) in chapter 5, the 
following gating strategy was used. Cells, single cells and live cells were 
identified as described above. Leucocytes were isolated based on CD45 
expression, following this any cells not belonging to the MP system was 
excluded from the analysis using a dump channel. These included: 
neutrophils, NK cells, eosinophils, pDCs, B cells, T cells using Ly6G, NK1.1, 
SiglecF, SiglecH, CD19 and CD3, respectively, all conjugated to the same 
fluorophore. Following this, cDCs1 cells were identified as: CD45+ XCR1Hi 
CD24Hi cDC1 and cDC2 cells as:CD45+ CD11cHi F4/80Lo. Hepatic monocytes 
were identified as: CD45+ F4/80Lo CD11bHi Ly6CHi MHCIILo. MDMs were 
identified as: CD45+ F4/80Int TIMD4Lo CD11bHi Ly6CInt/Lo MHCIIHi/Lo. KCs were 
identified as: CD45+ F4/80Hi TIMD4Hi CD11bLo. Hepatic monocytes were 
further defined based on CD62L or CXCR2. MDMs were further defined by 
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CD63, MHCII, IL7R. Expression of CD36, MerTK, CD24, CD9, CD11c was 
assessed on KCs and MDMs.  
 
Liver cells were quantified as absolute numbers or proportions of NPCs 
(represented as % of leucocytes; CD45+ cells, or as % of parent population). 
Absolute numbers were calculated by expressing each subset as a proportion 
of leucocytes, then the total number cells in the digested portion of the liver 
was counted and represented as cells/g of liver, based on the number of cells 
in the whole sample and the weight of the  portion of liver used for flow 
cytometry.  
 
The gating strategy for the identification of specific circulating leucocytes was 
similar to that of that of hepatic leucocytes with minor changes. B cell identified 
as: CD45+ B220+, T cells were identified as: CD45+ CD3+, NK were cells 
identified as: CD45+ NK1.1+. Eosinophils were identified as: CD45+ CD11b+ 
SiglecF+. Following this, circulating monocytes were isolated as: CD45+ 
CD11b+ CD115+ and further defined as Ly6CHi monocytes (CD45+ CD11b+ 
CD115+ Ly6CHi) and Ly6CInt monocytes (CD45+ CD11b+ CD115+ Ly6CInt) 
and Ly6CLo monocytes (CD45+ CD11b+ CD115+ Ly6CLo). Circulating subsets 
were quantified and represented as a portion of the leucocytes (CD45+ cells) 
or as absolute counts. Absolute counts were quantified using fluorescent 
precision count beads (Biolegend, 424902), at a known concentration, added 
to each sample at a volume of 50µL, immediately before flow cytometry 
acquisition. The number of beads per mL of whole blood was quantified and 
cell counts were expressed relative to the number of beads in the sample, to 







Table 2.2 Antibodies used for flow cytometry and FACS  
Antibody Fluorophore  Manufacturer  Cat.No. Dilution 
B220 BV421 Biolegend 103239 1:200 
CCR2 BV421 Biolegend 150605 1:100 
CD115 PE ThermoFisher 12-1152-82 1:100 
CD115 PE/Cy7 Biolegend 135523 1:100 
CD11b BUV737 BD Biosciences 564880 1:100 
CD11b APC/Cy7 Biolegend  101225 1:400 
CD11c PE/CY5 Biolegend 117316 1:400 
CD19 BV650 BD Biosciences 115541 1:50 
CD209a BV421 BD Biosciences 747827 1:50 
CD24 BV510 Biolegend  101831 1:50 
CD3 BV650 BD Biosciences 100229 1:50 
CD3 AF488 Biolegend 100212 1:100 
CD3 eFluor 450 e-Bioscience 48-0032-82 1:100 
CD31 PE/Dazzle Biolegend 102525 1:100 
CD36 AF647 Biolegend 102610 1:400 
CD45 BV605 BD Biosciences 563053 1:100 
CD45 PE Biolegend 103105 1:100 
CD62L PE/ Dazzle 594 Biolegend 104447 1:50 
CD63 APC Biolegend 143905 1:100 
CD63 PE Biolegend 143903 1:100 
CD64 BV421 Biolegend 139309 1:100 
CD9 PerCP/Cy5.5 Biolegend 124817 1:50 
CX3CR1 BV711 Biolegend 149031 1:50 
CXCR2 PE Biolegend 149303 1:100 
F4/80 BV785 Biolegend 123141 1:100 
F4/80 PE/Cy7 Biolegend 123113 1:200 
F4/80 APC/Cy7 Biolegend 123117 1:100 
ICAM2 AF647 Biolegend 105611 1:100 
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IL7R PE/Dazzle 594 Biolegend 135031 1:50 
IL7R APC Biolegend 135011 1:50 
Ly6C PercpCy5.5 Biolegend 128011 1:400 
Ly6C PE/Dazzle Biolegend 128043 1:100 
Ly6G AF700 Biolegend 127621 1:200 
Ly6G BV650 Biolegend 127641 1:100 
MerTK APC Biolegend 151507 1:200 
MHCII AF700 Biolegend 1076121 1:500 
NK1.1 BV650 BD Biosciences 108736 1:50 
NK1.1 PE/Cy7 Biolegend 108713 1:200 
SiglecF BV650 BD Biosciences 740557 1:50 
SiglecF PE-CF594 BD Biosciences 562757 1:200 
SiglecH BV650 BD Biosciences 747672 1:50 
TIMD4 PE/CY7 Biolegend 130009 1:400 
XCR1 AF647 Biolegend 148213 1:200 


















2.11 Tissue fixation and preparation  
 
Perfused livers were harvested, the median lobes were taken for paraffin-
embedding and left lobe was taken for fixed-frozen preparation using Optimal 
Cutting Temperature (OCT) embedding. For paraffin-embedding, livers were 
fixed overnight at room temperature in 4% formaldehyde, then transferred into 
70% ethanol before embedding in paraffin and sectioning. Liver tissue was 
sectioned at a thickness of 5-8µm.  For OCT embedding, livers were fixed at 
4°C in 4% paraformaldehyde for 2 hours, before washing in PBS, dehydrating 
through serial sucrose gradients (15% for 1 hour and then 30%, overnight at 
4°C). Following dehydration, tissue was placed in OCT embedding matrix 
(Thermo Fisher Scientific, 12678646) and subjected to freezing on dry ice. 
Sample were stored at -80°C until sectioning. Tissue was sectioned at 5µm, 
using a cryostat microtome (Bright instruments, 5040).  
 
2.12 Immunofluorescence  
 
Paraffin-embedded tissue sections were dewaxed in xylene, twice for 5 
minutes and rehydrated in decreasing concentrations of ethanol (100%,75%, 
65%, 2 minutes in each). Washed in dH2O and where stated heat mediated 
antigen retrieval was performed by microwaving the tissue in 10mM Sodium 
Citrate buffer, pH6, for 15 minutes. Endogenous peroxidase activity was 
inhibited with 3% hydrogen peroxide (10 minutes incubation). For the staining 
of frozen-fixed tissue there was no additional preparations except the tissue 
sections were allowed to reach room temperature for 20 minutes, before 
continuing with the staining protocol. All tissue sections were washed in PBS 
buffer and blocked using serum block (Biolegend, 927501), primary antibodies 
and secondary antibodies (Table 2.3) were diluted in antibody diluent (Abcam, 
ab64211) unless otherwise stated. Negative control section, lacking the 





2.12.1 HNF4a / EdU 
 
This protocol was performed on paraffin-embedded liver sections, prepared as 
outlined above and 0.5% Triton-X 100 was used for the washes (5 minutes). 
After performing antigen retrieval and quenching endogenous peroxidase, the 
tissue was permeabilized using 0.5% Triton-X 100 (Sigma, T8787) in PBS for 
20 minutes, at room temperature. Tissue was blocked in protein block for 1 
hours, followed by overnight incubation of HNF4a, at 4°C. Tissue was washed 
twice, then incubated in a drop of anti-mouse polymer ImPRESS (Vector 
Laboratories, MP-7402-15) for 30 minutes at room temperature, followed by 
two washes. TSA Plus Cyanine 3 (Perkin Elmer, NEL744001KT-1:1000) was 
applied for 10 minutes. After twice washing, sections were permeabilised in 
0.5% Triton-X100 as before. Click-iT Plus EdU Imaging Kit Alexa Fluor 647 
(Thermo Fisher Scientific, C10640) was used to detect incorporation of EdU in 
cells. EdU detection cocktail was made up as per manufacturer’s instructions 
and tissue sections were incubated with EdU cocktail, for 30 minutes at room 
temperature and twice washed after staining.  Nuclear counterstain was 
achieved with DAPI (Sigma, D9542) diluted 1:1000 in PBS, sections were 
incubated for 15 minutes, at room temperature, before mounting in ProLong 
Gold (Thermo Fisher Scientific, P36930).  
 
2.12.2 F4/80 / EdU 
 
This protocol was performed on fixed-frozen sections, prepared as outlined 
above. No antigen retrieval was required, tissue sections were washed twice, 
incubated with protein block for 30 minutes at room temperature. Anti-F4/80 
was applied, sections were incubated overnight, at 4°C, followed by two 
washes in PBS. For Click-iT Plus EdU Imaging sections were permeabilized 
with 0.5% Triton-x100 for 20 minutes at room temperature, followed by 
blocking with protein block for 30 minutes, at room temperature. EdU protocol 
was carried out exactly as above, following EdU staining, sections were 
counterstained with DAPI before mounting.  
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2.12.3 CLEC4F / TIMD4 
 
This protocol was performed on fixed-frozen sections, prepared as outlined 
above and required no antigen retrieval. Sections were washed and blocked 
described as previously, primary antibodies goat anti-CLEC4F and rat anti-
TIMD4 was applied simultaneously, incubated overnight at 4°C. Sections were 
washed twice in PBS to remove unbound primary antibodies then secondary 
antibodies: donkey anti-goat 555 and chicken anti-rat 647 were applied for 30 
minutes at room temperature. Following this counterstained with DAPI before 
mounting.  
 
2.12.4 CD63 / MacGreen / EdU 
 
This protocol was performed on fixed-frozen liver sections, from MacGreen GFP 
mice, and required no antigen retrieval. Sections were washed and blocked 
described as previously. As the fixation protocol can weaken the GFP signal, 
chicken anti-GFP primary antibody was applied, along with rat anti-CD63, 
sections were incubated overnight at 4°C. Secondary antibodies: horse anti-
chicken 488 and goat anti-rat 555 were applied for 30 minutes, at room 
temperature. Counterstain with DAPI was performed as before, followed by 
mounting.  
 
2.12.5 IL7R / MacGreen / EdU 
 
This protocol was performed on fixed-frozen liver sections, from MacGreen GFP 
mice, and required no antigen retrieval. Sections were washed and blocked 
described as previously. Chicken anti-GFP and rat anti-IL7R primary 
antibodies were applied overnight, at 4°C. Secondary antibodies: horse anti-
chicken 488 and goat anti-rat 555 were applied for 30 minutes, at room 




2.13 Histology staining  
 
To visualize liver architecture, the following histology stains were performed: 
Hematoxylin and Eosin, Hematoxylin, Masson’s trichrome, Picro Sirius Red, 
and Periodic Acid-Schiff. These stains were performed within the Histology, 
Immunodetection and Aquila-HistoPlex section of the Shared University 
Research Facilities within the Queen’s Medical Research Institute, according 
to a standard protocol.  
 
Table 2.3 Antibodies used for Immunohistochemistry  










Rat Anti-F4/80 1° Abcam Ab6640 1:200 
Goat Anti-CLEC4F 1° R&D Systems AF2784 1:500 
Rat Anti-TIMD4 1° Biolegend 130002 1:200 
Rat Anti-CD63 1° Biolegend 143901 1:100 
Chicken Anti-GFP 1° Abcam Ab13970 1:800 
Rat Anti-IL7R 1° Biolegend 121102 1:100 
Goat Anti-rat 555 2° ThermoFisher A-21434 1:200 
Chicken Anti-rat 
647 
2° ThermoFisher A-21472 1:200 
Donkey Anti-goat 
555         
2°     ThermoFisher A-21432 1:200 
Donkey Anti-
mouse 555 
2° ThermoFisher A-31570 1:200 
Donkey Anti-









2.14 Image capture  
 
Brightfield images and fluorescent images of whole tissue sections were 
captured using the slide scanner AxioScan.Z1 (Carl Zeiss, Oberkochen, 
Germany) at 20X magnification. Representative images of EdU / F4/80 stains 
were imaged using a confocal LSM780 microscope (EdU / F4/80 stains), at 
40X magnification, fields were chosen at random using the DAPI channel. 
Thresholds for all the fluorescent channels were set against the negative 
controls, were kept constant throughout the same experiment. Images were 
processed and scale bars were added on Zen Blue (Zeiss) software. 
 
2.15 Image quantification 
 
Slide scanned images were imported into a Definiens Tissue Studio 
workspace (Definiens AG, Munich, Germany) workspace, which is a machine 
learning platform that facilitates automated image quantification, based on 
contrast, intensity, and morphological features. The analysis was done with 
guidance and assistance from Dr. Daniel Soong, a post-doctoral researcher in 
Prof. Jeffrey Pollard’s lab. Tissue artefacts were removed from the analysis via 
automated segmentation, images were checked manually, to remove any 
artefacts that were missed by automated analysis.  
 
For the quantification of necrosis (Figure 3.1) random fields were chosen from 
a selection of training images (at least 4, to account for variations in staining 
intensity), these fields were segmented, and manually classified as “necrotic” 
(lighter staining) and “not-necrotic” (brighter staining). After several rounds of 
training on the randomly selected fields, analysis was performed on the actual 
images. The images were segmented automatically based on “necrotic” and 
“non-necrotic” classifications across the whole liver cross-section for all 
samples. Following the analysis, statistics for total area of the tissue, area of 
“necrotic” and “non necrotic” was exported.  
 
 72 
The immunofluorescence quantification was made up of three stages. In the 
primary stage (“ROI detection”) the tissue was segmented based on stained 
regions of interest (ROI). The secondary stage consisted of “Cellular analysis” 
where the DAPI channel was used to detect and segment nuclei. Cellular 
artefacts were discarded through five-cycles of trained intensity- and 
morphology-based machine learning; this included incomplete or low-quality 
cells. In order to detect cells of interest: CLEC4F+ TIMD4+ (Figure 3.2) and 
HNF4a+ EdU+ (Figure 3.6), cell stimulation was performed based on even 
growth from the nuclear detection object, cellular objects were then classified 
based threshold-based positivity appropriate channels. The third and final 
stage consisted of “Data Export” where statistics for the ROIs was exported. 
The statistics consisted of single positive, double positive and triple positive 
cells in per square millimeter of ROI (tissue). In order to quantify the 
percentage of proliferating hepatocytes (Figure 3.6) the number of DAPI+ 
HNF4a+ EdU+ cells were divided by DAPI+ HNF4a+ cells (total number of 
hepatocytes) and then multiplied by 100.   
 
2.16 Droplet-based scRNA-seq 
 
Single cells were processed through the ChromiumTM Single Cell Platform 
using the ChromiumTM Single Cell 3’ Library and Gel Bead Kit v2 (10X 
Genomics, PN-1200237) and the ChromiumTM Single Cell A Chip Kit (10X 
Genomics, PN-120236) as per manufacture’s protocol. As 10X is a fully 
commercial system, the exact primer and adapter sequences are not available. 
This section will contain a brief overview of the procedure (Figure 2.1).   
 
Single cells were sorted via FACS into PBS + 2% FBS, washed twice and 
counted using TC20 (Bio-Rad). 10,769 cells and 10X reagents were added to 
one lane of the 10X microfluidics chip, 10X gel beads into another and Oil into 
the third lane. The cells were then partitioned into Gel Beads in Emulsion in 
the Chromium TM instrument (Figure 2.1), where cell lysis and barcoded 
reverse transcription of RNA occurred (Figure 2.2), followed by amplification, 
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fragmentation and 5′ adaptor and sample index attachment (Figure 2.3). 















Figure 2.1 Schematic of 10X Chromium workflow. (a) Cells with reagents 
loaded in one channel of the microfluidic chip combines with Gel beads to form 
Gel beads in EMulsion (GEMs). Reverse transcription (RT) occurs inside the 
GEM, emulsions are lysed, and cDNA is pooled for amplification and library 
construction in bulk. (b) GEM formation. Gel bead containing primers and 
barcoded oligonucleotides are first mixed with cells and reagents and then 
subsequently partitioned into an oil droplet at a microfluidic junction. A successful 
GEM will contain single gel bead attached to one cell inside an oil droplet. (c) 
Composition of Gel beads. Each gel bead contains barcoded oligonucleotides 
containing Illumina adapters, unique 10X cellular barcodes, unique molecular 
identifiers (UMIs) and oligo dTs, required to prime RT of polyadenylated RNAs. 













Figure 2.2 Schematic of reaction workflow inside the GEMs. Captured cells 
inside the GEM lyses, Gel bead dissolves, releasing the oligo primers into the 
aqueous environment. The contents of GEM (lysed cell components, master mix 
reagents, oligos) are incubated in a reverse transcription reaction to generate full-
length, barcoded cDNA from poly A-tailed mRNA transcripts. Primed by barcoded 
Gel bead oligo, reverse transcriptase performs a template switch to a template 














Figure 2.3 Schematic of cDNA library construction. Following RT, the GEMs 
are lysed, pooling single-stranded, barcoded cDNA molecules from every cell. 
cDNA is amplified by bulk PCR, followed by Enzymatic Fragmentation and size 
selection for the optimized generation of the sequencing libraries. During library 
construction Read 2 is added by Adapter ligation. During the Sample Index PCR 
Illumina P5 and P7 sequences, and sample index sequences are added. The 
finished library construct will contain P5, P7, Read 1 and Read 2 sequences for 
Illumina bridge amplification and sequencing, in addition to 10x barcode and UMI 
used during data analysis. Reprinted from 10X Genomics. 
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2.17 Bioinformatics analysis of scRNA-seq data  
 
The analysis described below was carried out in collaboration with Dr. John 
Wilson-Kanamori, post-doctoral bioinformaticist in the Henderson group.  
 
2.17.1 Pre-processing  
FASTQ files, as retrieved from the sequencing facility, were aligned to the 
mm10 (Ensembl 84) mouse reference genome using the Cell Ranger v2.1.0 
Single-Cell Software Suite from 10X Genomics, and cell-containing partitions 
and associated UMIs estimated to create a counts matrix per sample. Genes 
expressed in fewer than three cells in a sample were excluded, as were cells 
that expressed fewer than 300 genes or mitochondrial gene content >10% of 
the total UMI count, prior to merge integration of all samples into one dataset. 
To create normalised expression values, cell counts in the dataset were 
adjusted by dividing the UMI count per gene with the total UMI count in the 
corresponding cell (En), and log-transformed by calculating ln(10
4*En+1). To 
create relative expression values, variation in normalised UMI counts between 
cells was regressed according to a negative binomial model, before scaling 
and centring the result by subtracting the mean expression of each gene and 
dividing by its standard deviation. 
2.17.2 Dimensionality reduction, clustering, and DE analysis  
Unsupervised (SNN graph-based) clustering and differential gene expression 
analyses were performed using the Seurat R package v2.3.075. The SNN 
graph was constructed using between 4 and 16 principal components 
as determined by dataset variability shown in principal components analysis 
(PCA); the resolution parameter to determine the resulting number of clusters 
was also tuned accordingly. 
In total, scRNA-seq data from 4 murine liver samples and 4 murine blood 
samples was analysed and presented here. Initial clustering was performed 
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on all 8 scRNA-seq datasets (2x uninjured liver tissue, 2x uninjured blood, 2x 
APAP liver tissue, 2x APAP blood), with the aim of identifying 1) populations 
of liver-resident and circulating cells and 2) contaminating circulatory cells 
within datasets generated from liver tissue digests, so as to remove them from 
downstream analysis. Upon further clustering followed by signature analysis 
(described below), the post-processed liver-resident dataset was interrogated 
for cell lineages. The mononuclear phagocyte lineage (MP) was isolated and 
re-analysed as above to identify robust lineage subpopulations. At this stage 
clusters expressing more than one unique lineage signature in more than 25% 
of their cells from the dataset were removed as probable doublets. 
All heatmaps, tSNE / UMAP visualisations, violin plots, and dot plots were 
produced using Seurat functions in conjunction with the ggplot2, pheatmap, 
and grid R packages. tSNE / UMAP visualisations were constructed using the 
same number of principal components as the associated clustering. 
Differential gene expression analysis was conducted in Seurat using the 
Wilcoxon rank sum test to assess significance. Genes with a log-fold change 
of at least 0.25 and expression in at least 10% of cells in the cluster under 
comparison were retained and the rest were excluded. Gene ontology 
enrichment analysis was performed on the positive genes which were 
differentially expressed using PANTHER 13.1 (pantherdb.org).  
2.17.3 Defining cell lineage signatures  
For each cell we obtained a signature score across a curated list of known 
marker genes per cell lineage in the liver (Appendix 4). This signature score 
was defined as the geometric mean of the normalised expression of the 
associated signature genes in that cell. Lineage signature scores were scaled 
from 0 to 1 across the dataset, and the score for each cell with signature less 
than a given threshold (the mean of said signature score across the entire 
dataset) was set as 0. 
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2.17.4 Inferring pseudotemporal dynamics 
To generate potential pseudotemporal trajectories, we used the velocyto R 
package v0.6.0 (Manno et al., 2018) to estimate cell velocities from the ratio 
of their spliced and unspliced mRNA content. We generated annotated spliced 
and unspliced reads from the 10X BAM files via the dropEst pipeline, before 
calculating gene-relative velocity using kNN pooling with k=25, fitting gene 
offsets with a gamma fit on the top/bottom 2% expression quantiles and 
determining slope gamma with the full range of cellular expression. We 
visualised the resulting aggregate velocity fields (using Gaussian smoothing 
on a regular grid) on the appropriate visualisation as generated previously. 
2.18 Statistical Analysis  
 
All non-bioinformatics data was analysed using Microsoft Excel for macOS 
(version 16.28) and GraphPad Prism 8 for macOS (version 8.3.0). All the 
graphs are shown as the mean +/- standard error of the mean (SEM) of all the 
individual data from repeated experiments, as indicated in the figure legend. 
Statistical analysis was done using GraphPad Prism 8 for macOS (version 
16.28) as described in the corresponding figures. Significant values: *P≤0.05, 
**P≤0.01, ***P≤0.001, ****P≤0.0001 
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3 Characterisation of leucocyte dynamics 





Acetaminophen (APAP) is an over-the-counter drug that is widely used as an 
analgesic. Overdose of  APAP represents the commonest cause of acute liver 
failure (ALF) in western countries (Bernal and Wendon, 2013). APAP induced 
liver injury (AILI) is a multiphasic process, the initial phase is often described 
as necroinflammatory, where overwhelming hepatocyte necrosis releases 
damage associated molecular patterns (DAMPs), leading to the activation of 
resident non-parenchymal cells (NPCs) (Woolbright and Jaeschke, 2017a). 
The activated NPCs release various proinflammatory and chemotactic 
molecules, which results in rapid infiltration of circulating inflammatory 
leucocytes into the liver, which further propagates inflammation. This is 
followed by the repair phase where the resident and recruited cells promote 
liver regeneration via the resolution of inflammation, hepatocyte proliferation, 
angiogenesis and matrix remodelling (Markose et al., 2018). In ALF patients 
there is a prolonged pro-inflammatory phase which fails to resolve, 
consequently, liver regeneration is severely compromised (Triantafyllou et al., 
2018). Previous studies using murine models of AILI have demonstrated the 
importance of different leucocytes in regulating liver injury and repair following 
AILI (Markose et al., 2018). The majority of the studies focus on monocytes 
and macrophages, because of their capacity to regulate inflammation and 
tissue repair. Their involvement in the clinical setting has also been highlighted 
by many studies, where monocyte and macrophage dysfunction positively 
correlates with poor prognosis in ALF patients (Antoniades et al., 2008; Moore 
et al., 2017). Due to their inherent plasticity where they exhibit a spectrum of 
activation states, influenced by various environmental cues (Guilliams and van 
de Laar, 2015), their therapeutic manipulation has been challenging.  
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In the murine model of AILI, monocytes/macrophages populating the liver can 
be categorized into three distinct subsets: Kupffer cells (KCs), Ly6CHi 
monocytes and Ly6CLo monocyte-derived macrophages (Ly6CLo MDMs)  
(Holt, Cheng and Ju, 2008; Zigmond et al., 2014). In an uninjured liver, KCs 
account for 80% of the hepatic macrophage pool and self-replenish without 
contribution from bone marrow-derived circulating monocytes and their 
progeny (Yona et al., 2013; Gomez Perdiguero et al., 2015). Following APAP 
overdose and hepatic injury circulating Ly6CHi monocytes infiltrate the liver in 
a CCR2/CCL2 dependent manner (You et al., 2013; Mossanen et al., 2016). 
Ly6CHi monocytes dominate the necroinflammatory phase and subsequently 
undergo transcriptional reprogramming towards a pro-reparative phenotype, 
commonly identified through downregulation of Ly6C, hence referred to as 
Ly6CLo MDMs (Ramachandran et al., 2012; Zigmond et al., 2014; Graubardt 
et al., 2017). Another feature of AILI that studies have observed is the 
depletion in KC numbers during the necroinflammatory phase, Zigmond et al. 
(2014) demonstrated their numbers are re-established through local 
proliferation in the repair phase. Most of the work in the field has relied on cell 
surface markers to identify and define these cells via flow cytometry and 
immunohistochemistry. KCs have been defined as: CD68+ F4/80Hi CD11bLo; 
Ly6CHi monocytes as CCR2Hi CX3CR1Lo F4/80Lo CD11bHi Ly6CHi; and Ly6CLo 
MDMs are defined as CCR2Lo CX3CR1Hi F4/80Int/Lo CD11bHi Ly6CLo (You et 
al., 2013; Zigmond et al., 2014; Graubardt et al., 2017; Triantafyllou et al., 
2017). Recently, CLEC4F and TIMD4 have been identified as unique markers 
of resident macrophages, the former is found exclusively on KCs (Beattie et 
al., 2016; Scott et al., 2016).  
 
Despite the distinct differences in immune cell composition and marker 
expression between rodents and humans (Heymann and Tacke, 2016), 
analysis of liver and blood from ALF patients has identified analogous 
monocyte and macrophage subsets with similar activation states, reported in 
murine models of AILI. Both resident macrophages (CD68+) and MDMs 
(MAC387+) are actively involved in the injury and repair process following AILI 
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and can been seen localized around the injury areas (Antoniades et al., 2012; 
Triantafyllou et al., 2017). Existence of  both pro-inflammatory macrophages 
(Mossanen et al., 2016) and pro-reparative macrophages with an 
immunoregulatory phenotype (Triantafyllou et al., 2017) have been identified 
in the livers of ALF patients. In addition to the hepatic immune response, the 
systemic immune response can also influence the outcome for ALF patients 
(Antoniades et al., 2012; Mossanen et al., 2016; Triantafyllou et al., 2018). In 
parallel to marked hepatic monocyte infiltration, ALF patients exhibit significant 
monocytopenia with reduced HLA-DR expression on monocytes, a molecule 
required to carry out antigen presentation functions, critical to innate immunity 
(Antoniades et al., 2006, 2012). They were also shown to have reduced 
inflammatory classical monocytes (CD14++ CD16+) and increased 
immunoregulatory intermediate monocytes (CD14+ CD16+), promoting 
peripheral immunosuppression (Antoniades et al., 2012; Moore et al., 2017). 
These features increase the risk of infections, which is associated with adverse 
clinical outcome (Antoniades et al., 2012; Moore et al., 2017).  
 
Macrophages have also been identified as key players in other models of liver 
injury, both chronic and acute (Selzner et al., 2003; Xu et al., 2007; 
Ramachandran et al., 2012; Campana et al., 2018). Partial hepatectomy (PHx) 
is an example of an acute liver injury model that is commonly used to study 
the mechanisms of liver regeneration. Surgical removal of 70% of the liver 
results in complete regeneration of the remnant lobes within 7-10 days in 
murine subjects (Michalopoulos, 2007).  Although leucocytes have not been 
investigated as extensively in PHx model as they have been in AILI, there are 
some reports of their involvement in liver regeneration following PHx. Both KCs 
and infiltrating macrophages were shown to influence liver regeneration 
following PHx but the methods of distinguishing KCs from infiltrating 
macrophages are not as reliable as the studies focusing on AILI (Selzner et 
al., 2003; Nishiyama et al., 2015). Studying leucocyte responses during liver 
regeneration in different models of liver injury could tell us if macrophages and 
other leucocytes have either an inherent post-injury response to regulate liver 
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regeneration or whether their response is unique to the type of insult. 
Identification of differences and commonalities in leucocyte behavior could be 
key to targeting them in a clinical setting.  
 
There are some conflicting views on whether monocytes/macrophages 
promote or hinder liver regeneration. Some studies report that KCs and 
infiltrating monocytes/macrophages have a pro-inflammatory role that might 
hinder liver regeneration and promote hepatotoxicity (Michael et al., 1999; You 
et al., 2013; Mossanen et al., 2016; Bird et al., 2018; Zhang et al., 2018). 
Whereas other studies highlight the importance of macrophages in promoting 
liver repair and hepatocyte proliferation through enhanced phagocytic 
capabilities (Triantafyllou et al., 2017) and release of mitogenic factors such 
as IL-6, IL-10, IL-4, IL-13 (Bourdi et al., 2002; Ju et al., 2002; Yee et al., 2007; 
Ryan et al., 2012). It has become apparent that these cells are very dynamic, 
exhibiting temporal changes in their function and phenotype. Additionally, 
macrophage phenotype and function can be influenced by other leucocytes 
such as neutrophils (Graubardt et al., 2017; Yang et al., 2019). Therefore, 
studying the temporal changes in macrophages during the different phases of 
AILI, in relation to other leucocytes and hepatocytes can facilitate better 
understanding of these cells and identify specific therapeutic targets 
(Graubardt et al., 2017; Yang et al., 2019).  
 
3.1.1 Aims 
• To characterise the temporal dynamics of liver injury and repair 
following AILI  
• To investigate the hepatic and systemic leucocyte response over the 
course of AILI 
• To numerically and phenotypically characterise monocytes and 
macrophage populations following AILI  
• To identify pro-repair macrophage subsets promoting liver regeneration  
• To compare the similarities and differences in leucocyte responses 
following PHx and AILI 
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3.2 Results  
 
3.2.1 Characterisation of hepatocyte death and proliferation during 
AILI 
 
In experimental models, the extent of the injury and the regenerative process 
that follows AILI can be influenced by multiple factors including the strain of 
mice, the dose and route of APAP administration (Mossanen and Tacke, 
2015). My colleagues in the Henderson lab have previously optimised the dose 
of APAP for mice bred on a C57BL/6 background, which gives a considerable 
degree of liver injury with minimal mortality. Based on this, a regenerative 
murine model of acute liver injury was generated by administration of APAP at 
a dose of 300mg/kg via a single intraperitoneal (i.p) injection.  
  
To fully understand the dynamics of both parenchymal and non-parenchymal 
cells during the different phases of AILI, I performed a time-course experiment 
and obtained liver tissue and blood for further analysis (Figure 3.1a). APAP 
overdose is reported to initiate liver injury, via hepatocyte necrosis (Martin-
Murphy, Holt and Ju, 2010). A comparison between various histology stains of 
the liver showed Periodic Acid Schiff (PAS) to be the optimal stain. The PAS 
stain demonstrates glycogen, as hepatocytes are glycogen rich it can be used 
as an indirect measure of hepatocyte death. The necrotic (lighter staining) area 
is clearly distinct from healthy liver tissue had (stronger staining), facilitating 
quantification of necrosis (Appendix 1). PAS staining showed APAP overdose 
induced centrilobular hepatocyte necrosis (Figure 3.1b). Quantification of 
necrotic area across the whole liver cross-sections demonstrated hepatocyte 
necrosis peaked as early as 6hrs post-APAP induction (Figure 3.1c), around 
45% of the liver lobule is necrotic at this timepoint. The necrotic area 
decreased at a fast rate, with very minimal necrosis from 48hrs onwards 
(Figure 3.1c). Serum was analysed for Alanine transaminase (ALT), Aspartate 
transaminase (AST) and Glutamate dehydrogenase (GLDH) to evaluate the 
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extent of liver damage (McGill, 2016). As these enzymes are found within 
hepatocytes, therefore their elevated levels in the serum indicates hepatocyte 
death and liver injury. Serum ALT and AST peaked at 6hrs post-APAP and 
significantly reduced at 48hrs post-APAP and returned to baseline by 72hrs 
(Figure 3.1d, Figure 3.1e). GLDH levels peaked later on in the time course at 
24hrs in the same animals, and stayed elevated during the repair phase at 
48hrs, 72hrs, therefore GLDH could be used as an indicator of liver injury in 
the later timepoints of AILI (Figure 3.1f).  
 
Having established the peak liver injury timepoints (6hrs-24hrs), I sought to 
characterise the dynamics of liver regeneration following AILI. Hepatocyte 
proliferation was used as an indicator of liver regeneration. In order to assess 
proliferation, mice were given 5-Ethynyl-2’-deoxyuridine (EdU), a nucleoside 
analogue to thymidine, 3 hours prior to harvest. Hepatocyte nuclear factor-4-
alpha (HNF4𝛼) was used as a marker for identifying hepatocytes and 4’,6-
diamindino-2-phenylindole (DAPI), a stain that potently binds to adenine-
thymine region of deoxyribonucleic acid (DNA), was used as a nuclear 
counterstain to identify all cells. EdU+ HNF4𝛼+ DAPI+ cells across whole liver 
cross sections were quantified to asses hepatocyte proliferation. Hepatocytes 
are quiescent under homeostatic conditions, the loss of parenchymal cells 
following APAP overdose promotes the remaining hepatocytes to proliferate 
to replace the dead cells (Figure 3.2a). Hepatocyte proliferation is localised to 
centrilobular regions, the percentage of proliferating hepatocytes at 48hrs and 
72hrs post-APAP are significantly increased (Figure 3.2a, b, n=5-9, two 
independent experiments). Hepatocyte proliferation is still elevated at 120h, 
144h (Figure 3.2b), when necrosis and serum ALT/AST levels have returned 















Figure 3.1 Assessment of liver injury following AILI. (a) Schematic of the 
experimental design to study the temporal dynamics of parenchymal and non-
parenchymal cells following APAP overdose; i.p., intraperitoneal. (b) 
Representative images of Periodic acid-Shiff (PAS) staining of whole liver-cross 
sections. (c) Quantitation of % necrotic area based on PAS staining for control 
(uninjured) and post-APAP animals (Scale bar=100µm). Measurement of serum 
AST (d), ALT (e), GLDH (f) levels for uninjured and post-APAP animals. (c) Data 
acquired from two independent experiments, n=5 per group, One-way ANOVA with 
Dunn’s multiple comparisons test. (d,e,f) Data acquired from two independent 
experiments, n=3-7 per group, One-way ANOVA with Dunn’s multiple comparisons 













3.2.2 Hepatic leucocytes show a dynamic response during AILI 
 
Following the assessment of liver injury and repair, I assessed the broad 
changes in the hepatic leucocyte populations during the different phases of 
AILI. To do this a previously reported NPC enriching liver digestion protocol 
was used (Bain et al., 2016; Lynch et al., 2018). A comprehensive flow 
cytometry panel consisting of lineage specific cell surface markers was 
devised to simultaneously isolate different lineages of leucocytes over the 
course of AILI (Appendix 2). Using the cell surface markers: CD45 and CD31, 
the NPCs were divided into three compartments: leucocytes (CD45+/CD31-), 
endothelial cells (CD45-/CD31+) and other NPCs (CD45-/CD31-) (Figure 3.3a). 
Figure 3.2 Assessment of hepatocyte proliferation following AILI. 
Representative images of immunofluorescence staining of whole liver cross 
sections for DAPI (blue); HNF4a (red) and EdU (green) for uninjured and 48hrs-
post APAP animals (Scale bar=50µm) and quantitation of % of proliferating 
hepatocytes (DAPI+ HNF4a+EdU+) over the time course of AILI and for uninjured 
animals. Data acquired from two independent experiments, n=4-9 per group, One-





Hepatic NPCs such as stellate cells and biliary cells, which are not identified 
through CD45 and CD31 expression may contribute to the “other NPCs” 
fraction. The number of leucocytes and “other NPCs” are both greatly elevated 
in both the injury and repair phase (from 6hrs to 120h), whereas endothelial 
cells decreased following APAP overdose at 12hrs, followed by an increase at 
72hrs (Figure 3.3b).  
Using cell surface markers shown in Appendix 2 I was able to identify and 
characterize majority of the leucocytes in uninjured and post-APAP livers. As 
this was done within one panel, it allowed me to see the dynamic changes in 
all the main leucocyte subsets throughout the course of AILI. The relatively 
small numbers of cells, termed “others” might account for basophils, mast cells 
and innate lymphoid cells (Figure 3.3c; see gating strategy in Appendix 2). 
Once the cells were annotated, I investigated how AILI affected the leucocyte 
numbers throughout the time course (n=5-10, from two independent 
experiments). Assessing the hepatic leucocyte composition, demonstrated 
that macrophages, T cells and B cells make up majority of the immune cells in 
an uninjured liver (Figure 3.3c). Following injury, a significant increase in 
neutrophil, macrophage and eosinophil numbers were observed (Figure 3.3c). 
APAP induced expansion of neutrophils in the liver at 6, 12 and 24hrs, followed 
by their decline from 48hrs onwards (Figure 3.4). A similar increase is seen 
with macrophages at 12hrs, however unlike neutrophils they stay elevated 
during the later timepoints (Figure 3.3c, 3.4). Expansion of eosinophils 
occurred much later at 72hrs-post APAP, which also marks peak hepatocyte 
proliferation (Figure 3.2, 3.4). There were no significant changes in the 
numbers of T cells, B cells, NK cells, conventional dendritic cells (cDCs) or 
plasmacytoid dendritic cells (pDCs) (Figure 3.4). This experiment highlighted 
that the temporal dynamics of different leucocytes varied during AILI and 
importantly, macrophages represented the most expanded subset of hepatic 
leucocytes during the inflammatory phase and the repair phase during AILI 












Figure 3.3 Flow cytometric characterization of the temporal dynamics of 
hepatic non-parenchymal cells following AILI. (a) Gating strategy used for the 
identification of leucocytes, endothelial cells and other hepatic non-parenchymal 
cells, based on CD45 and CD31 cell surface expression. (b) Changes in the 
absolute number of leucocytes, endothelial cells and other non-parenchymal cells 
in the liver during AILI. (c) Proportional changes in the hepatic leucocyte 
compartment during AILI. Data acquired from three independent experiments, 













3.2.3 Ly6CLo MDMs represents the most expanded macrophage subset 
in the liver during maximal liver regeneration  
 
Following a broad characterisation of all leucocytes during AILI, I focused 
specifically on monocytes and macrophages. A series of experiments were 
performed to characterize macrophage topography and phenotype. 
Immunofluorescent staining for F4/80, a cell surface glycoprotein commonly 
used as a murine pan-macrophage marker, showed that under homeostatic 
conditions macrophages are distributed throughout the liver parenchyma. 
However, at 48hrs post-APAP there is a population of F4/80+ DAPI+ cells 
localised around centrilobular areas of hepatic injury and repair (Figure 3.5a). 
EdU staining also demonstrated that under steady state conditions 
macrophages did not proliferate however, at 48hrs post-APAP EdU+ F4/80+ 
cells were seen around the centrilobular areas, indicating that these cells 
proliferate specifically in the areas of injury and repair (Figure 3.5a).  
 
As previously discussed, macrophages involved in AILI are broadly 
categorised into three different subsets: Kupffer cells (KCs), infiltrating 
monocytes and monocyte-derived macrophages (MDMs). Previous studies 
have utilised transgenic reporter mice (CCR2RFP and CX3CR1GFP mice) to 
assess the contribution of infiltrating monocytes/macrophages in AILI. My aim 
here was to see how these cells changed in a wild type C57BL/6 mouse. In 
order to do this, I used F4/80 and CD11b (an integrin, used as a murine pan-
monocyte/macrophage marker) to isolate macrophages by flow cytometry. 
Following this, TIMD4, a phosphatidylserine receptor which has been reported 
to exclusively mark resident macrophages, was used to identify KCs (Scott et 
Figure 3.4 Changes in leucocyte numbers over the course of AILI. Flow 
cytometric identification and quantitation of changes in the number of different 
types of hepatic leucocytes during stated timepoints following AILI. Data acquired 
from three independent experiments, n=5-10 per group, One-way ANOVA with 
Dunn’s multiple comparisons test. All data shown as Mean±S.E.M. 





al., 2016). Ly6C expression was used to define the infiltrating cells  as Ly6CHi 
monocytes (F4/80Lo CD11bHi TIMD4-) and Ly6CLo MDMs (F4/80Hi CD11bInt 
TIMD4- ) (Ramachandran et al., 2012; Scott et al., 2016) (Figure 3.5b).   
 
There are dynamic changes in the three subsets of monocytes/macrophages. 
Uninjured liver is composed predominantly of KCs (F4/80Hi CD11bLo TIMD4+), 
following injury KC numbers significantly decreased (Figure 3.5c, d). Previous 
studies have reported significant reduction in KCs at 24hrs post-APAP via flow 
cytometry (Zigmond et al., 2014), here it occurs as early as 6 h post APAP 
induction and their numbers were re-established at 72hrs and then 
subsequently peaked at 144hrs (Figure 3.5d). To confirm the KC 
disappearance seen by flow cytometry I performed immunohistochemistry 
staining for TIMD4 and CLEC4F (a KC specific C-type lectin receptor) in both 
uninjured and 48hrs post-APAP livers (Scott et al., 2016).  Interestingly, there 
was no reduction in KCs (TIMD4+ CLECF4+ DAPI+ cells) at 48hrs, as seen 
with flow cytometry. Quantification of KCs (TIMD4+ CLEC4F+ DAPI+ cells) 
within a liver cross-section of a whole lobule revealed KCs are significantly 
increased at 48hrs compared to uninjured livers (Figure 3.6). There were also 
topographical differences, where a proportion of KCs in post-APAP liver were 
localised to centrilobular region, whereas in the uninjured liver they are 
distributed throughout the parenchyma with no obvious zonation (Figure 3.6).  
 
Infiltration of circulating monocytes is a characteristic feature of liver injury, 
here infiltration of Ly6CHi monocytes can be seen as early as 12hrs post-APAP 
and they continued to expand between 12-24hrs, which marks the 
necroinflammatory phase of AILI. After 24hrs there is a reduction in Ly6CHi 
monocytes, in parallel the number of hepatic Ly6CLo MDMs increased (Figure 
3.5). Based on flow cytometric analysis Ly6CLo MDMs represent the 
predominant macrophage subset in the liver during maximal regeneration 
(48hrs-72hrs) and their numbers returned back to near baseline at 144h 
(Figure 3.5). Recent reports shows that neutrophils, Ly6CHi monocytes and 
Ly6CLo MDMs, spatially and temporally coincide at distinct phases of AILI and 
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an interplay between these cells can regulate neutrophil apoptosis and 
polarisation of Ly6CHi monocytes and Ly6CLo MDMs (Graubardt et al., 2017; 
Yang et al., 2019). I investigated the dynamics of these cells and found that 
neutrophil numbers declined from 12hrs onwards, when the Ly6CHi monocytes 
peaked in the liver, followed by a significant decline of both Ly6CHi monocytes 
and Neutrophils which was paralleled by an increase in Ly6CLo MDMs (Figure 
3.5g). This would fit with the existing data that Ly6CHi monocytes promote 
neutrophil apoptosis, and neutrophils in turn can mediate phenotypic 
conversion of Ly6CHi monocytes to Ly6CLo MDMs (Graubardt et al., 2017; 
Yang et al., 2019). Contrary to the observation made by Graubardt et al, 
(2017), in which neutrophil numbers were still elevated in the liver at 48hrs, 
and then subsequently declined at 72hrs, here, their decline occurred at an 
earlier timepoint (24hrs) (Figure 3.5g). This discrepancy may be due to the 
differences in the strain of mice used and the gating strategy followed to isolate 





























Figure 3.5 Analysis of the different subsets of macrophages during AILI. (a) 
Representative Immunofluorescence micrograph of uninjured and 48hrs-post 
APAP livers, staining of F4/80 (green), DAPI (blue) and EdU (Red) indicates that 
macrophages localize and expand around areas of injury during the regenerative 
phase (48hrs) (Scale bar=50µm, white arrows indicate F4/80+ EdU+ DAPI+ 
cells). (b) Gating strategy for the identification of resident and infiltrating 
macrophages via flow cytometry. (c) Temporal dynamics of KCs, Ly6CHi 
monocytes and Ly6CLo MDMs during AILI. Absolute changes in KCs (d), Ly6CHi 
monocytes (e) and Ly6CLo MDMs (f) numbers quantified via flow cytometry at 
stated timepoints following APAP overdose. (g) Temporal dynamics of Ly6CHi 
monocytes and Ly6CLo MDMs and Neutrophils during AILI. Data acquired from 
three independent experiments, n=5-10 per group, One-way ANOVA with Dunn’s 
multiple comparisons test. Data shown as Mean±S.E.M, * P≤0.05, **P≤0.01, 
***P≤0.001, ****P≤0.0001.   
 
 
Figure 3.6 Kupffer cells following AILI do not disappear but localize to 
centrilobular areas of injury and repair. (a) Representative 
Immunofluorescence micrograph of uninjured and 48hrs-post APAP livers, shows 
the topographical changes in KCs identified via staining of TIMD4 (green), 
CLEC4F (red) and DAPI (blue) (Scale bar=50µm). (b) Quantitation of TIMD4+ 
CLEC4F+ DAPI+ cells across the whole liver lobule cross-section, identified 
through immunofluorescence. Data acquired from two independent experiments, 
n=5-7 per group. Mann-Whitney, nonparametric t-Test. Data shown as 







Figure 3.3 Flow cytometric characterization of the temporal dynamics of 
hepatic non-parenchymal cells following AILI. (a) Gating strategy for 
identification of leucocytes, endothelial cells and other hepatic non-parenchymal 
cells, based on CD45 and CD31 cell surface expression. (b) Changes in the 
absolute number of leucocytes, endothelial cells and other non-parenchymal cells 
in the liver during AILI. (c) Proportional changes in the hepatic leucocyte 
compartment during AILI. Data shown as Mean±S.E.M.  
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3.2.4 Injury specific phenotypic changes indicate heterogeneity within 
the macrophage subsets during AILI 
KCs, Ly6CHi monocytes and Ly6CLo MDMs were further analysed for their 
expression of a major histocompatibility complex class II (MHCII), a molecule 
required to process and present antigens, and CD11c, an integrin with a role 
in antigen uptake and activation. MHCII and CD11c are commonly used to 
define dendritic cells (DCs) but also reported to be on macrophages during 
inflammation (Yu et al., 2016). Plasmacytoid DCs and conventional DCs were 
removed from this analysis on the basis of B220 and CD11c expression and 
lack of F4/80 expression (Appendix 2). Focussing on KCs, in an uninjured liver 
majority are MHCII+/CD11c- or MHCII-/CD11c-, a relatively small proportion 
of KCs are MHCII+/CD11c+. Following injury MHCII expression is 
downregulated, at 48hrs most of the KCs are MHCII-/CD11c- and by 144hrs 
the expression of MHCII and CD11c on KCs were comparable to uninjured 
setting (Figure 3.7a).  
There are minimal phenotypic changes in the Ly6CHi monocytes, almost all of 
them are MHCII-/CD11c-, suggesting these cells are immature (Figure 3.7b). 
On the other hand, Ly6CLo MDMs undergo major phenotypic changes 
following AILI. Varying expression of MHCII and CD11c in Ly6CLo MDMs 
revealed a high degree of heterogeneity within these cells. On the basis of 
MHCII and CD11c, in an uninjured liver Ly6CLo MDMs can defined as three 
main subsets: MHCII-/CD11c-, MHCII+/CD11c- and lastly, MHCII+/CD11c+, 
which represents the most dominant subset (figure 3.7c). Following injury both 
MHCII-/CD11c- and MHCII+/CD11c+ subsets expand and most critically there 
is an emergence of a fourth subset of cells, which are MHCII-/CD11c+. These 
three subsets expand considerably at 48hrs and 72hrs, during maximal liver 
regeneration (Figure 3.7c). These phenotypic changes appeared to be 
transient, the expression of MHCII and CD11c on the Ly6CLo MDMs at 144hrs 







Figure 3.7 Injury specific phenotypic changes in macrophages following 
AILI. Phenotypic characterization of KCs (a), Ly6CHi Monocytes (b) and Ly6CLo 
MDMs (c) based on the expression of MHCII and CD11c via flow cytometry. Data 








Figure 3.3 Flow cytometric characterization of the temporal dynamics of 
hepatic non-parenchymal cells following AILI. (a) Gating strategy for 
identification of leucocytes, endothelial cells and other hepatic non-parenchymal 
cells, based on CD45 and CD31 cell surface expression. (b) Changes in the 
absolute number of leucocytes, endothelial cells and other non-parenchymal cells 
in the liver during AILI. (c) Proportional changes in the hepatic leucocyte 
compartment during AILI. Data shown as Mean±S.E.M.  
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3.2.5 Systemic changes following AILI 
 
AILI induces dynamic changes in the hepatic leucocyte populations, there is a 
dramatic increase in the number of non-resident cells, especially in the 
monocyte/macrophage compartment (Figure 3.3, 3.5).  I was interested in 
investigating whether these changes are also reflected in the systemic 
leucocyte compartment. In order to do this, blood from uninjured and injured 
mice at specific timepoints following APAP overdose was obtained and 
circulating leucocytes were immunophenotyped via flow cytometry (n=3-5; See 
appendix 3 for gating strategy).  
 
Circulating Neutrophils (Ly6G+ CD11b+) were significantly elevated at 6hrs-
post APAP (Figure 3.8), corresponding to their increase in the liver at the same 
timepoint (Figure 3.4). Their relative numbers stayed elevated until 48hrs and 
then decreased to basal levels. Circulating monocytes on the other hand 
(CD11b+ CD115+) increased significantly at 12hrs following AILI (Figure 3.8), 
in parallel with their increase in the liver (Figure 3.4). NK cells proportionally 
decreased at 6 and 12hrs, however this was not significant. The percentage 
of B cells and T cells decreased at 12h before increasing at 72h, however this 
changed was not significant (Figure 3.8).  
 
Three phenotypically distinct circulating murine monocyte subsets have been 
identified: Ly6CHi monocytes (CD14Hi CD16- in humans), Ly6CInt monocytes 
(CD14Int CD16+ in humans) and Ly6CLo monocytes (CD14Lo CD16+ in 
humans) (Mildner et al., 2017; Patel et al., 2017; Guilliams, Mildner and Yona, 
2018). Numerical and phenotypical changes in these subsets have been 
associated with patient prognosis following APAP-induced ALF (Antoniades et 
al., 2006, 2012; Abeles et al., 2012; Moore et al., 2017). Currently there is no 
data on how these cells respond during specific phases of AILI in mice, 
therefore, I investigated the changes in these subsets in mouse blood following 
AILI.  Monocytes (CD115+ CD11b+) were identified as circulating 
mononuclear cells, and then subdivided on their expression of Ly6C and 
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CD11c, I subdivided the circulating monocytes into Ly6CHi, Ly6CInt and Ly6CLo 
(Mildner et al., 2017) (Figure 3.9a). During the necroinflammatory phase (6hrs-
12hrs) the percentage of circulating Ly6CHi monocytes and Ly6CInt monocytes 
increased significantly (Figure 3.9b 3.9c), this coincides with the increased 
influx of Ly6CHi monocytes into liver (Figure 3.5e). Ly6CHi monocytes are 
precursors of Ly6CLo monocytes in blood, their rapid infiltration into the liver 
could explain the decline in circulating Ly6CLo monocytes (Figure 3.9c). 
Previous studies have associated reduced expression of HLA-DR, a major 
histocompatibility complex class II (MHCII) receptor on monocytes with ALF 
disease severity (Antoniades et al., 2006, 2012; Abeles et al., 2012; Moore et 
al., 2017). Therefore, I was interested to see if there were any changes in the 
expression of MHCII on circulating monocytes in the murine model of AILI. AILI 
induced upregulation of MHCII on Ly6CInt monocytes but not Ly6CHi and 
Ly6CLo monocytes (Figure 3.9d). Further studies are required to increase the 











Figure 3.8 Changes in the circulating leucocytes following AILI. The number 
of circulating monocytes, neutrophils, NK cells, eosinophils, B cells and T cells at 
stated timepoints following AILI. Data acquired from a single experiment, n=3-4 
per group. One-way ANOVA with Dunn’s multiple comparisons test. Data shown 














Figure 3.9 Changes in the circulating monocyte numbers and phenotype 
following AILI. (a) Gating strategy used to identify Ly6CHi, Ly6CInt and Ly6CLo 
monocytes from murine blood following AILI. Representative flow cytometry plots 
(b) and quantitation of the percentage of monocyte subsets (c) at specific 
timepoints following APAP overdose, compared to uninjured animals. (d) 
Expression of MHCII on Ly6CHi, Ly6CInt and Ly6CLo monocytes at stated time 
points following APAP induction, compared to uninjured group. Data acquired from 
a single experiment, n=3-5 per group. One-way ANOVA with Dunn’s multiple 
comparisons test. Data shown as Mean±S.E.M.* P≤0.05, **P≤0.01.  
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3.2.6 Leucocyte dynamics following partial hepatectomy  
 
Partial hepatectomy (PHx) is a commonly used surgical model of liver 
regeneration. In comparison to AILI, leucocytes in the context of PHx have not 
been extensively characterized. Past studies have focused on specific 
leucocytes such as macrophages and T cells to show they promote liver 
regeneration following PHx (Tumanov et al., 2009; Nishiyama et al., 2015) 
however, the broad leucocyte response following PHx has not been previously 
studied. Thus, I investigated the hepatic and systemic leucocyte composition 
following PHx and compared it to AILI and uninjured conditions.  
 
Here, wildtype C57BL/6 mice underwent 70% PHx (see methods for more 
details), liver and blood were obtained from these mice and leucocytes were 
immunophenotyped using flow cytometry. Previous studies from the 
Henderson lab performed by Dr. Kylie Conroy showed that 48hrs represents 
peak hepatocyte proliferation following PHx in C57BL/6 mice, therefore, all 
immunophenotyping of leucocytes following PHx were done at this time point. 
In order to account of technical variability and reliably compare any changes 
between PHx and AILI, livers from 48hrs post-APAP were analysed alongside 
uninjured livers.  
 
Using the same surface markers and gating strategy shown in Appendix 2, 
hepatic leucocytes were identified via flow cytometry and their numbers were 
quantified. Leucocyte numbers changed minimally following 70% PHx, during 
peak liver regeneration, the relative proportion of leucocytes in PHx group 
were similar to uninjured conditions (Figure 3.10a). The most significant 
changes were observed with the number of pDCs, which increased post-PHx 
compared to AILI and Uninjured livers. Although there is a slight expansion in 
B cells, NK cells, neutrophils, macrophages and cDCs there changes were not 
significant (Figure 3.10b). To see if there are any changes within the 
macrophage subsets, KCs (TIMD4+ F4/80Hi CD11bLo), Ly6CHi monocytes 
(F4/80Lo CD11bHi Ly6CHi) and Ly6CLo MDMs (F4/80Int/Lo CD11bHi Ly6CLo) were 
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identified. The macrophage compartment in PHx was comparable to uninjured 
livers, the changes are not as significant as seen post-APAP (Figure 3.11). 
Flow cytometric characterisation of circulating leucocytes (See appendix 3 for 
gating strategy) following PHx showed that the proportion of systemic 
leucocytes post-PHx were comparable to basal levels, whereas post-APAP 
the neutrophil and monocytes numbers are increased and lymphocyte (T cells 










Figure 3.10 Comparison of changes in hepatic leucocyte responses 
following PHx and AILI. (a) Proportional changes in the absolute number of 
hepatic leucocytes following 48hrs post- PHx and AILI compared to uninjured 
animals. (b) Quantitation of different types of leucocytes following 48hrs post-PHx 
and AILI compared to uninjured animals. Data acquired from a single experiment, 
n=4-8 per group. One-way ANOVA with Dunn’s multiple comparisons test. Data 











Figure 3.11 Comparison of changes in hepatic macrophage responses 
following PHx and AILI. Quantitation of KCs, Ly6CHi monocytes and Ly6CLo 
MDMs following 48hrs post-PHx and AILI compared to uninjured animals. 
Data acquired from four independent experiments, n=10 per group. One-way 
ANOVA with Dunn’s multiple comparisons test. Data shown as Mean±S.E.M. * 

















In this chapter I have extensively characterised the temporal dynamics of 
parenchymal and non-parenchymal cells (NPCs) during AILI. Based on 
detection of liver enzymes (ALT, AST, GLDH) in the serum and necrosis 
quantitation, I established that liver injury peaks between 6-24hrs (Figure 3.1). 
Previous studies have relied on cell cycle markers and cell size to detect 
proliferating hepatocytes (Singhal, Ganey and Roth, 2012; Bird et al., 2018), 
here I used HNF4a, as a positive marker for hepatocytes, in conjunction with 
EdU to demonstrate peak regeneration occurs between 48-72hrs post-APAP 
(Figure 3.2).  
 
Previous studies looking at the leucocyte response during AILI have either 
focused on specific lineages or partitioned the immune response into innate 
and adaptive (You et al., 2013; Zigmond et al., 2014; Graubardt et al., 2017; 
Yang et al., 2019). Here, I wanted to get a global picture of the leucocyte 
response in the liver during AILI. Using a comprehensive flow cytometry panel, 
I managed to isolate almost all immune cell types in the liver (Appendix 2, 
Figure 3.3). The “others” group represents cells which were unidentified, 
however their numbers are relatively low and based on the literature they could 
be mast cells, basophils and innate lymphoid cells, further analysis using 
appropriate markers is needed to confirm this. Leucocytes show a dynamic 
response following APAP overdose, different lineages expanding at specific 
timepoints during AILI.  
 
Figure 3.12 Comparison of changes in systemic leucocyte response 
following PHx and AILI. (a) Proportional changes in the % of leucocytes (CD45+ 
cells) following 48hrs post- PHx and AILI compared to uninjured animals. (b) 
Quantitation of different types of circulating leucocytes following 48hrs post-PHx 
and AILI compared to uninjured animals. Data acquired from single experiment, 
n=3-4 per group. One-way ANOVA with Dunn’s multiple comparisons test. Data 





Figure 3.3 Flow cytometric characterization of the temporal dynamics of 
hepatic non-parenchymal cells following AILI. (a) Gating strategy for
identification of leucocytes, endothelial cells and other hepatic non-parenchymal 
cells, based on CD45 and CD31 cell surface expression. (b) Changes in the 
absolute number of leucocytes, endothelial cells and other non-parenchymal cells 
in the liver during AILI. (c) Proportional changes in the hepatic leucocyte 
compartment during AILI. Dat  shown as Mean±S.E.M.  
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Neutrophils represent the first responders following injury, their numbers are 
elevated both in the blood and liver during the injury/inflammatory phase (6hrs-
24hrs) (Figure 3.4). Neutrophils are professional phagocytes responsible for 
clearance of necrotic debris, however, they also promote inflammation 
therefore their appropriate clearance is required for the resolution of 
inflammation and initiation of the repair process (Graubardt et al., 2017). In line 
with this, neutrophil numbers decline from 24hrs onwards (Figure 3.4). A 
caveat to looking at broad leucocyte responses is that you lose resolution 
within lineages. For instance, there is a huge variation in T cells especially 
during the repair phase (48-72hrs), probably due to distinct T cells (CD4+, 
CD8+, TREG cells) behaving differently. Additional markers are required to 
confirm if there are any significant changes within T cell subsets (Wang et al., 
2015). Elevation in eosinophils coincides with peak hepatocyte proliferation, 
eosinophil derived IL4 has been to promote liver regeneration following acute 
liver injury (Goh et al., 2013), implying a similar role here. Interestingly, 
although liver architecture at 144hrs is comparable to uninjured conditions 
(Figure 3.1b, c) hepatocyte proliferation and leucocyte numbers are still above 
basal levels (Figure 3.2, 3.3c), suggesting that homeostasis is not completely 
restored at this timepoint and immune cell response is long lasting. The most 
striking finding was that macrophages represented the most expanded 
immune cell type in the liver during the repair phase (Figure 3.4).  
 
AILI induced dynamic changes in macrophage numbers, phenotype and 
location (Figure 3.5, Figure 3.6, Figure 3.7). Using F4/80, CD11b, TIMD4 and 
Ly6C I was able to identify KCs, Ly6CHi monocytes and Ly6CLo MDMs (Figure 
3.5c) (Zigmond et al., 2014). Flow cytometric analysis demonstrated that 
uninjured liver is composed predominantly of KCs (F4/80Hi CD11bLo TIMD4+) 
however following APAP induction KC numbers are depleted (Figure 3.5c, d). 
Depletion of tissue resident macrophages following inflammatory stimuli has 
been widely reported, both in the context of liver injury (Ramachandran et al., 
2012; Zigmond et al., 2014; Blériot et al., 2015; Ju and Tacke, 2016) and also 
in other tissues such as the peritoneum (Cassado, D’Império Lima and 
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Bortoluci, 2015). Zigmond et al., 2014 showed KCs number are depleted at 
24hrs post-APAP, followed by their self-replenishment at 72hrs. The flow 
cytometry experiments here are in agreement with this observation (Figure 
3.5c, d). Interestingly, the immunofluorescence staining data at 48hrs post-
APAP suggests that “KC disappearance reaction” is a technical artefact, 
resulting from a failure to liberate these cells from the liver tissue. TIMD4+ 
CLEC4F+ cells (KCs) were seen in the tissue at 48hrs post-APAP, furthermore 
their numbers increase significantly post-injury when compared to basal 
conditions (Figure 3.6a, b). KCs are sessile cells, found within the sinusoids, 
following APAP there is a subset of KCs localised around the central vein, 
where you would expect hepatocyte necrosis and proliferation (Figure 3.1, 3.2, 
3.6). This data suggests that there is a subpopulation of KCs which migrate 
towards areas of injury. A very recent study has suggested “macrophage 
disappearance reaction” during peritonitis is a result of coagulation (Zhang et 
al., 2019). Flow cytometric analysis showed administration of heparin to mice 
with peritonitis liberated significantly more tissue resident macrophages 
(TRMs), whilst the no heparin group with peritonitis had reduced number of 
TRMs. Through intravital imaging the authors revealed following bacteria 
induced inflammation peritoneal macrophages were more adherent and 
formed clots to combat bacterial load more effectively and this was mediated 
by coagulation factor V (Zhang et al., 2019). It would be interesting to see if 
heparin administration can liberate more KCs at 48hrs-post APAP.  
 
As discussed previously, depletion studies show that KCs are crucial in liver 
repair post-APAP (Ju et al., 2002), however, their precise role in promoting this 
remains to be investigated. Microarray data reports that KCs from 72hrs post-
APAP livers have a similar transcriptional profile to KCs from uninjured livers 
(Zigmond et al., 2014), however this is not to say they might have functional 
differences. Analysis of MHCII and CD11c expression on KCs following APAP 
overdose demonstrated downregulation of MHCII on KCs, suggesting a switch 
towards a more immature phenotype. Tissue resident macrophages in the 
kidney downregulate MHCII following acute injury, a phenotypic switch to be 
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akin to that seen on developmental macrophages, and the authors postulated 
that this downregulation might serve as immunoregulatory mechanism to 
prevent chronic inflammation (Lever et al., 2019). A similar functionally 
important switch might be happening here. It is also important to note that from 
6hrs-48hrs we are only liberating a fraction of KCs populating the liver during 
AILI. Therefore, future experiments which focus on optimisation of digestion 
protocols facilitating their liberation from the liver is necessary in dissecting 
their role during AILI. Intravital imaging (IVM) studies of the liver following AILI 
and other forms of sterile injury has revealed dynamic role of leucocytes such 
as neutrophils and macrophages (Marques et al., 2015; Liew, Lee and Kubes, 
2017). Given the current challenges associated with relying on flow cytometry 
to study KCs during AILI, future studies should use IVM to visualize KCs in 
vivo. Either using injectable fluorescently conjugated antibodies to TIMD4 and 
CLEC4F or using a KC reporter mice (Scott et al., 2016) will allow KC labelling 
in vivo. However, currently there is no evidence to suggest that TIMD4 and 
CLEC4F exclusivity to KCs is maintained during injury and inflammation (Scott 
et al., 2016). Although unlikely, considering their inherent plasticity infiltrating 
macrophages could gain expression of these markers. An inducible cre/lox 
system based on either TIMD4 or CLEC4F is required to faithfully lineage trace 
KCs during AILI.  
 
Previous studies have demonstrated a key role for bone marrow derived 
monocytes and their progeny in regulating liver injury and repair during AILI. 
Authors have used transgenic mouse models to show infiltration of CCR2+ 
monocytes into the liver during the inflammatory phase and their differentiation 
into CCR2Lo CX3CR1Hi  macrophages during the resolution phase (You et al., 
2013; Zigmond et al., 2014; Mossanen et al., 2016; Graubardt et al., 2017). To 
study their dynamics in a wild type mouse I relied on differential expression of 
Ly6C, in combination with standard markers F4/80 and CD11b.  CCR2Hi 
monocytes were defined as: F4/80Lo CD11bHi TIMD4- Ly6CHi and the 
CX3CR1Hi monocyte derived macrophages were defined as F4/80Lo CD11bHi 
TIMD4- Ly6CLo.  
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In parallel with neutrophil infiltration into the liver, APAP induced significant 
increase in Ly6CHi monocytes (Figure 3.5c,e), infiltration of circulating Ly6CHi 
monocytes into the liver is a characteristic feature of liver injury and 
inflammation (Tacke and Zimmermann, 2014). Ly6CHi monocytes and 
neutrophils are the most dominant leucocytes in the liver during the 
inflammatory phase. These cells have the capacity to promote injury and 
inflammation during  AILI, but also facilitate the repair process (You et al., 
2013; Zigmond et al., 2014; Mossanen et al., 2016; Graubardt et al., 2017; 
Yang et al., 2019). Ly6CHi monocytes have a role in regulating neutrophil 
function and clearance to promote the generation of pro-reparative Ly6CLo 
MDMs (Graubardt et al., 2017). The temporal dynamics between these cells 
were also demonstrated here (Figure 3.5g). Notably, Ly6CLo MDMs are the 
principle macrophage subset in the liver during the regenerative phase (Figure 
3.5c, f) and phenotypical characterisation of Ly6CLo MDMs macrophages 
using antigen presenting markers: MHCII and CD11c suggests these broadly 
classified cells are more heterogenous than we currently appreciate (Figure 
3.6c). At 48 and 72hrs post-APAP (maximal liver repair), three distinct subsets 
of Ly6CLo MDMs (MHCII- CD11c-, MHCII- CD11c+ and MHCII+ CD11c+) 
expanded, a more detailed analysis of macrophages at a higher resolution will 
aid in dissecting this heterogeneity (Figure 3.6c).  
 
It is widely accepted that circulating Ly6CHi monocytes are the main 
responders following tissue injury (Ramachandran et al., 2012; Zigmond et al., 
2014). However, Ly6CLo monocytes are also capable of rapidly infiltrating into 
damaged tissues and have been shown to differentiate into macrophages with 
tissue repair and remodeling properties (Auffray, Sieweke and Geissmann, 
2009). The data presented in this chapter shows that AILI leads to significant 
changes in systemic leucocyte composition. Circulating Ly6CHi monocytes are 
increased at 12hrs, coinciding with their accumulation in the liver (Figure 3.9c). 
Suggesting that during AILI, Ly6CHi monocytes have a more prominent role. 
Transcriptional profiling of circulating monocytes have shown that Ly6CInt 
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monocytes are more heterogenous than Ly6CHi and Ly6CLo monocytes 
(Mildner et al., 2017). The varying levels of MHCII expression on these cells 
and their proportional increase following injury, suggests that they might also 
be functionally more heterogenous during AILI (Figure 3.9d). These 
observations demonstrate that APAP induces numerical and phenotypical 
changes in the circulating monocyte subsets. Whether circulating monocytes 
during AILI have a dichotomous differentiation potential and function remains 
unknown. Studying the transcriptome of these cells during AILI may give us 
more insight into the functional relevance of these changes. Other significant 
changes included an increase in circulating neutrophils and reduction in 
lymphocytes, especially T cells, during the inflammatory phase (12hrs), which 
returned back to baseline levels during the repair phase (Figure 3.8). 
Neutrophilia and lymphocytopenia are both clinical features often observed in 
patients suffering from APAP poisoning, when they are initially admitted to the 
hospital, which resolves back to normal once they recover from the liver injury 
(Moore et al., 2017).  
 
Hepatic and systemic leucocyte numbers between PHx and AILI indicated 
leucocyte composition at 48hrs-post PHx was comparable to uninjured livers. 
Unlike AILI, there was a lack of involvement from inflammatory cells such as 
neutrophils and Ly6CHi monocytes (Figures 3.10 and 3.12). Perhaps this is 
unsurprising given the “clean” nature of the injury which induces regeneration 
in the remnant lobes, without any necrotic materials, DAMPs and other signals 
required to initiate an inflammatory response (Michalopoulos, 2007; Martin-
Murphy, Holt and Ju, 2010). Nevertheless, given the role for macrophages in 
regulating liver regeneration following PHx (Selzner et al., 2003; Nishiyama et 
al., 2015; Wyler et al., 2016), I expected macrophages to change numerically. 
To my surprise there were no significant changes in both KCs and infiltrating 
macrophages (Figure 3.11). I cannot ignore that dynamics of liver regeneration 
following PHx might vary in comparison to AILI. Therefore, analysis of a single 
timepoint may be insufficient and time course experiments are needed before 
drawing any conclusions. We know that KC-derived IL-6 and TNF-a promotes 
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hepatocyte proliferation following PHx and depletion studies have indicated 
that both KCs and infiltrating macrophages are necessary for hepatocyte 
proliferation following PHx, therefore phenotypic and functional differences in 
these cells are likely to drive liver regeneration (Selzner et al., 2003; Nishiyama 
et al., 2015; Wyler et al., 2016). The number of hepatic pDCs increased 
significantly following PHx, compared to uninjured and APAP groups (Figure 
3.10). A pro-regenerative role for DCs following PHx has been highlighted, but 
the authors did not delineate pDCs from cDCs, to pinpoint the key player 
(Castellaneta et al., 2006).  
 
Overall, this body of work enabled me to see the global changes in the 
parenchymal and leucocyte compartments over the course of AILI. I have 
characterised liver injury and repair process following AILI to pinpoint 6-24hrs 
as the necroinflammatory phase, 48hrs-144hrs as the repair phase, in which 
42hrs and 72hrs represent timepoints where hepatocyte proliferation is the 
most significant. Some of the findings here are in concordance with the existing 
literature such as dynamics seen between neutrophils, Ly6CHi monocytes and 
Ly6CLo MDMs. Importantly, I have also embarked upon novel observations, 
which warrants further study. Namely the dynamic changes in the KCs at 
48hrs-post APAP and the phenotypic heterogeneity within the Ly6CLo MDMs 





4 Single cell sequencing of mononuclear 





Gene expression changes occurring following AILI have been studied using 
microarray and bulk RNA sequencing techniques and distinct gene expression 
profiles for monocytes/macrophages have been identified, facilitating their 
delineation into three main subtypes: Kupffer cells (KCs), Ly6CHi monocytes, 
Ly6CLo monocytes derived macrophages (MDMs) (Togo et al., 2004; Zigmond 
et al., 2014; Mossanen et al., 2016; Graubardt et al., 2017). However, there is 
considerable evidence to suggest functional heterogeneity within these 
broadly classified subsets, especially Ly6CLo MDMs, during liver regeneration 
following AILI (Chapter 3).  
 
The transcriptional profiling of single immune cells can facilitate the 
identification of subtle but crucial heterogeneity within cell populations, which 
would be masked in population-averaged measurements generated through 
bulk-RNA sequencing or microarrays. Single-cell mRNA sequencing (scRNA-
seq) is a powerful tool to systematically dissect heterogeneity within these cells 
types and characterize the transcriptome of individual cells. It has been 
successfully employed to discover new immune cell types, cell states, and 
novel molecular pathways in healthy and diseased tissues (Grün et al., 2015; 
Macaulay et al., 2016; A.-C. Villani et al., 2017; C. Zheng et al., 2017; Miragaia 
et al., 2019). For example, a recent study used scRNA-seq to identify 
heterogeneity in hepatic macrophages in humans, and reported two distinct 
subsets of KCs in homeostasis, showing different functional capabilities 
(MacParland et al., 2018). ScRNA-seq has an advantage over traditional 
methods using conventional cell surface markers and single-cell qPCR, as it 
doesn’t heavily rely on pre-defined surface markers.  
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 The process of scRNA-seq can be condensed into five stages:  
 
1) Isolation and lysing single cells from tissue of interest 
2) Reverse transcription (RT) to select for mRNA  
3) cDNA amplification and Library preparation  
4) Sequencing  
5) Analysis 
 
Isolation of immune cells from the liver can be challenging; cell types such as 
macrophages can become adherent to tissue following injury. Currently there 
is no consensus on the methods used to generate single cell suspensions of 
murine liver leucocytes (Blom et al., 2009; Ramachandran et al., 2012; 
Zigmond et al., 2014; Bain et al., 2016; Mossanen et al., 2016). Most 
macrophage tissue dissociation protocols use a combination of mechanical 
and enzymatic digestion methods. The number and duration of spins, the 
composition and selection of enzymes used, and filtering steps can all 
influence cell purity and yield and can therefore bias the proportion of cell types 
to be analysed (Lynch et al., 2018). The single cell suspension needs to be 
generated in an efficient manner, taking the shortest time possible to minimize 
cell stress to yield viable cells which are a representative “snapshot” of the in 
vivo setting. Isolated cells can be processed through steps 2-4 outlined above 
by different sequencing protocols, varying in transcript coverage, sequencing 
depth, strand specificity and positional bias. Droplet-based scRNA-seq permits 
3’ mRNA counting, although limited in information on the full transcriptome, it 
allows you to sequence thousands of single cells per sample (G. X. Y. Zheng 
et al., 2017; Ziegenhain et al., 2017). This system has been used to uncover 
rare cell types and dissect heterogeneity in various tissues (Grün et al., 2015; 
Camp et al., 2017). The inclusion of unique molecular identifiers (UMIs) to 
samples in this method can reduce these technical variabilities introduced by 
RT efficiency, temperature differences, differences in sequencing depth and 
amplification bias etc.  In addition, cells are passed through quality control 
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steps at various stages of the process, to ensure poor quality libraries are 
discarded from the downstream analysis. A large part of scRNA-seq is the 
bioinformatic analysis of the vast amount of transcriptomic data generated and 
there are a wide range of computational tools available which are used to 
answer specific biological questions (Rostom et al., 2017).  
 
This chapter outlines the methodology used for scRNA-seq of leucocytes an 
unbiased manner during liver regeneration, following AILI. The includes 
optimisation of cell isolation protocol and gating strategy used to select viable 
leucocytes for scRNA-seq and the post-sequencing quality control metrics 
used to filter misrepresented cells. Following this, the results from the 
computational analysis of scRNA-seq of leucocytes and mononuclear 
phagocytes (MPs) are presented via a range of visualisations graphs (t-SNE, 
heatmaps, violin plots, dot plots).  
 
4.1.1 Aims 
• To develop an efficient method to generate viable single cell 
suspensions of macrophages from murine liver  
• To develop a strategy for the scRNA-seq of hepatic and systemic 
myeloid cells  












4.2 Results  
 
4.2.1  Tissue digest optimisation 
 
A collagenase-based protocol reported in Lynch et al., 2018 (Protocol 1), which 
is efficient in isolating murine hepatic macrophages was used in chapter 3 to 
characterize leucocyte dynamics during AILI. However, the data from chapter 
3 demonstrates that this protocol, along with others protocols reported in the 
literature, are inefficient in isolating KCs at specific timepoints during AILI (You 
et al., 2013; Zigmond et al., 2014), especially at 48hrs post-APAP (Figure 3.6). 
In order to address this issue, I compared the protocol used in Lynch et al, 
2018 (Protocol 1) to a pronase based protocol standardly used in the 
Henderson lab for mesenchymal cell liberation from murine liver (Mederacke 
et al., 2015) (Protocol 2) (Figure 4.1).  
 
Previous work in the lab by Dr. Ross Dobie, Dr. Prakash Ramachandran and 
Dr. Jamie Smith demonstrated the requirement for pronase in the isolation of 
mesenchymal and leucocytes from cells from fibrotic livers, kidney and lung 
(data not shown). Therefore, I tested whether this protocol could improve the 
efficiency of leucocytes isolation, especially the number of KCs from murine 
livers following injury. To do this, livers from C57BL/6 mice (uninjured and 
injured) were harvested, liver lobules were weighed and partitioned equally to 
be processed following either protocol 1 or protocol 2. The cells were then 
stained for surface markers using the same concentration of antibodies and 
cell populations were analysed via flow cytometry. It is important to note that 
though pronase based enzymatic digestion protocols can be efficient at 
liberating non-parenchymal cells from the liver, they do cleave off certain cell 
surface proteins. Consequently, this limits the range of cell-surface markers 
that can be used for flow cytometry analysis. After several iterations, a 
leucocyte flow cytometry panel consisting of markers that survive a pronase-




The protocols differed in duration by a minute between tissue harvest and flow 
cytometry stages (Figure 4.1). Analysis of DAPI+ cells showed that protocol 2 
yielded significantly more viable cells than protocol 1 (Figure 4.2b). The 
proportion of leucocytes isolated was consistently high (~80%) from both 
protocols, with negligible differences between them (Figure 4.2a). Since the 
main goal was to gain information of hepatic macrophages, I wanted to see if 
there were any differences in the number of macrophages isolated with 
protocol 1 and 2 from an injured liver (Figure 4.2c). There was increased 
variance in the percentage of macrophages (F4/80+ CD11b+) isolated from 
both protocols, with no significant differences between protocols (Figure 4.2c). 
As TIMD4 is cleaved by pronase, I relied on F4/80 and CD11b expression to 
identify KCs and MDMs. On average Protocol 2 isolated more KCs, whereas 
Protocol 1 isolated more MDMs, from an injured liver, but these differences 






















Figure 4.1Liver digestion protocols for isolating NPCs.  Comparison of main 











Figure 4.2 Optimisation of liver digestion protocols for scRNA-Seq. (a) 
Comparison of viability of cells between protocol 1 and 2. Comparison of leucocyte 
(b), macrophage (c) liberation between protocol 1 and 2. (d) Fraction of KCs 
(F4/80Hi CD11bLo) and MDMs (F4/80Lo/Int CD11bHi) liberated from injured liver, from 
protocol 1 and 2; represented as percentage of total macrophages. (a,b) Data 
acquired from two independent experiments (c,d) Data acquired from single 
experiment, n=4-7 per group. Mann-Whitney nonparametric t-Test. Data shown as 
Mean±S.E.M. **P≤0.01. 
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To summarise there were insignificant differences in leucocyte or macrophage 
liberation from inflamed livers between protocol 1 and protocol 2. Overall 
protocol 2 generated significantly more viable cells, therefore a pronase-based 
protocol (protocol 2) was deemed more appropriate for the scRNA-seq 
experiment. Additionally, protocol 2 was previously employed by members in 
the Henderson lab to perform scRNA-seq of mesenchymal cells at 48hrs-post 
APAP. Therefore, in the hopes of amalgamating these datasets with this 
particular body of work to gain insight into the interplay between these cells in 
regulating liver repair following AILI, I decided to proceed with protocol 2 to 
generate single-cell preparations of murine liver leucocytes for scRNA-seq.  
 
4.2.2 Methodology for scRNA-seq of hepatic and systemic leucocytes  
 
As discussed previously AILI is a dynamic, with distinct phases. The hepatic 
and systemic leucocyte composition changes depending on the phase of AILI. 
In addition, macrophage phenotype can also vary during AILI (Figure 3.3, 3.5, 
3.7). As the main aim of this body of work was to identify pro-reparative subsets 
by investigating the transcriptomic changes occurring in cells at a single cell 
resolution, it was important to select a timepoint which represents the repair 
phase. Based on the data shown in chapter 3 48hrs post-APAP was chosen 
as the timepoint to perform scRNA-seq. This timepoint represents a phase of 
AILI with minimal necrosis and significantly high hepatocyte proliferation 
(Figure 3.1, 3.2). The most dominant leucocytes in the liver at this timepoint 
are macrophages (Figure 3.3, 3.4). Furthermore, it also represented a 
timepoint when Ly6CLo MDMs peaked in the liver and these macrophages 
display a significant level of heterogeneity (Figure 3.7c).  
 
AILI has been shown to induce systemic changes in the clinical setting which 
can affect the outcome for patients, despite this, none of the murine studies 
have interrogated the changes in the circulating leucocyte compartment in a 
regenerative model of AILI (Antoniades et al., 2012; Moore et al., 2017). The 
data in the previous chapter highlights numerical and phenotypical changes in 
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the leucocyte compartment (Figure 3.8, 3.9). Therefore, I performed scRNA-
seq analysis of circulating leucocytes from uninjured and 48hr post-APAP 
animals, to investigate the systemic transcriptomic changes following AILI. 
Liver and blood cells from the same animal were used for the analysis, to 
facilitate discrimination between hepatic and circulating leucocytes following 
sequencing. Liver and blood from paired, uninjured and 48hrs post-APAP 
C57BL/6 wild type mice were collected, and single cell suspensions were 
prepared for fluorescence activated cell sorting (FACS). In order to sort cells 
from the liver, the gating strategy relied on CD45 to detect leucocytes. As 
pronase cleaves CD31, ICAM 2 was used as substitute endothelial marker. 
100,000 CD45+ cells from each liver of uninjured or 48hr post-APAP animals 
were sorted for scRNA-seq, in an unbiased manner. Studies have reported 
that a subpopulation of bone marrow-derived liver sinusoidal endothelial cells 
(LSECs) expressing CD45, to have a key role in promoting liver regeneration 
following injury (Wang et al., 2012). With the intention of interrogating this 
population CD45+ ICAM2+ population was also included in the gating (Figure 
4.3a, b).  
 
For the blood samples, 50,000 CD45+ cells from uninjured or 48hr post-APAP 
animals were sorted. My previous data demonstrated at 48hrs-post APAP only 
~10% of the circulating leucocytes were monocytes, whereas neutrophils 
contributed to ~40% of leucocytes (Figure 3.8). In order to dissect monocyte 
heterogeneity during AILI I needed to enrich for monocytes, therefore, 30% of 
the sorted cells in each sample represented CD11b+ CD115+ cells 
(monocytes) and 70% contained the remaining leucocytes (not CD11b+ 
CD115+) (Figure 4.3c). The average sort time for the liver samples ranged 












Figure 4.3 Methodology for scRNA-seq of hepatic and circulating leucocytes 
(a) Schematic of the methodology used for scRNA-seq. Gating strategy used for 
the FACS for generating viable single cell suspensions of liver (b) and blood (c) 
leucocytes. (n=2 for each group). 
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Before proceeding with the scRNA-seq protocol the quality and quantity of the 
sorted cells were assessed for all samples (Table 4.1). Cell viability and 
concentration was measured on a TC20 (Bio-Rad) using trypan blue, which 
selectively stains dead cells. All of the samples were off excellent quality, with 
no cell debris or clumps, the cell viability varied between 81-97% depending 
on the sample (Table 4.1). Following this, cells were loaded onto the 10x 
Genomics Chromium Single Cell platform, a droplet-based microfluidics 
system. A protocol generated by 10x genomics was followed (See Methods), 
with assistance from Dr. Beth Henderson. The uninjured and 48hrs-post APAP 
liver and blood samples were run in parallel (4 samples in total at a time) to 
avoid batch effects, the experiment was then repeated on a different day (n=2 
for each group). 
 
The official capture rate for this machine is 65%, however previous scRNA-
seq experiments performed by researchers in the Henderson lab found the 
capture rate to be around 30-40%. Therefore, I loaded 10769,000 cells from 
each of the four groups (Uninjured Liver, APAP Liver, Uninjured Blood, APAP 
Blood), with the hopes of capturing transcriptomic information from 3000-4000 
cells per sample. The GEMs underwent RT and PCR steps to generate 10x 
barcoded cDNA. Quantification of the cDNA using Qubit (Thermo Fisher) 
showed the yield varied from 1.41-6.71 ng/µL, between samples; APAP 
samples generally had more cDNA than uninjured samples (Table 4.1). The 
10x system allows successful library construction from cDNA yields as low as 
~1-2 ng/µl and all of the samples were within this range, therefore I proceeded 
with library construction for NGS. Samples were analysed further on a Perkin-
Elmer LabChip post library construction. The electropherogram showed sharp 
peaks, with no evidence of primer dimers or PCR artefacts, which indicated 
excellent cDNA library quality for all samples (Figure 4.4). The cDNA libraries 
were sequenced on an Illumina sequencing platform at the Sanger institute 


























100000 85 0.85x106 10769 1.47 32.27 
APAP 
Liver 1  
100000 91 1.77x106 10769 4.46 28.57 
Uninjured 
Blood 1 
50000 81 0.7x106 10769 1.42 40.46 
APAP 
Blood 1 
50000 86 0.72x106 10769 2.88 30.73 
Uninjured 
Liver 2 
100000 97 1.10X106 10769 4.86 59.13 
APAP 
Liver 2  
100000 86 0.6x106 10769 6.71 50.58 
Uninjured 
Blood 2 
50000 96 0.67x106 10769 3.47 31.46 
APAP 
Blood 2 
50000 94 0.7x106 10769 2.58 38.81 
Table 4.1 Pre-sequencing quality control metrics. Number of cells sorted via 
FACS, viability and concentration of cell post-sort, number of cells loaded onto 
the 10x machine, cDNA quantification pre and post library construction for each 









Figure 4.4 Representative results from cDNA analysis for scRNA-seq 
samples (Uninjured Liver, APAP Liver, Uninjured Blood, APAP Blood) following 
the 1st run (a) and the 2nd run (b). The measurement was taken after RT, cDNA 
amplification and library construction on a 10x genomics chromium technology. 
DNA fragment size range is depicted on the x-axis (in Base Pairs) and signal 
intensity (fluorescent units) on the y-axis.  
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4.2.3 Quality control and cell filtering post-sequencing  
 
Table 4.2 shows the number of cells, genes, and UMIs recovered from each 
sample after sequencing. The capture efficiency varied between samples (23-
61%), the number of genes and UMIs for APAP samples (Liver, Blood) were 
higher than of Uninjured samples. ScRNA-seq generates a highly complex 
dataset, the analysis and correct interpretation of this requires a combination 
of in-depth computational tools and biological expertise. For the computational 
analysis of the scRNA-seq data I sought the expertise of Dr. John Wilson-
Kanamori, a postdoctoral bioinformatician in the Henderson lab. The initial 
stages of the bioinformatic analysis consisted of quality control (QC) 
measures, to remove cells with low reads or missing transcripts (“dropout” 
events). Genes expressed in fewer than three cells in a sample were excluded, 
along with cells that expressed fewer than 300 genes (Figure 4.5). Cell reads 
that contained more than 10% of mitochondrial genes were also removed, as 
this indicated cell stress, cytoplasmic breakdown and cell death (Figure 4.5). 
Notably, the variation in the number of genes and transcripts (UMIs) between 
samples is high, indicating heterogeneity. The APAP Liver samples generally 
had the most transcriptional diversity and activity (Table 4.2, Figure 4.5). After 
removing the low-quality cells, the 8 datasets were merged, normalized to 
obtain correct relative gene expression abundances between cells, 
appropriately scaled and, finally, technical and biological covariates were 
corrected for by regression based on the number or UMIs. 
 
4.2.4 Unsupervised clustering of hepatic and systemic leucocytes  
 
The resulting 31567 cells from the eight samples (Uninjured Liver; n=2, 
Uninjured Blood; n=2, APAP Liver; n=2, APAP Blood; n=2) were analysed 
using Seurat, a publicly available clustering package developed specifically for 
the analysis of scRNA-seq data. Unsupervised clustering of liver and blood 
cells from uninjured and 48h post-APAP conditions generated 28 distinct 
clusters, this was visualized via t-distributed stochastic neighbourhood 
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embedding (t-SNE) plot (Figure 4.6a). In a t-SNE plot each cell is represented 
as a single dot and cells with similar gene expression profile cluster together. 
Labelling the clusters according to the source (Liver or Blood), revealed cells 
from Liver samples clustered separately from Blood (Figure 4.6b). Further 
labelling based on the condition of tissue cells were isolated from 
demonstrated injury specific clusters (3,11,7), composed of cells from APAP 
samples (Figure 4.6a, c). All clusters expressed CD45 with no contamination 
from CD45 negative cells, further validating the FACS sort strategy (Figure 
4.d). Labelling the cells according the individual sample of origin suggested 
the transcriptional profile of liver cells changed more dramatically with injury 
than blood cells (Figure 4.6e). It also indicated there was good reproducibility 







Source Condition nCell nGene nUMI 10x Capture 
Efficiency (%) 
Liver Uninjured 2495 1858 5041 23 
Liver Uninjured 6572 1994 5335 61 
Liver APAP 3616 2916 11739 34 
Liver APAP 3575 2956 11199 33 
Blood Uninjured 3199 1323 3556 30 
Blood Uninjured 3216 1310 3296 30 
Blood APAP 5199 1467 4035 48 
Blood APAP 3977 1246 3107 37 
Table 4.2 Post-sequencing information on the scRNA-seq samples. The table 
above summarizes the number of cells, total gene and UMI counts generated from 










Figure 4.5 Cell filtering metrics used for quality control. Violin plots showing 
the number of genes, Unique Molecular Identifiers (UMIs) and fraction of 
mitochondrial RNA per cell for the 1st run (a) and the 2nd run (b). Black dots 
indicate a cell and the red dotted line represents the cut off parameter used to 
remove “low quality” cells based on number of genes and mitochondrial RNA 









Figure 4.6 Unsupervised clustering of hepatic and systemic leucocytes. (a) t-
SNE visualization clustering of hepatic and systemic leucocytes from uninjured and 
APAP samples. Cells labelled by their source (b) and condition (c). (d) Violin plot 
demonstrating the expression of PTPRC (CD45) genes expression across the 
clusters. (e) Cells labelled by individual samples. 
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4.2.5 Annotation of leucocyte lineages in the scRNA-seq dataset 
 
Having performed initial clustering on these cells, the next aim was to annotate 
the clusters relying on known lineage specific marker genes. In order to do 
this, I collated a list of marker genes that could identify the different leucocyte 
lineages, based on a literature search. The expression of the selected genes 
across the clusters are shown in Figure 4.7b, the full list of genes used can be 
found in Appendix 4. Using this list, Dr. Wilson-Kanamori performed gene 
signature analysis on the cells, which facilitated annotation of all the expected 
cell lineages: mononuclear phagocyte (MP; clusters: 0, 2, 5, 6, 7, 9, 10,11, 13, 
17, 18, 20, 21, 22, 24), plasmacytoid dendritic cell (pDC; cluster: 16), innate 
lymphoid cell (ILC; clusters: 6, 28), T cell (clusters: 4, 8, 19, 25), B cell 
(clusters:1, 14), Mast cell (cluster: 23), Neutrophil (cluster: 12) (Figure 4.7a, c). 
There was some red blood cell (RBC) contamination (cluster 26) but notably, 
very little contamination from mesenchymal or epithelial cells (Figure 4.7c). 
Clusters 21 and 28 revealed cell cycle gene signatures, which indicated a 
portion of MPs and ILCs, respectively, were proliferating (Figure 4.7c).  
 
We identified cluster 15 as endothelial cells (Figure 4.7c), these group of cells 
expressed CD45 (PTPRC) (Figure 4.6c), along with endothelial specific genes 
such as: PECAM1, ICAM2, CDH5, and KDR (Figure 4.8b). Interestingly, they 
also expressed MP lineage genes, including CD68 and CSF1R (Figure 4.8b). 
The endothelial cluster was composed of both uninjured and 48hrs-post APAP 
cells, from the broad clustering there was no indication of heterogeneity 
(Figure 4.8a). The genes which differentiated cluster 15 from the rest of the 
clusters were related to angiogenesis (FLT1, ADGRL4), matrix remodelling 
(TIMP3), proliferation (IGFBP7, IL6ST) and phagocytosis (CLEC4G, STAB2, 
FCGR2B). In comparison to other leucocytes, the endothelial cells had high 
transcriptional diversity (nGene), and transcriptional activity (nUMI) during 
basal conditions (Uninjured; grey), which increased following AILI (APAP; 
blue) (Figure 4.9b, c). Increased nGene and UMI suggested these cells might 
represent doublets rather than a true population.  
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Looking closely at the leucocyte lineages, the lymphocytes (T cells, B cells, 
ILCs) displayed low transcriptional diversity and activity both under basal 
conditions (Uninjured) and following injury (APAP) (Figure 4.9b, c). The T cell 
lineage contained both liver and blood cells that formed three separate 
clusters: 8,19 (Liver) and 4 (Blood), indicating hepatic and circulating T cells 
have distinct transcriptional profiles (Figure 4.7a, 4.9a). The blood T cell cluster 
(8) was dominated by APAP cells. B cells (clusters: 1,14) and ILCs (clusters 
3, 28) were mainly from blood samples and did not have any injury specific 
clusters associated with them (Figure 4.7a, 4.9a). As this is very broad 
clustering, the differences between lineages are more dominant, than the 
subtle differences between subpopulations within a lineage. So, isolating these 
cells and re-analysing them will aid in gaining resolution into lymphocyte 
heterogeneity. Despite sorting based on CD45+ there were no hepatic 
neutrophils or eosinophils in the dataset, the neutrophils cluster (12) consisted 
of circulating neutrophils, primarily from APAP blood samples (Figure 4.7, 
4.9a). Neutrophils also displayed very low transcriptional diversity and activity 
(Figure 4.9b, c). Cluster 16 was identified as pDC, mainly containing liver-
resident cells (Figure 4.7, 4.9a) and clustered distant from the MP lineage 
which contained cDCs (Figure 4.7, 4.9). The MP lineage dominated the whole 
dataset and partitioned into 15 distinct clusters (Figure 4.7). MP lineage 
represented a very heterogenous group of cells, even at a very broad level of 
clustering, revealing injury (APAP) specific blood (9) and tissue clusters 
(13,7,11,17) (Figure 4.7). The number of genes per cell and the UMI count for 
MP clusters were higher in the APAP samples than uninjured samples (Figure 
4.9b, c). To study these cells at a higher resolution, we isolated the MP cluster 










Figure 4.7 Annotation of clusters based on gene signature analysis. (a) t-SNE 
visualization of the cell based on clusters, lineage and source. (b) t-SNE plots 
showing the expression of stated genes, used for the annotation of cells, across 
the clusters, (red indicates high expression and blue indicates low expression) (c) 
Dotplot annotating liver and blood cell clusters by lineage signature. Circle 
indicated cell fraction expressing signature greater than mean; color indicates 









Figure 4.8 Endothelial cluster with macrophage markers (a) t-SNE 
visualization of the cell based on clusters, lineage and source. (b) Violin plots 
showing the expression of common endothelial -associated (PECAM1, ICAM2, 
CDH5, KDR) and macrophage-associated (CD68, CSF1R) genes across the 
identified lineages. (c) t-SNE plots showing the expression differentially expressed 
genes in cluster 15 (endothelia), red indicates high expression and blue indicated 









Figure 4.9 Proportional changes and transcript metrics for leucocyte lineages. 
(a) Pie charts showing the proportion of cells from liver and blood samples from 
uninjured and APAP animals in each cell lineage. Violin plots displaying the 
distribution and the total number of unique genes (nGene) (b) and total Unique 
Molecular Identifiers (UMIs) (c) expressed across the cell lineages in uninjured vs 
APAP livers.  
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4.2.6 Investigating heterogeneity within the mononuclear phagocyte 
compartment  
 
Cells belonging to the MP lineage were re-clustered, 16,399 MPs from eight 
datasets (uninjured liver (n=2), APAP liver (n=2), uninjured blood (n=2), APAP 
blood (n=2)) partitioned into twelve distinct clusters (Figure 4.10a). Using the 
same principle as previously, based on known maker genes I annotated each 
cluster by major cell lineage. MACRO, CD5L, CLEC4F and TIMD4 were highly 
expressed by cells in clusters: 0,12, and 8, therefore they were identified as 
Kupffer (Kupffer cells; KCs) (Scott et al., 2016) (Figure 4.10, Appendix 6). 
Clusters 9 and 10 showed the highest expression of H2-AA, gene that encodes 
murine MHCII, indicating these cells might be conventional dendritic cells. The 
expression of ITGAX (CD11c) and XCR1 facilitated annotation of cluster 9 as 
cDC1 and cluster 10 as cDC2 (Figure 4.10). Clusters 1, 2 and 6 were from 
blood samples and these clusters also exhibited increased expression of 
monocytic genes: S100A4 and LYZ2, therefore I identified them as the 
monocytes (Figure 4.10) (Hoeffel et al., 2015; Shi et al., 2018). The remaining 
five clusters (3,4,5,7,11) consisted of cells exclusively from APAP Liver 
samples (Figure 4.10). These cells had high expression of LYZ2, a 
myelomonocytic marker, and CSF1R, a gene required for macrophage survival 
and maintenance (Pollard, 2009; Gow et al., 2014; Shi et al., 2018). 
Furthermore, varying expression of CCR2, LY6C2 and H2-AA and the lack of 
expression of KC and DC related genes led me to annotate these cells as 
monocyte derived macrophages (MDM) (Figure 4.10). Overexpression of cell 
cycle genes such as: STMN1, MKI67 in cluster 11, highlighted that a proportion 
of the MDMs were in cycle (Figure 4.10b). Examining the proportion of cells 
within each cluster that came from each sample (uninjured liver (n=2), APAP 
liver (n=2), uninjured blood (n=2), APAP blood (n=2) demonstrated that 
clusters (3,4,5,7,10,11) belonging to the MDM clusters are APAP specific 
(Figure 4.11a). and the most heterogenous population of cells (Figure 4 10a).  
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The MDM clusters also contained the most transcriptionally diverse and 
transcriptionally active cells during injury, indicated by the high number of 
number of genes and UMIs per cell seen in the cell from the APAP group 
(Figure 4.11b). Unsurprisingly, majority of the Kupffer clusters contained cells 
from uninjured livers, only small proportion of injury specific cells (APAP Liver) 
(Figure 4.10, 4.11). Despite this, based on the nUMIs and nGenes the APAP 
specific cells in the Kupffer lineage were more transcriptionally diverse and 
had more transcripts than cells from uninjured livers (Figure 4.11). They also 
formed a separate cluster (cluster 8) that is distinct to the uninjured Kupffer 
clusters (0,12) (Figure 4.10a). Clusters 9 and 10, belonging to the cDC1 and 
cDC2 lineage, respectively, contained a small fraction of blood cells, majority 
of the cells were liver cells from both APAP and uninjured samples (Figure 
4.11a). Cells belonging to the cDC2 lineage (cluster 10) clustered more closely 
with MDMs (Figure 4.10a) and were more transcriptionally active following 
APAP induction, when compared to cDC1 (cluster 9) (Figure 4.11b). The 
monocyte clusters contained cell from blood samples, the small fraction of liver 
cells in this group were identified as contaminating blood cells in the liver 
samples, which survived the liver perfusion (Figure 4.11a). The close proximity 
of monocytes clusters to MDM clusters suggested a differentiation trajectory 
from blood into tissue (Figure 4.10a). There were no major differences in the 
number of genes and number of UMIs between Uninjured and APAP groups 
for the monocyte lineage (Figure 4.11b). Nevertheless, cluster 6 represented 
an injury specific population of circulating monocytes, which indicated 
transcriptional changes in the circulating monocytes at 48hrs post-APAP, prior 








Figure 4.10 Unsupervised clustering of mononuclear phagocytes (a) t-SNE 
visualization of mononuclear phagocytes (MP) from uninjured and APAP liver and 
blood based on clusters, lineage and source. (b) Violin plots showing the expression 












Following the clustering of MPs and establishing the identity of the clusters I 
was interested in dissecting the heterogeneity within the different MP lineages. 
Performing differential gene expression (DE) analysis is one of the most 
common ways which enables the identification of specific genetic features 
which could indicate differences in phenotype and function. Gene expression 
in one cluster to another, as well as across all 12 clusters was analysed to 
identify differentially expressed genes (Appendix 5). The analysis was 
performed in Seurat (Methods) and only those genes with log-fold changes of 
at least 0.25 and expression in at least 20% of cells in the cluster under 
comparison were retained.  Figure 4.12a displays DE analysis as a heatmap, 
where each column represents a single cell, and each row represents a gene. 
The 12 main clusters identified by the unsupervised clustering are represented 
at the top and on the left. The source (liver: blue, blood: red), and condition 
(Uninjured: grey, APAP: light blue) of the cells are represented on the top of 
the clusters. The expression of a certain gene is indicated by the colour red 
and absence by blue.  
 
Firstly, the Kupffer cells (cluster 0,8,12) had a very differential gene expression 
profile to the other hepatic MP lineages (MDM, cDC) and to the circulating 
monocytes. A distinct set of genes such as: TIMD4, VSIG4, FCNA were 
exclusively expressed in the Kupffer clusters (Figure 4.12a). The genes which 
distinguished APAP Kupffer cells (cluster 8) from uninjured Kupffer cells 
(clusters: 0 and 12) were cell cycle related (TK1, MCM3) (Figure 4.12a, 
Appendix 6). This suggested that APAP induced local proliferation of Kupffer 
cells. We could not identify any non-cell cycle related genes which were 
exclusive to cluster 8. The DE analysis failed to generate any unique genes 
Figure 4.11 Proportional changes and transcript metrics for mononuclear 
phagocyte lineages (a) Pie charts showing the proportion of cells from liver and 
blood samples from uninjured and APAP animals in each MP lineage. Violin plots 
displaying the distribution and the total number of unique genes (nGene) (b) and total 
Unique Molecular Identifiers (UMIs) (c) expressed across the MP lineages in 
uninjured vs APAP livers.  
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for cluster 12 (Figure 4.12.a, Appendix 5, 6). Circulating monocytes (cluster 
1,2,6) expressed a distinct set of genes to the tissue MPs, but they also shared 
some sets of genes with tissue MPs; cluster 7 in particular (Figure 4.12a, 
Appendix 7, 9). Amongst the MDM clusters, cluster 7 has the most distinct 
gene profile, compared to its liver counterparts. Genes such as LCN2, 
WFDC21, VCAN, MCEMP1 were upregulated in cluster 7, interestingly these 
were also expressed by the APAP specific circulating monocyte cluster (6) 
(Figure 4.12a; Appendix 6). MDM clusters 3 and 4 displayed a relatively 
discrete transcriptional profile, whereas cluster 5 shared genes with 3 and 4, 
suggesting these cells might represent an intermediate phenotype (Figure 
4.12a; Appendix 7). There were a select number of genes unique to each of 
the MDM clusters: cluster 3: SPP1, IL7R, CCL7, cluster 4: NR4A2, IFIT1, 
IFIT3: cluster 4, cluster 5: STAB1, IGFBP4 and Cluster 7: LCN2, CXCL2, 
CXCR2, RETNLG (Figure 4.12a, Appendix 7). As noted before, cell cycle 
marker genes delineated cluster 11 from the other MDMs (Figure 4.12a). 
There were no other uniquely expressed genes in cluster 11. cDC1 cells could 
be easily delineated from the rest of the MPs; they distinctly expressed a 
number of dendritic cell (DC) marker genes (XCR1, CD24, FLT3, CLEC9A). 
Cells in cDC2 on the other hand had very limited number of unique DC related 
genes (CD209A, CIITA), furthermore, these cells shared a lot of features with 
MDMs, expression of CD63, STAB1, MS4A7, SLAMF7 amongst various other 
macrophage related genes such as CSFR1, ADGRE1 and FCGR1 (Figure 










Figure 4.12 Differential gene expression analysis of mononuclear phagocytes. 
(a) Scaled heatmap (red, high expression; blue, low expression) showing MP cluster 
marker genes (color coded at the top by cluster, condition and source), exemplar 
genes labelled right. (b) Gene ontology enrichment analysis of APAP specific tissue 




Following the identification of differentially expressed genes across the 
different MP clusters, my next aim was to interrogate whether the 
transcriptomic differences dictated any functional differences in the MP 
clusters during acetaminophen induced liver injury (AILI). Based on the marker 
gene list Dr Wilson-Kanamori generated, I performed Gene Ontology (GO) 
enrichment analysis for clusters: 3,4,5,7,8,9 and 10 to delineate the functional 
profile of the injury specific liver cells during AILI. MDMs in cluster 3 were 
enriched for ontology terms relevant to ribosomal assembly, cholesterol 
storage, response to IL-7, in addition to phagocytosis and tissue regeneration; 
terms associated with a pro-repair macrophage phenotype (Figure 4.12b). 
MDMs in cluster 4 were enriched for terms of macrophage and lymphocyte 
migration, responses to IFN𝛽, production of TNF and leucocyte differentiation, 
which are associated with a pro-inflammatory macrophage phenotype. Cluster 
5 had similar GO terms to MDM cluster 4, consisting of TRAIL regulation, 
myeloid cell migration and response to IL-4, considering these clusters had a 
number overlapping genes this was unsurprising (Figure 4.12b). The GO terms 
for cluster 7 were related to phagocytic clearance, response to IL-8 and 
neutrophil aggregation. Notably, cluster 7 also showed enrichment for 
glutathione biosynthesis, these cells upregulated of genes such as SLC7A11 
and NFE212 (figure 4.12b), required for glutathione production (Clemons et 
al., 2017; Ryoo and Kwak, 2018). The injury specific Kupffer cluster 8 showed 
significant enrichment for GO terms involving cholesterol and iron 
homeostasis, complement activation, IL-6 synthesis and apoptotic cell 
clearance, which are all known functions of KCs in mice (Ju et al., 2002; 
Zigmond et al., 2014; Scott and Guilliams, 2018). Both of the cDC clusters 
gave expected GO terms, with cDC2 showing enrichment of genes relating to 
regulation of lymphocyte migration and survival (Figure 4.12b). Overall, the 
GO enrichment analysis of injury specific clusters revealed distinct GO terms 
for the injury specific MP clusters and revealed novel ontology terms of 
macrophages in the context of AILI.  
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4.2.7 APAP induces transcriptional changes in the circulating 
monocyte compartment  
 
To study the transcriptional landscape of circulating monocytes in more depth 
cells were isolated from the “Monocyte” lineage from the MP clustering 
analysis, contaminating cells from Liver samples were removed and they were 
re-clustered. A total of 4896 cells gave three distinct clusters: 1,2,3 (Figure 
4.13a). Labelling the cells according to the sample of origin revealed cluster 3 
to be APAP specific, whereas cluster 1 and 2 contained both uninjured and 
APAP cells (Figure 4.13b). As previously discussed, murine monocytes are 
broadly categorized into two main subsets: Ly6CHi Monocytes (classical) and 
Ly6CLo (non-classical monocytes) (Yona et al., 2013). All three clusters 
expressed LYZ2, which confirmed the cells belonged to the monocytic lineage. 
Furthermore, cells in cluster 1 and 3 exhibited high expression of LY6C2 and 
CCR2 (Figure 4.13c) and was therefore identified as Ly6CHi monocytes 
(labelled as: Ly6CHi mono1 and Ly6CHi mono2, respectively) (Figure 4.13a). 
Lack of LY6C2 and CCR2 expression and distinguished expression of NR4A1, 
identified cells in cluster 2 as Ly6CLo Monocytes (Figure 4.12a, c). Mildner et 
al, 2017 has shown the existence of a third murine monocyte subtype, termed 
Ly6CInt monocytes, which shares transcriptomic signature with both Ly6CHi 
monocytes and Ly6CLo monocytes. Comparative DE analysis on three clusters 
revealed Ly6CLo mono (cluster 2) exhibited a unique gene profile that has 
previously been reported, which included upregulation of genes such as 
NR4A1, CD36, CD9 and TREML4 (Ingersoll et al., 2009; Mildner et al., 2017). 
Whereas, the Ly6CHi mono1 (cluster 1), had overlapping gene expression to 
Ly6CHi mono2 and Ly6CLo mono clusters (Figure 4.13d). Ly6CHi mono2 which 
consisted of cells solely from APAP blood displayed a very distinct gene profile 
to the other two clusters, with enrichment of neutrophil signature in these cells 
















The goal of this body of work was to investigate the heterogeneity within 
murine hepatic and systemic monocytes and macrophages following 
acetaminophen induced liver injury (AILI), using scRNA-seq. A successful 
scRNA-seq experiment relies on efficient liberation of macrophages from 
uninjured and injured livers and subsequent generation of viable, single cell 
suspensions. The experiments in the previous chapter demonstrated that 
current digestion methods used in the field are inefficient at liberating Kupffer 
cells (KCs), from injured livers. Considering the success pronase had in the 
dissociation of mesenchymal cells from injured livers, I hoped a pronase-based 
digestion protocol (protocol 2), would increase the dissociation of KCs from 
injured livers. However, there was no significant differences in the percentages 
of total macrophages, KCs or MDMs liberated using protocol 2 compared to 
protocol 1 (collagenase-based) (Figure 4.2). In comparison to protocol 1, 
protocol 2 did generate more viable cells, which is crucial for scRNA-seq 
experiments (Figure 4.2a). Accepting the limitations associated with protocol 
2 in liberating KCs from the liver post-APAP samples, I proceeded with a 
pronase-based digestion protocol for the scRNA-seq experiments, with the 
aim of gaining more resolution into the recruited macrophage subsets (Ly6CHi 
monocytes, Ly6CLo MDMs).  
 
AILI is a highly dynamic model and macrophage transcriptome, proteome and 
function can vary over the course of AILI, consequently, timepoint selection for 
the scRNA-seq experiment was important. As shown in chapter 3 hepatocyte 
proliferation at 48hrs post-APAP is on an incline, thus increasing the chances 
of detecting pre-programming in macrophages towards a pro-repair 
Figure 4.13 Transcriptomic analysis of peripheral monocytes. (a) t-SNE 
visualization of circulating Monocyte clusters from uninjured and APAP samples. (b) 
Annotating clusters based on condition. (c) Conventional genes used for monocyte 
identification. (d) Heatmap (red, high expression; blue, low expression) showing 
differentially expressed marker genes in the monocyte cluster (color coded at the 
top by cluster and condition), genes labelled right.  
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phenotype. It also represented a timepoint at which hepatocyte necrosis was 
minimal, but not completely absent (Figure 3.1). Given the link between 
phagocytosis and tissue repair following  injury in various organs (Yang et al., 
2015; Woo et al., 2016), including the liver (Campana et al., 2018), I was 
interested in seeing potential changes in macrophage transcriptome that 
influenced their ability to phagocytose. Moreover, there was considerable 
heterogeneity observed within the Ly6CLo MDMs at this timepoint (Figure 
3.7c). Based on these reasons 48hrs post-APAP was chosen as the timepoint 
for the scRNA-seq experiment.  
 
Previous studies have selected a specific subset of monocyte/macrophage, 
based on cell surface markers such as: F4/80, CD11b, Ly6C, CCR2, CX3CR1 
for their transcriptome analysis. Selection of particular subsets based on prior 
knowledge neglect cells which do not conform to these definitions, which can 
massively underestimate heterogeneity. For this reason, a broad, unbiased 
FACS gating strategy, based on CD45 expression was used to isolate hepatic 
and systemic leucocytes for scRNA-seq (Figure 4.3). Amongst the various 
scRNA-seq techniques available I decided to use a droplet-based approach 
using the 10x Genomics Chromium platform. As the 10x technology is based 
on a 3’-tag sequencing method, it generates partial transcripts, therefore the 
rate of “dropout” genes is high (Ziegenhain et al., 2017). However, this 
technology was ideal for the question at hand, as it facilitated the capture of 
thousands of cells to give an aggregate view of transcriptional heterogeneity 
within cells. It also increased the chances of gaining transcriptomic information 
on rare, underrepresented cell types in the dataset, such as KCs from APAP 
livers.  
 
The quality control (QC) checks before and after the 10x protocol indicated the 
protocol followed here generated good quality cells and resulting cDNA for 
sequencing. The stringent post-sequencing QC checks implemented by Dr. 
John Wilson-Kanamori filtered out any cells of low quality prior to downstream 
clustering analysis. Despite using a broad gating strategy to select for 
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leucocytes certain cell types such as hepatic neutrophils and eosinophils were 
underrepresented in the liver dataset. This could be because these cells are 
prone to RNA degradation or because the 10x scRNA-seq technique might not 
be best suited for these cells. All the other expected leucocyte lineages were 
identified and annotated.  
 
The discovery of an endothelial signature (cluster 15) in the dataset was an 
interesting find but not a novel one. Liver sinusoidal cells (LSECs) with 
hematopoietic potential have been described before in rat livers, these CD45+ 
LSECs where shown to be important in liver regeneration following partial 
hepatectomy (Wang et al., 2012). Lynch et al., 2018 report that endothelial 
cells can form aggregates with CD45+ cells, consequently contaminating 
macrophage liver preparations and highlights the importance of endothelial 
makers such as CD31 in removing these contaminants. As CD31 gets cleaved 
by pronase digestion, ICAM2 was used here, it was evident that there was a 
population of ICAM2+ CD45+ cells in the preparations (Figure 4.3b). These 
dual positive cells were included in the sorted samples to see whether scRNA-
seq would permit their delineation. Cluster 15 had a very strong endothelial 
signature; however, these cells also expressed several other macrophage 
related genes such as: LYZ2, CSF1R. Cells in cluster 15 could represent 
doublets, though we did not find other leucocyte gene signatures except 
signatures for MPs in these cells. Given the “sticky” nature of macrophages, 
especially following injury, it is possible that macrophages preferentially form 
aggregates with endothelial cells. Conversely, it is also possible that these 
cells are truly derived from bone marrow derived hematopoietic progenitors, 
and display MP characteristics. In depth comparative analysis of these cells is 
needed to decipher this, as there was a small fraction of these cells in the 
dataset, we did not perform any further analysis.  
 
MP clusters represented a highly heterogenous group of cells (Figure 4.10), 
apparent even at the very broad clustering stage. Isolating the MPs and 
performing unsupervised clustering we saw that much of the heterogeneity 
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was exhibited by blood monocytes and tissue macrophages. Identification of 
marker genes and DE analysis on the MP clusters allowed for annotation and 
delineation of these cells. Dendritic cell clusters (9,10) accounted for only a 
small fraction of MPs and consisted mainly of injury specific cells. While cDC2 
cells showed enrichment for GO terms associated with DCs, they lacked FLT3 
expression, and displayed overlap in gene expression to MDM clusters (Figure 
4.12). This suggests that these cells might be akin to the CD209+ monocyte-
derived dendritic cell subtype reported by Menezes et al., 2016. Using a 
pronase-based protocol (protocol2) I managed to liberate KCs from APAP 
livers albeit not very many (Figure 4.10). These cells formed a distinct cluster 
(8) to the uninjured KCs (0,12). DE analysis highlighted cluster 8 upregulated 
cell cycle genes, indicating there is local proliferation of KCs during AILI. Data 
from chapter 3 demonstrated that KCs showed a dynamic behaviour and 
localized to repairing areas at 48hrs-post APAP (Figure 3.6), here 
transcriptomic analysis of KC from 48hrs post-APAP livers showed no 
upregulation of migratory genes. In fact, APAP specific KCs (cluster 8) had a 
very similar gene profile to uninjured KCs (0,12), and except for the cell cycle 
genes, did not display unique gene modules. A pronase-based protocol 
(protocol 2) used here and the other protocols reported in the literature (Holt, 
Cheng and Ju, 2008; Zigmond et al., 2014; Bain et al., 2016; Graubardt et al., 
2017; Lynch et al., 2018; Krenkel et al., 2019) are not efficient in liberating the 
true “injury specific KCs” seen around the repairing areas of the liver post-
APAP. One of the ways the digestion protocol could be optimised in the future 
is by perfusing the liver in situ with enzyme cocktail, prior to dissection, this 
has been proven to yield more cells in the case of hepatic stellate cells  
(Mederacke et al., 2015). 
 
MDMs represented the most expanded MPs post-APAP, they were also the 
most heterogenous. Bulk RNA-seq and microarray analysis of 
monocytes/macrophages during AILI highlights two distinct gene profiles for 
these cells (Zigmond et al., 2014; Graubardt et al., 2017). Following scRNA-
seq analysis they partition into four clusters. Three clusters (3,4,7) showing 
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very distinct profiles and one cluster (5) showing an intermediate gene 
expression profile (Figure 4.10). Clusters 4 and 7 upregulated various 
proinflammatory genes, and the expression of LY6C2 and CCR2 in these 
clusters (Appendix 7) indicated they might be akin to proinflammatory Ly6CHi 
CCR2Hi CX3CR1Lo monocytes reported in previous studies (You et al., 2013; 
Zigmond et al., 2014; Mossanen et al., 2016; Graubardt et al., 2017). They 
also expressed a range of discriminatory genes and the GO enrichment 
analysis also suggested these cells might have different functions (Figure 
4.12). Cluster 4 exhibited macrophage migratory and pro-inflammatory 
cytokine response terms and cluster 7 had terms related to neutrophil 
aggregation and clearance. Regulation of neutrophil survival and clearance by 
Ly6CHi monocytes during AILI has been shown to promote a pro-repair 
phenotype (Graubardt et al., 2017). Cluster 7 might represent a subpopulation 
of Ly6CHi monocytes responsible for this, furthermore these cells also 
preferentially upregulate apoptotic cell bridge molecules and receptors 
(THBS1, CLEC4E, CLEC4D). Cluster 5 had commonalities with cluster 4 and 
cluster 3, which to me suggests they represent cells on a differentiation 
trajectory from Ly6CHi monocytes to Ly6CLo MDMs (Appendix 7). Whereas, 
cluster 3 had a very distinct transcriptional profile to cluster 4, these cells 
showed enrichment for IL7R, GPNMB, CLEC4D, SPP1, CD9, CD63, IGF1 
thus, giving GO enrichment for term relating to IL7 signalling, tissue 
regeneration and phagocytosis.  
 
Although there are many studies reporting on the transcriptome, proteome and 
function of monocytes while they are in the liver. To my knowledge, there are 
no studies which have interrogated these cells in the blood during AILI or in 
the context of other acute liver injuries. Here, scRNA-seq of circulating 
monocytes from uninjured and APAP samples permitted an in-depth 
transcriptomic analysis of murine monocytes during homeostasis and following 
AILI. I identified the two main subsets of murine monocytes during 
homeostasis: Ly6CHi monocytes and Ly6CLo monocytes as cluster 1 and 2, 
respectively. Both of the clusters exhibited expected gene signatures (Figure 
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4.13). The key observation from this analysis was the identification of cluster 
3, composed of cells exclusively from APAP blood (Figure 4.13). These cells 
were counterparts of Ly6CHi monocytes, seen during homeostasis and 
expressed conventional genes CCR2, LY6C2. They also had a unique gene 
signature, showing enrichment of S100A8, S100A9, RETNLG, LCN2, SELL, 
MCEMP1, this gene expression profile was also evident in liver cluster 7 in the 
MP clustering analysis (Appendix 7). These cells exhibited gene expression 
modules akin to that seen in neutrophils, it is important to highlight that 
neutrophils were excluded following their identification based on gene 
signature analysis, therefore it is highly unlikely the signatures seen in cluster 
3 (blood monocyte cluster) and cluster 7 (Liver MP cluster) are from 
contaminating neutrophils. These findings indicate that APAP induces an 
inflammatory transcriptional pre-programming in Ly6CHi monocytes prior to 
their entry into the liver. Injury induced pre-programming of Ly6CHi monocytes 
in the bone marrow has been reported before. Krenkel et al., 2019 
demonstrates a metabolic transcriptional re-programming of Ly6CHi 
monocytes in the bone marrow during non-alcoholic fatty liver disease 
(NAFLD). Contrary to the inflammatory signature exhibited here (Figure 4.13), 
the “NAFLD myeloid phenotype” downregulated inflammatory genes such as 
S100A8/A9, demonstrating a distinct signature. Adoptive transfer of NAFLD 
monocytes had the capacity to modulate injury responses in mice during AILI, 
indicating this signature is stable even on changes to their micromilieu (Krenkel 
et al., 2019). Ikeda et al., 2018 reports Ly6CHi monocyte transcriptional pre-
programming to an immunoregulatory phenotype in a mouse model of colitis, 
these monocytes promoted tissue repair in the colon. (Ikeda et al., 2018). 
These studies and the findings reported here indicate tissue injury can have a 
wide systemic impact and further studies are needed to interrogate the 
functional relevance of the systemic transcriptional switching observed here.   
 
In summary scRNA-seq of hepatic and systemic monocytes and 
macrophages in an unbiased manner revealed heterogeneity in circulating 
monocytes and hepatic macrophages following AILI. It is clear that a 
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dichotomous M1 (pro-inflammatory) and M2 (anti-inflammatory) phenotype 
classification is not sufficient to describe these cells. Injury specific MDM 
clusters showing enrichment for distinct GO terms highlights that monocytes 
and macrophages exists in different activation states and can have different 
functions following injury. While scRNA-seq analysis of cells allows to study 
their transcriptome at a great resolution, uncovering crucial details which 
were previously masked, it is critical to remember that gene expression in a 
cell is a stochastic process (Raj and van Oudenaarden, 2008). This coupled 
with the dropout transcripts, and technical artefacts can generate a very 
noisy data (Ziegenhain et al., 2017; Haimon et al., 2018). Therefore, in order 
to make reliable and relevant assumptions the findings from scRNA-seq 
analysis needs to be phenotypically and functionally validated.  
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5 Validation of scRNA-seq results to identify 
injury specific monocyte and macrophage 





Monocytes and macrophages have been suggested as therapeutic targets for 
the treatment of acute and chronic liver diseases for some time now. One of 
the main challenges in developing macrophage-based therapies is that these 
cells are very dynamic, exhibiting a spectrum of phenotypes and functions 
based on their environmental cues (Guillot and Tacke, 2019). Generally, KCs 
and Ly6CLo MDMs are regarded as the pro-regenerative subsets and Ly6CHi 
monocytes are thought to be the pro-injury subset but recent transcriptomic 
analysis has revealed heterogeneity in these cells. For example Ly6CHi 
monocytes show upregulation of both proinflammatory and pro- regenerative 
genes, both in the context of AILI (Zigmond et al., 2014; Graubardt et al., 2017) 
and models of chronic liver injury (Ramachandran et al., 2012). This highlights 
that monocyte and macrophage response following liver injury is multifaceted 
and although this heterogeneity has been acknowledged, thus far the existing 
studies have not attempted to dissect this during AILI.  
 
Phagocytosis represents one of the mechanisms by which macrophage 
promote liver repair. In the context of AILI, studies have highlighted the role of 
Ly6CLo MDMs to mediate efferocytosis (clearance of apoptotic cells) of 
neutrophils (Graubardt et al., 2017). Both Ly6CHi monocytes and Ly6CLo 
MDMs show upregulation of apoptotic bridging genes such as Gas6, 
complement complex genes, Mertk and Axl, which are necessary molecules 
for recognizing “find me” signals on apoptotic cells in both mice and humans 
(Fujimori et al., 2015; Healy et al., 2016; Graubardt et al., 2017; Grabiec et al., 
2018). MerTK is upregulated at a protein level on monocytes and 
macrophages in murine models of AILI and in humans suffering from ALF 
(Triantafyllou et al., 2017). MerTK deficient mice exhibit persistent liver injury 
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and inflammation during AILI, higher number of neutrophils and lower number 
of pro-reparative macrophages (defined as F4/80+ MHCIIHi Ly6CLo) 
(Triantafyllou et al., 2017). This highlights a role for efferocytic receptor MerTK 
in mediating tissue repair in AILI, via suppression of neutrophil activation and 
clearance (Triantafyllou et al., 2017).  
 
In addition to possessing efferocytic receptors, efficient efferocytosis also 
depends on the ability to process and degrade internalized cargo, a process 
referred to  as phagosome maturation (Kinchen and Ravichandran, 2008; 
Hochreiter-Hufford and Ravichandran, 2013). The in vivo molecular 
mechanisms involved in phagosome maturation has not been studied as 
extensively as its preceding stages (recognition, binding and engulfment of 
particulates) (Kinchen and Ravichandran, 2008). Nevertheless, key features 
of this process have been highlighted. Phagosomes go through a series of 
progressive acidification steps, acquire different proteins which leads to its 
fusion with lysosome structures, containing hydrolytic enzymes necessary for 
the breakdown of internalised cargo. Acidification of the phagosome 
necessary to activate the hydrolytic enzymes, therefore it is commonly used 
as readout for successful degradation of cargo (Kinchen and Ravichandran, 
2008). The role for phagosome maturation in promoting tissue repair has been 
demonstrated by a number of studies. Animals lacking glycoprotein non-
metastatic protein B (GPNMB), a protein needed for phagosome maturation, 
demonstrate extensive tissue injury and increased mortality following acute 
kidney injury (Li, Castano, Hudson, Nowlin, S. L. Lin, et al., 2010). Similarly, 
GPNMB deficient mice in the context of acute liver injury have higher necrosis 
and an impaired ability to generate pro-reparative macrophages (Campana et 
al., 2018). These studies highlight the therapeutic potential of phagocytosis in 
modulating the repair process. 
 
In my previous chapter I used scRNA-seq in an unbiased manner to study the 
transcriptional changes in mononuclear phagocytes (MPs), with a focus on 
monocyte and macrophages during AILI. The findings highlighted the major 
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changes in the gene expression profile of monocytes and macrophages, 
during the repair phase (48hrs post-APAP). The MDMs showed striking 
heterogeneity, they partitioned into 5 distinct clusters, demonstrating distinct 
gene signatures, namely for: inflammation, immune cell recruitment, tissue 
repair, phagocytosis. This chapter consists of validation of the tissue MP 
clusters identified via scRNA-seq at protein level. Firstly, by identifying the 
hepatic MP cell lineages (cDC1, cC2, KC, MDM), following this, delineating the 
heterogeneity within the MDMs based on specific marker genes identified 
through scRNA-seq, to find key pro-regenerative subsets that has the potential 
to drive liver repair and regeneration following AILI. 
 
5.1.1 Aims 
• To use a combination of unique markers generated through scRNA-seq 
and known biology to identify the MP lineages populating the liver 
during AILI via flow cytometry  
• To use flow cytometry and immunohistochemistry to delineate the MDM 
clusters and define them on their protein expression 
• To investigate the dynamics of any pro-regenerative subsets identified 
and phenotypically characterize them 







5.2.1 Validation of conventional dendritic cell clusters  
 
Unsupervised clustering of hepatic and systemic MPs identified various marker 
genes which facilitated the annotation of clusters into 5 main cell types: cDC1, 
cDC2, MDM, KC and Monocyte (Chapter 4). For the identification of tissue MP 
cell types, I isolated non-parenchymal cells (NPCs) from the livers of uninjured 
and 48hrs post-APAP (300mg/kg) C57BL/6 wild type mice and analyzed them 
via flow cytometry (Figure 5.1). As the pronase-based tissue dissociation 
protocol (protocol 2) cleaved many cell surface antigens, protocol 1 (Methods) 
was used for the validation experiments. The primary gating strategy remained 
the same as before, where single live cells (DAPI+) were analyzed for their 
expression of various surface markers. Leucocytes were identified based on 
CD45 expression, to define the MPs further, rest of the leucocytes were “dump 
gated” based on the expression of conventional lineage markers (Figure 5.1). 
Identification of MP lineages and the MDM clusters at a protein level relied on 
membranal antigens. Different antibody fluorophore combinations were tried 
alongside isotype FMOs, especially for the novel markers identified and 
antibodies were titrated to determine the optimal concentration for flow 









Within the MPs, cluster 9 (cDC1) (Figure 5.2a) selectively expressed XCR1 
and had high expression of CD24 and ITGAX (Figure 5.2b, c). Based on this 
XCR1+ CD24+ cells were identified as cDC1 via flow cytometry (Figure 5.2c), 
these cells also had higher levels of CD11c (ITGAX) expression when 
compared to the other MP lineages (Figure5.2d), confirming their identity as 
cDC1. Enumeration of cDC1 cells during homeostasis and at 48hrs post-APAP 
showed they expanded significantly following injury (Figure5.2e). Validating 
cDC2 (cluster 10) proved to be more challenging (Figure 5.3a), as they lacked 
unique cell surface markers. CD209A was one top marker genes identified by 
differential expression analysis, t-SNE visualization indicated CD209A to be 
selectively upregulated in cluster 10 (Figure 5.3b). However, the violin plots 
suggested the expression was low (Figure 5.3c). This translated across to 
protein expression, I failed to detect any CD209a+ cells in the liver at 48hrs-
post APAP when compared to an isotype control antibody (Figure 5.3d). 
Cluster 10 (cDC) had higher transcript expression of ITGAX (CD11c) and H2-
AA (MHCII) when compared to other MP lineages but as macrophages also 
upregulated MHCII and CD11c during inflammation (Yu et al., 2016), I feared 
this gating strategy will include macrophages. Therefore, I used CD11c and 
F4/80 (a pan-macrophage marker) and identified CD11cHi and F4/80Lo cells as 
Figure 5.1 Methodology and gating strategy for flow cytometric validation 
of tissue MP clusters from scRNA-seq analysis.  
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cDC2s (Figure 5.3e). Quantification of the number of cDC2 cells indicated an 










Figure 5.2 Identification of cDC1 cells in uninjured and APAP livers. (a) t-SNE 
visualization of mononuclear phagocyte (MP) by cluster, source and cell type, red 
dotted line indicates the cell type being validated. Violin plots (b) and t-SNE 
visualization (c) of top marker genes for cluster 9; cDC1. (d) Identification of cDC1 
cells via flow cytometry. (e) Protein expression of CD11c on different MP lineages 
via flow cytometry. (f) Quantification of the changes in cDC1 cells during steady 
state (uninjured) and at 48hrs post-APAP. Data acquired from two independent 
experiments, n=4 per group. Mann-Whitney nonparametric paired t-Test. Data 











Figure 5.3 Identification of cDC2 cells in uninjured and APAP livers. (a) t-SNE 
visualization of mononuclear phagocyte (MP) by cluster, source and cell type, red 
dotted line indicates the cell type being validated. Violin plots (b) and t-SNE 
visualization (c) of top marker genes for cluster 10; cDC2. (d) Identification of cDC2 
cells via flow cytometry on CD209a and CD11c expression (e) Identification of 
cDC2 cells via flow cytometry on F/480 and CD11c expression (f) Quantification of 
the changes in cDC2 cells during steady state (uninjured; grey) and at 48hrs post-
APAP (blue). Data acquired from two independent experiments n=4-6 per group. 




5.2.2 Validation of kupffer cell clusters 
 
Once cDC1 and cDC2 cells were identified and removed from subsequent 
analysis, I focused on delineating the MDM and KC compartment (Figure 
5.4a). Macrophage associated genes such as ADGRE1 (F4/80), ITGAM 
(CD11b) were expressed at high levels in MDM and Kupffer clusters (Figure 
5.4b, c), therefore macrophages were isolated via flow cytometry based on 
their expression of F4/80 and CD11b (Figure 5.4d). In concordance with 
existing literature transcriptomic analysis revealed that KCs (Kupffer) had a 
very unique gene signature compared to MDMs, monocytes and cDCs 
(Chapter 4). As before, separation of KCs from MDMs relied on TIMD4 
expression (Figure 5.4b, d). Quantification of absolute changes in KC 
(TIM4+/CD11bLo) and MDM (TIM4-/CD11bInt/Hi) numbers in uninjured and 
48hrs post-APAP supported my previous flow cytometry findings (Chapter 3) 
where, KC numbers declined and MDMs increased significantly post-APAP 
(Figure 5.4e, f).  
 
The functional role of KCs during the initial phase of AILI has been 
characterized, they have been shown to release various chemokines and 
cytokines, which results in the recruitment of leucocytes, such as monocytes 
into the liver (You et al., 2013; Ju and Tacke, 2016). However, their precise 
role during liver repair remains elusive, partly because flow cytometric analysis 
suggested their numbers declined during the repair phase (24hrs-48hrs post 
APAP), hence previous studies have focused more on the role of infiltrating 
monocytes and MDMs during the repair phase of AILI (You et al., 2013; 
Zigmond et al., 2014; Mossanen et al., 2016; Graubardt et al., 2017). One of 
the reasons for using a droplet-based scRNA-seq technique here was to 
increase the chances of gaining transcriptomic information on KCs during the 
repair phase of AILI (48hrs post-APAP). Albeit low in numbers, scRNA-seq 
analysis contained KCs from 48hrs post-APAP livers and these cells (cluster 
8) clustered separately from uninjured KCs (cluster 0; Figure 5.4a). Differential 
gene expression analysis failed to detect any unique gene expression profiles 
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between these clusters, but t-SNE visualization of top marker genes for cluster 
0 and 8 indicated that certain genes in cluster 8 were downregulated (C3, 
TIMD4), whereas genes such as MARCO was upregulated (Appendix6). 
Based on this observation I wanted to see if APAP induction resulted in any 
cell surface phenotypic changes during the peak regenerative phase of AILI 
(48hr-72hrs post-APAP, Figure 5.5). Therefore, expression of CD36, MerTK, 
and CD9, molecules which are known to mediate phagocytosis on 
macrophages (Huang, Febbraio and Silverstein, 2011; Healy et al., 2016; Woo 
et al., 2016), along with CD24, and antigen presenting molecules MHCII and 
CD11c on KCs were analyzed (Figure 5.5). APAP induced increased 
expression of both CD36 and CD24 following APAP compared to basal levels 
and as previously observed (chapter 3) MHCII expression was downregulated 
on KCs from APAP livers, whereas there were no major changes observed 
with CD11c expression (Figure 5.5). This suggested that at 72hr-post APAP 
there are noticeable phenotypic changes in KCs, the functional relevance of 






















Figure 5.4 Identification of KCs and MDMs. (a) t-SNE visualization of 
mononuclear phagocyte (MP) by cluster, source and cell type, red dotted line 
indicates the cell types being validated. Violin plots (b) and t-SNE visualization (c) 
of top marker genes for KCs and MDMs. Macrophages were identified first, 
following this KCs and MDMs were defined (d). Quantification of KCs (e) and 
MDMs (f) in the liver at steady state (uninjured; grey) and at 48hrs post-APAP 
(blue). Data acquired from two independent experiments n=4-6 per group. Mann-








Figure 5.5 Phenotypic characterization of KCs. Steady state (grey), 48hrs 
(blue) and 72hrs (orange) post-APAP. 
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5.2.3 Identification of phenotypic heterogeneity in the Ly6CHi 
monocytes during AILI 
 
The MDM lineage was composed of 5 clusters, cluster 11 as discussed in 
chapter 4 was identified to be cycling cells. Expression of CCR2, LY6C2 and 
CX3CR1 across the MDMs clusters indicated that cluster 4 and 7 represented 
the pro-inflammatory Ly6CHi CCR2Hi CX3CR1Lo monocytes whereas, 5 and 3 
represented pro-reparative Ly6CLo CCR2Lo CX3CR1Hi MDMs, described by 
Zigmond et al., (2014). Here, relying on my previous gating strategy (Chapter 
3) I isolated these cells via F4/80 and CD11b expression and negative 
expression of TIMD4 (Figure 5.4d). Using Ly6C in combination with CCR2 and 
CX3CR1 failed to effectively separate monocytes from MDMs but Ly6C 
against MHCII gave a clear distinction between Ly6CHi monocytes (Ly6CHi 
MHCIILo) and Ly6CLo MDMs and this gating strategy was followed for the 
subsequent experiments (Figure 5.6c). Quantitation of Ly6CHi monocytes and 
Ly6CLo MDMs showed that both populations increased significantly and 
Ly6CLo MDMs represented the principal subset at 48hrs-post APAP, 
confirming my previous findings in chapter 3 (Figure 5.6d, e).  
 
Unsupervised clustering demonstrated heterogeneity within the hepatic Ly6CHi 
monocytes (cluster 4 and 7). Overall, cluster 4 and 7 shared a proinflammatory 
gene profile, expressing genes such as CCR1, CCR2, CCL2 involved in 
recruitment and activation of inflammatory cells (Saiman and Friedman, 2012). 
However, cluster 7 also exhibited a unique granulocytic (LCN2, RENTLG, 
VCAN, CXCR2) and immune clearance (CLEC4D, CLEC4E) gene signature. 
To delineate this heterogeneity at a protein level I had to rely on markers genes 
in cluster 7, which encoded cell surface proteins and based on availability of 
antibodies for flow cytometry, CXCR2 was chosen. Expression of CXC 
chemokine receptor 2 (CXCR2) on hepatic Ly6CHi monocytes was analyzed, 
although there were subtle changes in CXCR2 expression compared to an 
isotype control (Figure 5.7c), it was not sufficient to distinctly subset the Ly6CHi 
monocytes (Figure 5.7b). Another gene that was selectively expressed in 
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cluster 7 was SELL (CD62L) (Figure 5.7a) and analysis of CD62L expression 
on Ly6CHi monocytes showed a significant increase of CD62L+ Ly6CHi 
monocytes in the liver at 48hrs post-APAP (figure 5.d, e) and around 20% of 

















Figure 5.6 Identification of Ly6CHi monocytes and Ly6CLo MDMs in uninjured 
and APAP livers. (a) t-SNE visualization of mononuclear phagocyte (MP) by 
cluster, source and cell type, red dotted line indicates the clusters being validated.  
(b) t-SNE visualization of conventional marker genes for MDMs. (c) Defining the 
MDMs into Ly6CHi monocytes and Ly6CLo MDMs, based on Ly6C and MHCII 
expression. Quantification of Ly6CHi monocytes (Ly6CHi MHCIILo) (d) and Ly6CLo 
MDMs (Ly6CLo MHCIILo/Hi) (e) in the liver at steady state (uninjured; grey) and at 
48hrs post-APAP (blue). Data acquired from two independent experiments n=4-
















Figure 5.7 Validating heterogeneity in the Ly6CHi monocytes in uninjured and 
APAP livers. (a) t-SNE visualization of unsupervised clustering of mononuclear 
phagocytes (MPs), red dotted line indicates the clusters being validated. (b) t-SNE 
visualization of top marker genes for cluster 7. (c) Defining the Ly6CHi monocytes 
by CXCR2 expression. (d) Expression of CXCR2 on Ly6CHi monocytes at 48hrs 
post-APAP (blue), in comparison to an isotype FMO (orange). (e) Defining the 
Ly6CHi monocytes based on CD62L expression. (f) Quantification of CD62L+ 
Ly6CHi monocytes in the liver at steady state (uninjured; grey) and at 48hrs post-
APAP (blue). (g) Proportion of CD62L+ and CD62L- cells in the Ly6CHi monocyte 
compartment. Data acquired from single experiment, n=4 per group. Mann-




5.2.4 Identification of phenotypic heterogeneity within the Ly6CLo 
MDMs during AILI 
 
Expression of conventional marker genes (LY6C2, CX3CR1, CCR2) 
suggested clusters 3 and 5 represented Ly6CLo MDMs (Figure 5.6a, b). My 
previous work characterizing Ly6CLo MDMs using MHCII and CD11c 
suggested heterogeneity within these cells, during the repair phase of AILI 
(Chapter 3). Here, they partitioned into two clusters, cluster 3 was of particular 
interest, as these cells did not fit the conventional criteria currently used to 
define hepatic MDMs. Cluster 3 cells downregulated genes such as LY6C2 
and CCR2 but also had low expression of CX3CR1, a marker previously used 
to define Ly6CLo MDMs (Figure 5.6a, b). In order to delineate this 
heterogeneity, I relied on marker genes for cluster 3, as cluster 5 lacked 
uniquely expressed cell surface genes, which could be verified on protein level 
via flow cytometry. CD63 expression, was primarily in cluster 3 cells, therefore 
this was used to delineate Ly6CLo MDMs (Figure 5.8a, b). CD63 belongs to 
the tetraspanin family, its functions are mainly associated with endosomal 
pathways and it can be expressed on exosomes, plasma membranes and 
endosomes (Pols and Klumperman, 2009). Though scRNA-seq analysis did 
not identify H2-AA (MHCII) and ITGAX (CD11c) as discriminatory markers for 
MDMs, quite possibly due to their expression in DCs, I observed that a subset 
of Ly6CLo MDMs cells also expressed H2-AA (MHCII). Therefore, I used MHCII 
in combination with CD63 to investigate heterogeneity within the Ly6CLo MDMs 











In an uninjured liver the Ly6CLo MDMs separated into two main subsets: 
MHCII+ and MHCII-, with MHCII- MDMs being the dominant subset (Figure 
5.8d). In line with the scRNA-seq data, APAP induction resulted in an 
expansion of CD63+ Ly6CLo MDMs confirmed by an isotype-FMO (Figure 
5.8c). Furthermore, at 48hrs post-APAP the Ly6CLo MDMs could be separated 
into four distinct subsets, based on CD63 and MHCII expression (Figure 5.8d). 
It is important to highlight that there is an overlap in marker expression 
between macrophages and cDC2 cells, currently there are no unique surface 
markers capable of accurately separate one from the other at protein level. 
The chances that DCs could be contributing to the CD63+ MHCII+ and CD63- 
MHCII+ subsets here is minimal, as cDCs were identified and gated out prior 
to selecting cells expressing F4/80 and CD11b. I discovered CD63- MHCII- 
MDMs (green) and CD63+ MHCII- MDMs (orange) expanded significantly at 
48hrs post-APAP (three independent experiments, Figure 5.8d). ScRNA-seq 
analysis revealed a proportion of cells in cluster 3 expressed IL7R, and cluster 
3 also showed ontology enrichment for IL-7 signaling. Therefore, I was 
interested in seeing if this expression translated across to protein levels, and 














Figure 5.8 Identification of two distinct subsets of Ly6CLo MDMs populating 
the liver during the repair phase of AILI. (a) t-SNE visualization of MP clusters, 
red dotted line represents the clusters being validated. (b) t-SNE visualization of 
expression of two of the top marker genes for cluster 3 (CD63, IL7R) and MHCII. 
(c) Delineating Ly6CLo MDMs based on CD63 and MHCII expression on flow 
cytometry identified four distinct subsets of Ly6CLo MDMs at 48hrs post-APAP. (d) 
Quantification of the four subsets of Ly6CLo MDMs in the liver at steady state 
(uninjured) and at 48hrs post-APAP. (e) Upregulation of IL7R on CD63+ MDMs 
(orange and blue) at 48hrs post-APAP. Data acquired from three independent 
experiments, n= 9-12 per group. Ordinary Two-way ANOVA, using Tukey’s multiple 




5.2.5 Validation of Ly6CLo MDM heterogeneity using macrophage 
reporter mice  
 
Following identification of two specific subsets of Ly6CLo that populated the 
liver during the repair phase in wild type mice (W/T). I wanted to confirm the 
existence and the identity of these subsets in a macrophage reporter mouse. 
To do this, I characterised the Ly6CLo MDMs in a MacGreenGFP mice (Figure 
5.9a), in these mice green florescent protein (GFP) expression is driven by the 
colony stimulating factor 1 receptor (CSFR1) promoter, which is expressed 
selectively in macrophage and trophoblast lineages (Sasmono et al., 2003). 
NPC isolation and flow cytometry gating strategy were kept the same as 
before. Analysis of Ly6CLo MDM compartment in the MacGreenGFP mice also 
showed significant expansion of CD63+ MHCII- (orange) and increase in 
CD63- MHCII- (green) MDMs at 48hrs-post APAP, though the changes were 
not deemed significant, due to the low-test subjects (Figure 5.9b, c). 
Importantly, all four subsets of MDMs were positive for GFP, confirming a MP 
lineage identity for these cells (Figure 5.9d, e). Furthermore, 
immunofluorescence staining also supported the presence of CD63+ 
macrophages in the liver at 48hrs post-APAP (white arrows; Figure 5.10b). 
These cells were localized to the regenerative niches (indicated by EdU+ 
proliferating cells) of the liver at 48hrs-post APAP (Figure 5.10a). There were 
also CD63+ cells which were negative for GFP, while the CD63+ GFP+ cells 
displayed a circular morphology, the CD63+ GFP- cells were elongated and 
spindle-shaped (Figure 5.10b) ScRNA-seq data of mesenchymal cells at 48hrs 
post-APAP from the Henderson lab demonstrated CD63 expression in 
mesenchymal cells therefore based on morphology, CD63+ GFP- cells are 
likely to be mesenchymal cells. Additionally, IL7R staining in MacGreenGFP 
mice confirmed the presence of IL7R+ macrophages (IL7R+ MacGreenGFP+) 
in the liver at 48hrs post-APAP (Figure 5.11a, b). Due to antibody availability 
and technical difficulties I was not able to confirm the expression of CD63 in 
IL7R+ macrophages. Nevertheless, IL7R+ macrophages were also localized 
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to the repairing areas of the liver, and similar to the CD63+ macrophages, they 
also had a circular shape (Figure 5.11a, b).   
 
Zigmond et al., (2014) relied on GFP expression driven by fractalkine receptor 
C-X3-C motif chemokine receptor 1 (CX3CR1), to define the three subsets 
involved in AILI: KCs (CX3CR1Lo), Ly6CHi monocytes (Ly6CHi CD11bHi MHCII- 
CX3CR1+) and Ly6CLo MDMs (CX3CR1Hi, Ly6CLo). Here, the scRNA-seq data 
indicated that CX3CR1 expression is downregulated in cluster 3, this might 
explain why heterogeneity in the Ly6CLo MDMs went undetected in the past 
(Figure 5.13a). Following the same methodology and gating strategy used for 
MacGreenGFP mice, I used CX3CR1GFP/+ mice to confirm the presence of two 
main Ly6CLo MDMs at 48hrs-post APAP AILI via flow cytometry and 
immunofluorescence (Figure 5.12a). As seen with W/T mice and MacGreenGFP 
mice the MHCII- CD63+ (orange) and MHCII- CD63- (green) MDMs increased 
in numbers following APAP, when compared to their MDM counterparts and 
uninjured livers (Figure 5.12b). Future experiments with higher number of test 
subjects is needed to confirm any significant difference. In keeping with 
scRNA-seq data (Figure 5.13a), assessment of GFP expression at protein 
level showed that a subset of CD63+ MDMs (around 40%) did not express 
CX3CR1 (Figure 5.13b, c). This was supported by immunofluorescence, 
where both, dual positive CD63+ CX3CR1+ cells (white arrows) and single 
positive CD63+ cells (blue arrows) were seen localized to the repairing 
centrilobular areas of the liver (Figure 5.14). While I cannot be certain CD63+ 
GFP- here are macrophages, based on the circular morphology they are most 
















Figure 5.9 Validation of MDM clusters in MacGreenGFP mice. (a) APAP was 
administered to MacGreenGFP mice, EdU was injected to asses proliferation in the 
mice three hours prior to cull, livers were collected for flow cytometry and 
immunofluorescence analysis, uninjured MacGreenGFP mice were used at controls. 
(b) Delineation of Ly6CLo MDMs on CD63 and MHCII expression. (c) Quantification 
of double negative (green), double positive (blue), CD63+ MHCII- (orange) and 
CD63- MHCII+ (red) MDMs at 48hrs post-APAP and at steady state (uninjured). 
(d) Representative plot of GFP expression in CD63+ MHCII- MDMs. (e) Proportion 
of GFP+ and GFP- cells in each of the four subsets of Ly6CLo MDMs. Data 
acquired from two independent experiments, n=3-5 per group. Mann-Whitney 
nonparametric paired t-Test.  Data shown as Mean±S.E.M.  









Figure 5.10 Localization of CD63+ MDMs to repairing areas of the liver at 
48hrs post-APAP (a) Representative immunofluorescence images of 
MacGreenGFP mice at 48hrs post-APAP, cells were stained for CD63 (red), GFP 
(macrophages), EdU (white) and DAPI (blue) was used for nuclear detection. (b) 
Magnified image of regenerative niche (white dotted square) where CD63+ GFP+ 
are seen (white arrows), along with CD63 single positive cells (pink arrows) and 



















Figure 5.11 Localization of IL7R+ MDMs to repairing areas of the liver at 48hrs 
post-APAP (a) Representative immunofluorescence images of MacGreenGFP mice 
at 48hrs post-APAP, cells were stained for IL7R (red), GFP (macrophages), EdU 
(white). (b) Magnified image of the regenerative niche (white dotted square) showed 
IL7R+ GFP+ macrophages (white arrows), along with IL7R- GFP+ macrophages 

















Figure 5.12 Validation of MDM clusters in CX3CR1GFP/+ mice. (a) APAP was 
administered to CX3CR1GFP mice, livers were collected for flow cytometry and 
immunofluorescence analysis, uninjured CX3CR1GFP mice were used at controls. (b) 
Delineation of Ly6CLo MDMs on CD63 and MHCII expression via flow cytometry. (c) 
Quantification of the percentage of double negative (green), double positive (blue), 
CD63+ MHCII- (orange) and CD63+ MDMs (red) MDMs in 48hrs post-APAP and 
uninjured livers. Data acquired from single experiment, n=2-4 per group. Data shown 














Figure 5.13 Validation of CX3CR1GFP/+ expression in CD63+ MDMs. (a) t-SNE 
visualization of MP clusters, and the expression of CX3CR1 and CD63 across the 
MDM clusters. (b) Representative flow plots of GFP expression in CD63+ MHCII- 
MDMs, indicated the presence of GFP+ and GFP- subsets. (c) Proportion of GFP+ 
and GFP- CD63+ MDMs. Data acquired from two independent experiments, n=4 per 














Figure 5.14 Identification of CX3CR1+ CD63+ MDMs and CX3CR1- CD63+ 
MDMs in the regenerative niche of the liver at 48hrs post-APAP (a) 
Representative immunofluorescence images of CX3CR1GFP mice at 48hrs post-
APAP, cells were stained for CD63 (red), GFP (macrophages). (b) Magnified image 
of the regenerative niche (white dotted square) showed CX3CR1+ CD63+ cells 
(white) and CX3CR1- CD63+ cells (blue) (Scale bar=50µm).  
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5.2.6 CD63+ MHCII- MDMs expand during the regenerative phase of the 
AILI 
 
As discussed before, AILI is a highly dynamic model, and macrophages are 
plastic cells that change their phenotype according to their environment. In 
order to gain insight into the temporal changes in the Ly6CLo MDMs, I 
performed a time course experiment. Mice were given APAP and livers were 
harvested at: 24hrs, 48hrs, 72hrs and 96hrs post-APAP (Figure 5.15). Ly6CHi 
monocytes and Ly6CLo MDMs were identified as discussed before and 
following this Ly6CLo MDMs were assessed for their expression of MHCII and 
CD63 (Figure 5.15a). Following APAP induction all four subsets increased in 
numbers, during the inflammatory phase of AILI (24hrs) CD63- MHCII- MDMs 
were the primary subset (Figure 5.15b). However, during the peak 
regenerative phase of AILI (48 and 72hrs-post APAP) CD63+ MHCII- MDMs 
expanded the most and represented the predominant subset (Figure 5.15b). 
One of the gene ontology terms for cluster 3 was phagocytosis, C-type lectin 
genes (CLEC4D) and various phagolysosomal genes (CD63, CD9, GPNMB) 
were upregulated in cluster 3. Therefore, I assessed the expression of various 
scavenger receptors on CD63+ MHCII- MDMs when they expanded the most 
in the liver following APAP (48 and 72hrs post-APAP) and compared to the 
rest of the MDMs, to gain insight into the functional differences between them 
(5.16a, b). CD63+ macrophages as a whole had higher expression of 
scavenger receptors CD36 and MerTK, compared to the CD63- macrophages 
at 48hrs post-APAP and this expression was elevated at 72hrs post-APAP 
(Figure 5.16b). There were no major differences in the expression profile of 
CD9 and CD24 between the four subsets. CD63+ MDMs also had higher 
CD11c expression compared to the MHCII- CD63- MDMs at 48hrs post-APAP 
(Figure 5.16b). This highlighted the major phenotypic differences between the 
two main macrophage subsets: CD63+ MHCII- and MHCII- CD63- MDMs were 
the upregulation of scavenger receptors CD36 and MerTK on the former. 
Based on these results, I decided to assess functional capacity in these 

















Figure 5.15 Dynamics of CD63+ MHCII- and CD63- MHCII- MDMs during AILI. 
(a) Representative flow plots of Ly6CLo MDMs at specific timepoints during AILI. (b) 
Quantification of the four subsets of Ly6CLo MDMs during AILI shows expansion of 
CD63+ MHCII- MDMs during peak liver regeneration (48hrs-72hrs post-APAP). 















Figure 5.16 Phenotypic characterization of Ly6CLo MDMs. (a) The four subsets 
of Ly6CLo MDMs were identified on flow cytometry, based on CD63 and MHCII 
expression. (b) Representative histograms showing the expression of stated 
surface proteins with functional relevance on CD63- MHCII- (green), CD63+ 
MHCII- (orange), CD63+ MHCII+ (blue) and CD63- MHCII+ (red) macrophage 




5.2.7 CD63+ MHCII- MDMs show enhanced phagocytic capacity  
 
I used two different phagocytosis assays to assess the phagocytic capacity of 
the macrophage subsets following APAP induction. PKH26PCL is a 
commercially available cell labelling dye which forms aggregates, that are 
selectively engulfed by phagocytic cells. Detection of dye via flow cytometry 
and/or immunofluorescence can be used as an indicator of phagocytic 
capacity of cells (Campana et al., 2018). While in vivo administration of 
PKH26PCL can give you an indication of the phagocytic capacity of different 
cells, it does not tell you precisely which cells have actively phagocytosed 
during AILI. In order to address this, I used a low-pH sensing fluorescent 
probe, developed in Dr. Marc Vendrell’s lab (CIR, QMRI), that enabled the 
detection of phagosomal acidification in cells of interest (Vázquez-Romero et 
al., 2013). Two different fluorescent probes were acquired from Dr. Vendrell: 
PhagoGreen and PhagoRed, both of which operated on the same principle but 
had two different fluorophore conjugations. Optimization experiments were 
conducted to determine the optimal concentrations for each probe (Figure 
5.17). Liver NPCs from uninjured and post-APAP mice were incubated with 
either PhagoGreen or PhagoRed at varying concentrations recommended by 
Dr. Vendrell and the dye incorporation in different leucocytes were assessed 
via flow cytometry (Figure 5.17). Comparing to the FMO sample the intensity 
of PhagoRed labelling was higher than PhagoGreen (Figure 5.17), however 
delineating positive cell labelling from background proved to be more 
challenging with PhagoRed (Figure 5.17a). For example, almost all of the 
CD45+ cells appeared to be positive for the dye (Figure 5.17a). Whereas, 
PhagoGreen labelling had a clear unlabeled population of leucocytes (CD45+ 
cells; Figure 5.17b) and non-phagocytic cells such as T and B cells were 
clearly separated from phagocytic cells (KCs and MDMs) in their expression 
of PhagoGreen (Figure 5.17c). Based on these results, I decided to use 











PKH26PCL was injected intravenously into mice following APAP induction, 
16hrs prior to tissue harvesting (72hrs post-APAP), when both liver 
regeneration and CD63+ MHCII- MDMs peaked in the liver (Figure 5.18a). 
Following NPC isolation, cells were incubated with PhagoGreen, stained with 
cell surface markers and then analyzed via flow cytometry (Figure 5.18a, b). 
Geometric mean fluorescence intensity (GMFI) for PKH26PCL and 
PhagoGreen in the four subsets of Ly6CLo MDMs were calculated by 
subtracting the GMFI of FMO controls. PKH26PCL and PhagoGreen 
fluorescence was the highest in CD63+ MHCII- MDMs and CD63+ MHCII+ 
MDMs, indicating these cells had high phagocytic capacity and increased 
acidified-phagosomal content compared to the CD63- MDMs (Figure 5.18c, d). 
As discussed previously, efficiency of KC liberation at 48hrs-post APAP is low, 
but at 72hrs KCs can be liberated efficiently from APAP livers (Chapter3). 
Therefore, I compared the phagocytic capacity of CD63+ MDMs to KCs, there 
was no significant difference in PKH26PCL detection between KCs, CD63+ 
MDMs and Ly6CHi monocytes (Figure 5.18e). PhagoGreen expression on the 
Figure 5.17 Optimisation of ex vivo phagocytosis assay. Representative flow 
plot of PhagoRed+ CD45+ cells (a) and PhagoGreen+ CD45+ cells (b) and the 
expression of dye+ CD45+ cells following incubation with different concentrations 






other hand was significantly higher in CD63+ MHCII- MDMs compared to KCs 













Figure 5.18 In vivo and ex vivo assessment of phagocytosis in macrophages. 
(a) Schematic of the methodology used for phagocytosis assessment of 
macrophages. (b) Flow gating strategy to subdivide the Ly6CLo MDMs. Flow 
histograms showing the detection of PKH26PCL (c) and PhagoGreen (d) in the four 
different subsets of Ly6CLo MDMs. To the right is the measurement of PKH26PCL 
(c) and PhagoGreen (d) detected in each subset based appropriate FMO controls, 
represented as geometric mean fluorescence intensity. (e) Comparison of 
PKH26PCL and PhagoGreen expression in CD63+ MHCII- (orange) and CD63+ 
MHCII+ (blue) MDMs in comparison to KCs (purple) and Ly6CHi monocytes (green). 
Data acquired from single experiment, n=3 per group. One-way ANOVA with Dunn’s 






5.2.8 Origin of CD63+ MHCII- macrophages  
 
Having established there are four distinct subsets of Ly6CLo MDMs that 
populates the liver during the repair phase, I wanted to investigate the origin 
of these macrophages, as macrophage ontogeny can influence its function and 
behavior (Ginhoux and Guilliams, 2016). Hepatic macrophages can have one 
of two origins, they can be embryologically derived or and bone marrow 
derived. KCs have an embryological origin and it is thought the Ly6CLo MDMs, 
as the name indicates, are derived from bone marrow derived, circulating 
monocytes (Yona et al., 2013; Ginhoux and Guilliams, 2016; Guilliams, Mildner 
and Yona, 2018). Here, I have defined CD63- MHCII+, CD63+ MHCII+, CD63+ 
MHCII- and CD63- MHCII- macrophages as “MDMs”, as these cells clustered 
distinctly from KCs, and lacked KC specific markers at transcript (CLEC4F, 
TIMD4, CD5L) and protein (TIMD4) level (Appendix 6, Figure 5.4). However, 
this does not conclusively prove these cells are monocyte-derived, as 
transcriptional reprogramming of KCs to an “MDM phenotype” is also possible. 
One of the reasons for performing scRNA-seq on circulating MPs alongside 
tissue MPs was to use the transcriptional profile of these cells to assess the 
contribution of circulating monocytes to the ontogeny of hepatic macrophages, 
using in silico trajectory analysis. Unsupervised clustering on 16,399 MPs from 
eight different datasets (uninjured liver n=2, APAP liver n=2, uninjured blood 
n=2, APAP blood n=2), showed that indeed the circulating blood monocytes 
clustered next to tissue monocytes (MDM cluster 4), implying a differentiation 
trajectory from blood into tissue (Figure 5.19a). To interrogate the origin of 
CD63+ MHCII- and CD63- MHCII- macrophages, Dr. John Wilson-Kanamori 
performed Velocyto analysis on the dataset. Velocyto analysis essentially 
predicts the future transcriptional state of individual cells based on 
distinguishing spliced and unspliced precursor mRNAs ratios (RNA velocity) in 
a single cell and directionality of the differentiation process can be displayed 
by arrows (Manno et al., 2018) (Figure 5.19b). Despite the blood monocytes 
clustering closely to liver Ly6CHi monocytes (cluster 4,7), there was no 
directionality from blood MPs to tissue MPs. The arrows from cluster 4,7, 5 and 
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11 towards CD63+ MDMs (cluster 3) indicated a differentiation trajectory from 
tissue monocytes to tissue resident CD63+ MDMs. More importantly, there 
was no differentiation trajectory observed from KCs (clusters; 0,8 and 12) to 
CD63+ MDMs (cluster 3; Figure 5.19b).  
 
To confirm and validate the in-silico findings in vivo, I utilized a CCR2-/- 
transgenic mouse system, in which mice are deficient for the chemokine 
receptor CCR2, required for the recruitment of circulating Ly6CHi monocytes 
into the liver (Zigmond et al., 2014; Mossanen et al., 2016). CCR2 deficient 
mice have been used to model AILI to investigate the role of monocytes in the 
progression of liver injury (Mossanen et al., 2016). The purpose of this study 
was to investigate the origin of CD63+ MHCII- and CD63- MHCII- MDMs, 
therefore the macrophage compartment in CCR2-/- mice (n=4) was compared 
to C57BL/6 W/T (n=3) mice, following APAP overdose (Figure 5.20a). Animals 
were culled at 48hrs-post APAP, blood was drawn for serum analysis and 
livers were harvested for flow cytometric analysis (Figure 5.20a). Serum ALT 
and AST levels of CCR2-/- mice at 48hrs post-APAP were lower in comparison 
to W/T mice, however this reduction was not significant (Figure 5.20b). 
Nevertheless, CCR2-/- have been reported to exhibit less liver injury than W/T 
mice, especially in the earlier phases of AILI (12-24hrs post-APAP) (Mossanen 
et al., 2016).  Differences in the composition of KCs and MDMs were analyzed 
on flow cytometry, using the standard gating strategy as described before 
(Figure 5.20c). This showed whilst the KC numbers between CCR2-/- and W/T 
groups are comparable (Figure 5.20c, d), CCR2-/- mice showed reduction in 
both Ly6CHi Monocytes and Ly6CLo MDMs (Figure 5.20e, f). Crucially, CD63+ 
MHCII- MDM numbers were significantly lower in CCR2-/- mice in comparison 
to the W/T group, additionally, they also had lower numbers of CD63- MHCII- 
MDMs. Collectively, the in-silico analysis and experiments in CCR2-/- mice 
supported CD63+ MHCII- and CD63- MHCII- MDMs were the progeny of bone-














Figure 5.19 Computational analysis of differentiation trajectories in MP 
cluster via Velocyto (a) t-SNE visualization of mononuclear phagocyte (MP) by 
cluster, source and cell type, these cells were analyzed on Velocyto. (b) Velocyto 
results show no differentiation trajectory from blood monocytes to tissue MPs 
(indicated by the absence of arrows) but show differentiation trajectory from Ly6CHi 
























5.2.9 Identification of Ly6CLo MDM heterogeneity in other models of 
acute liver injury  
 
Having identified heterogeneity within the Ly6CLo MDMs and demonstrated the 
emergence of four distinct subsets Ly6CLo MDMs during AILI, I wanted to see 
if a similar macrophage programming could be seen during other types of liver 
injury. To investigate this, I used two different models of liver injury: Carbon 
tetrachloride (CCl4) and partial hepatectomy (PHx). CCl4 is a standardly used 
model of liver cirrhosis, chronic iterative administration of CCl4 leads to 
recurrent hepatocyte necrosis which results in fibrosis and cirrhosis. For the 
purposes of this study, animals were administered a single dose of CCl4 to 
induce hepatocellular death and acute inflammation and livers were collected 
at stated timepoints (Figure 5.21a). PHx (70% surgical resection) was 
performed as previously described, and livers were harvested at 48hrs-
following PHx (Figure 5.21a). Livers were also collected from uninjured and 
post-APAP animals for comparison (Figure 5.21a).  Analysis of the Ly6CLo 
MDMs demonstrated that MDMs during CCl4 injury the Ly6CLo MDMs adopted 
four distinct phenotypes similar to that seen during AILI (Figure 5.21b). Both 
CD63+ MHCII- (orange) and CD63- MHCII- MDMs (green) were significantly 
increased at 72hrs-post CCl4 in comparison to basal levels (Figure 5.21c). 
Whereas, there was no significant difference between the composition of 
Figure 5.20 Assessing the origin to CD63+ MHCII- and CD63- MHCII- MDMs 
using CCR2 deficient mice (a) Methodology used to study the origin of hepatic 
CD63+ MHCII- and CD63- MHCII- MDMs consisted of administering APAP to CCR2-
/- and wildtype (W/T) mice, prior to liver and serum analysis at 48hrs post-APAP. (b) 
Serum AST and ALT measurements of CCR2-/- and W/T mice at 48hrs post-APAP. 
Representative flow plots (c) and quantitative analysis (d) showing the differences in 
KCs and MDMs in CCR2-/- and W/T mice. Representative flow plots (e) and 
quantitative analysis (f) showing the differences in Ly6CHi monocyte and Ly6CLo MDM 
numbers in CCR2-/- and W/T mice. The Ly6CLo MDMs were defined on CD63 and 
MHCII expression (g), and the four subsets of MDMs were quantified for both CCR2-
/- and W/T mice (h). Data acquired from single experiment, n=3-4 per group. Mann-
Whitney nonparametric paired t-Test. Data shown as Mean±S.E.M, **P≤0.01, 




Ly6CLo MDMs following PHx versus uninjured livers (Figure 5.21b, c). 
Strikingly, expansion of both MDMs was more pronounced (around fourfold 
increase) following CCl4 than APAP (Figure 5.21c). These findings suggested 
that macrophage differentiation and heterogeneity in the liver is heavily 
























In this chapter I have attempted to validate the scRNA-seq findings at a protein 
level to dissect the heterogeneity within the MDM compartment during the 
repair phase of AILI, to identify specific pro-regenerative subpopulations of 
macrophages. Validation of broad MP lineages (cDC1, cDC2, KC and MDM) 
were made possible by the top marker genes generated through differential 
expression analysis. Defining of most of the lineages were relatively straight 
forward, though identifying cDC2 cells required prior knowledge (cDC2 cells). 
The significant expansion of MP lineages at 48hrs post-APAP, in comparison 
to uninjured livers highlighted the contribution from these cells during the repair 
phase of AILI. Transcriptional profile of KCs from uninjured and post-APAP 
livers indicated these cells are not dramatically different post-injury, they 
exhibited subtle changes in the degree of expression of certain genes rather 
than an on and off expression. That was not to say these subtle changes will 
not result in major phenotypical and functional differences in these cells and 
indeed there were changes in the expression of various cell surface proteins. 
Significant upregulation of CD36 gene expression in KCs at 72hrs post-AILI 
has  been reported previously (Graubardt et al., 2017), here, I have shown 
CD36 expression is dramatically increased at protein level as well. CD36 on 
macrophages has been shown to promote inflammation resolution via 
promotion of phagocytosis (Woo et al., 2016).   CD24 also has a functional 
role in AILI, where they were shown to dampen tissue injury and damage to 
Figure 5.21 Characterizing the Ly6CLo MDM compartment on CD63 and MHCII 
expression in PHx and CCl4 models of liver injury. (a) Mice were subjected to 
acute liver injury by one of the following ways: single administration of APAP, single 
administration of CCl4 or 70% partial hepatectomy (PHx), livers were harvested and 
analyzed via flow cytometry at stated timepoints, following injury. (b) Representative 
flow plots from at Ly6CLo MDM compartment at stated specific time points following 
APAP, PHx and CCl4, compared to uninjured groups. (c) Quantification of the Ly6CLo 
MDM subsets in each group. Data acquired from single experiment, n=3 per group. 
3way ANOVA with Tukey’s multiple comparisons test. Data represented as 





promote an anti-inflammatory phenotype (Chen et al., 2009). Timely 
upregulation of these molecules indicate KCs are programmed towards a pro-
regenerative phenotype during the repair phase of AILI. Post-APAP KCs did 
not show any changes in the expression of MerTK, my findings indicate 
upregulation of MerTK by Ly6CLo MDMs (Figure 5.16) but not KCs (Figure 5.5). 
This was in contradiction with the observation made by Triantafyllou et al 
(2018), where the authors show a dramatic increase in MerTK+ KCs via flow 
cytometry, at 24 and 48hrs post-APAP. A possible reason of this disparity 
might be the differences in gating strategy, the lack of KC specific markers 
(TIMD4, CLEC4F) in their study could have led to the inclusion of MerTK+ 
F4/80+ Ly6CLo MDMs in their analysis (Triantafyllou et al., 2017). Contrary to 
the general belief in the field that KCs are sessile cells localized to sinusoids, 
my previous findings (Chapter 3, Figure 3.6) revealed that KCs localize to the 
repairing areas of the liver during AILI. Additionally, in this chapter I have 
demonstrated that there are major phenotypic changes in the KCs during the 
repair phase of AILI. Collectively these findings call for future studies to 
interrogate the precise function of these cells.  
 
Ly6CHi monocytes were long thought to be an injury promoting subset (Holt, 
Cheng and Ju, 2008), transcriptomic analysis showing an upregulation of 
angiogenic, wound healing and matrix remodelling genes in Ly6CHi monocytes 
and their role in promoting neutrophil apoptosis has painted them in a different 
light recently (Zigmond et al., 2014; Graubardt et al., 2017). Here, Ly6CHi 
monocytes split into two distinct clusters, gene ontology enrichment analysis 
in chapter 4 suggested that these two clusters might not only be 
transcriptionally distinct but functionally distinct. While cluster 7 showed 
enrichment of genes which regulated neutrophil recruitment, neutrophil 
clearance and, and glutathione biosynthesis, cluster 4 showed upregulation of 
genes relating to leucocyte migration and differentiation. What has been 
lacking until now is the distinction of this duality in Ly6CHi monocytes at a 
protein level, therefore I attempted to delineate this heterogeneity via flow 
cytometry. Characterization of Ly6CHi monocytes on CD62L expression 
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(unique to clusters 7) showed an expansion of CD62L+ Ly6CHi monocytes at 
48hrs post-APAP, compared to steady state, however there was not a clear 
distinction between CD62L+ Ly6CHi monocytes and CD62L- Ly6CHi 
monocytes. Perhaps this is not surprising, as Ly6CHi monocytes are on a 
differentiation spectrum, where they undergo transcriptional programming 
towards a pro-restorative phenotype (Zigmond et al., 2014; Mossanen et al., 
2016). Nevertheless, CD62L+ Ly6CHi monocytes represented 20% of the 
overall Ly6CHi monocyte subset in APAP mice. Future studies looking at 
expression of markers generated via scRNA-seq at both transcript and protein 
level in CD62L+ Ly6CHi monocytes vs CD62L- Ly6CHi monocytes could help 
delineate any functional differences in these cells.  
Currently, Ly6CLo MDMs are broadly characterized as the “pro-reparative” 
subset showing ability to promote matrix remodelling, angiogenesis, and 
phagocytosis during AILI (Zigmond et al., 2014; Graubardt et al., 2017). 
ScRNA-seq of these cells has revealed heterogeneity, the distinct gene 
ontology terms associated with cluster 5 and 3 suggested functional 
differences in these cells. Phenotypically delineating cluster 5 and cluster 3 
was more challenging, though cluster 3 had a range of discriminatory genes 
including SYNGR, SPP1, GPNMB, ADAM8, LMNA, EMP1 (Appendix 7) 
identifying these targets via multi-parametric flow cytometry was challenging. 
This meant I had to rely on known biology, my previous data (chapter 3) 
indicated differentially expression of MHCII by Ly6CLo MDMs (Figure 3.7). 
Based on this, using MHCII in combination with CD63 I identified four distinct 
subsets of Ly6CLo MDMs.  
The temporal dynamics of CD63- MHCII- and CD63+ MHCII- macrophages, 
whereby they expanded at 24hrs and 48hrs post-APAP suggests they might 
have distinct functions during AILI. The main functional difference between 
CD63+ MHCII- and CD63- MHCII Ly6CLo MDMs identified here was their 
ability to phagocytose. CD63+ MHCII- macrophages demonstrated a number 
of phagocytic characteristics, which has been associated to tissue repair. They 
upregulated MerTK and CD36 at 48 and 72hrs post-APAP. MerTK expressing 
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macrophages promote tissue resolution during ALF resulting from APAP 
overdose in both humans and murine models (Triantafyllou et al., 2017). CD36 
on the other hand is a scavenger receptor, which functions in oxidized low-
density lipoprotein uptake and its role to promote efficient efferocytosis by both 
murine and human macrophages is well-known (Park, 2014; Greenlee-
Wacker, 2016). CD36+ macrophages has also been shown to promote tissue 
resolution through phagocytosis in a murine model of ischemic stroke (Woo et 
al., 2016). At transcript level CD63+ MDMs (cluster 3) expressed phagocytosis 
promoting genes such as CLEC4D and GPNMB. GPNMB functions to mediate 
phagosomal maturation and degradation of cargo in macrophages (Li, 
Castano, Hudson, Nowlin, S. L. Lin, et al., 2010; Campana et al., 2018).  My 
data showed that PhagoGreen (detects phagosomal acidification) expression 
was significantly higher in CD63+ MHCII- MDMs than KCs at 72hrs-post 
APAP, this fits with the scRNA-seq data. These findings in addition to the 
topography of the CD63+ macrophages in liver, where they localize in the 
regenerative niche (Figure 5.10) suggests that these cells might function to 
clear necrotic and apoptotic debris. Notably, KCs also exhibit phagocytic 
features and are found within the repairing areas of the liver during AILI, 
therefore there might be functional redundancies between KCs and Ly6CLo 
MDMs. The role of CD63- MHCII- MDMs also needs to be addressed, the 
temporal dynamics suggested that these cells are involved in the repair 
process. Flow cytometric phenotypic characterizations demonstrate they are 
distinct to CD63+ MHCII- MDMs, however this was insufficient to interrogate 
the function of these cells.  
Additionally, in line with the scRNA-seq data, the CD63+ MDMs (cluster 3) 
showed upregulation of IL7R at protein level and IL7R+ GFP+ cells were 
detected in the repairing areas of the liver at 48hrs post-APAP, these cells had 
a monocytic appearance (Figure 5.11). IL-7 signaling is commonly associated 
with lymphogenesis and very recently been associated with macrophages 
development (Fry and Mackall, 2009; Leung et al., 2019). Their role in 
pathological conditions is limited to autoimmune conditions such as 
rheumatoid arthritis, where IL7R+ monocytes were shown to promote 
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inflammation via TNF-a production (Chen et al., 2013). ScRNA-seq of synovial 
fluid of spondyloarthritis patients in a recent study identified a distinct subset 
of monocytes expressing IL7R+, the function of these cells is unknown (Al-
mossawi et al., 2018). Currently there is no evidence to show that they are 
involved in tissue repair and resolution.  
Despite the transcriptional similarities in circulating Ly6CHi monocytes to tissue 
Ly6CHi monocytes, namely cluster 7, computational trajectory analysis of MPs 
failed to show directionality from blood monocytes to tissue monocytes and 
MDMs. One of the reasons for this could be because the dataset consisted of 
cells from a single time-point and infiltration of Ly6CHi monocytes into the liver 
occurred at earlier timepoints (Chapter3, Figure 3.5). However, the Velocyto 
analysis did show directionality from tissue Ly6CHi monocytes towards CD63+ 
Ly6CLo MDMs (Cluster 3). Experiments in CCR2 deficient mice suggests the 
four subsets of Ly6CLo MDMs are derived from CCR2+ Ly6CHi circulating 
monocytes and are not derived from resident KCs. However, I cannot deny the 
possibility that there might be tissue resident CCR2+ precursors in the liver 
that could give rise to Ly6CLo MDM subsets. In order to confirm a systemic 
origin, I would need to do additional experiments to trace circulating 
monocytes. For instance, the MacBlueCFP transgenic reporter system, in which 
CFP expression is driven by truncated CSF1R promoter represents an 
effective tool to investigate this. In these tissue resident KCs do not express 
CFP, whereas circulating monocytes do (Sauter et al., 2014). Additionally, 
labelling BM-derived circulating monocytes with DNA intercalators such as 
EdU or BrdU and then using proliferation as a readout is another way to prove 
or disprove origin from circulating cells in this context (Yona et al., 2013).  
The finding that CCR2-/- mice exhibit less injury than W/T mice is in keeping 
with existing literature, based on the study by Mossanen et al (2016). This 
reduction in injury is one of the main reasons why CCR2+ Ly6CHi monocytes 
have been considered to be a pro-injury subset during AILI, consequently, 
CCR2 blocking or inhibition has been suggested as a therapeutic strategy in 
the clinical setting. It is important to note that the effect of ablating CCR2+ 
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Ly6CHi monocytes led to significant reduction in the pro-regenerative Ly6CLo 
MDM subset here. Furthermore, Yang et al. (2019) reports significantly lower 
hepatocyte proliferation in CCR2-/- mice, in comparison to wild type 
counterparts. Therefore, CCR2 inhibition represents a potential early 
therapeutic intervention, which might be ineffective in late-presenting cases in 
the clinical setting and while CCR2 inhibition dampens liver injury, it does not 
promote the regenerative capacity of the liver (Mossanen et al., 2016).  
There are a lot of similarities and differences in the characteristics and 
dynamics of MPs in the context of acute liver injury. In chapter 3 I showed the 
lack of contribution from bone-marrow derived Ly6CHi monocytes and MDMs 
during the regenerative phase of PHx, in comparison to AILI. This highlights 
that macrophage response during liver injury and regeneration is dependent 
on the type of injury inflicted. Similar to AILI, CCl4 also show expansion of 
CD63+ MHCII- and CD63- MHCII- MDMs, whereas following PHx these 
populations did not expand and was similar to basal levels. Perhaps this is not 
surprising as both the hepatic and systemic environment is widely different in 
AILI and CCl4 compared to PHx and we know that macrophage phenotype is 
influenced by environmental cues. Both AILI and CCl4 cause centrilobular 
necrosis, resulting in massive inflammatory response, while PHx represents a 
relatively non-inflammatory model, showing minimal systemic involvement. 
Further studies need to be carried out to determine the Ly6CLo phenotype in 
other models of injury and repair, where there is a systemic involvement, both 
in the liver and other organs. There is a lot of transcriptional and phenotypic 
overlap in the phenotype of CD63+ MHCII- MDMs identified here and the 
Ly6CLo MDM subset responsible for resolution of fibrosis, reported in 
Ramachandran et al.  (2015). Namely, the upregulation of genes such as IGF1, 
GPNMB, MerTK, CD36 and the increased capacity to phagocytose, 
additionally they share a common origin from circulating Ly6CHi monocytes. 
Although these cells share some phenotypic similarities, there are also 
differences between them, the matrix metalloproteinase signature displayed 
by the “pro-restorative Ly6CLo MDMs” reported in Ramachandran et al. (2012) 
is not observed in the Ly6CLo MDMs here.  
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Non-alcoholic steatohepatitis (NASH) is another model of characterized by the 
similar features seen in AILI; infiltration of CCR2+ Ly6CHi monocytes and their 
differentiation into Ly6CLo MDMs. Recently, scRNA-seq of myeloid cells during 
NASH revealed heterogeneity within the macrophages and a subset of these 
macrophages displayed a distinct anti-inflammatory metabolic gene signature, 
which the authors termed as “NAFLD gene signature” (Krenkel et al., 2019). 
Collectively, these observations demonstrate the multitude of functional 
adaptations of circulating Ly6CHi monocytes to differentiate into phenotypically 
and functionally distinct Ly6CLo MDMs.  
 
In this final chapter I have validated the scRNA-seq results, identified and 
characterized the broad MP lineages populating the liver during the repair 
phase of AILI (48hrs post-APAP). Centered around the markers identified 
through scRNA-seq and known markers I attempted to dissect the 
heterogeneity within the MDMs. This led to the discovery that following acute 
inflammation Ly6CHi monocytes can differentiate into four distinct macrophage 
populations, two of which are heavily involved in the injury and repair process 
(CD63+ MHCII- and CD63- MHCII- MDMs). Phenotypic characterization and 
functional assays suggest a phagocytic role for CD63+ MHCII- MDMs, while 
the role of CD63- MHCII- MDM subset remains unknown. While we are moving 
away from the M1 and M2 dichotomous classification, this chapter has 
highlighted that solely relying on predefined markers to classify and study 
monocytes and macrophages can massively underestimate functionally 
relevant heterogeneity in these cells. The findings presented here suggests 
CD63+ MHCII- Ly6CLo MDMs may represent a pro-reparative subset, future 










In my doctoral studies I utilised scRNA-seq to investigate circulating and 
hepatic monocyte and macrophage heterogeneity in an unbiased manner 
during AILI, facilitating the identification of injury-specific subsets. 
Transcriptome analysis of circulating Ly6CHi monocytes revealed AILI-induced 
monocyte reprogramming towards a “granulocytic signature” prior to their entry 
into the liver and indicated heterogeneity within the hepatic Ly6CHi monocytes 
and Ly6CLo MDMs. Subsequent phenotypic validation delineated Ly6CHi 
monocytes into two subsets:  CD62L+ and CD62L-. It also led to the 
identification of four distinct subsets of Ly6CLo MDMs populating the liver 
during the repair phase of AILI, characterized by differential expression of 
CD63 and MHCII. This was confirmed in two different macrophage reporter 
mice (CX3CR1GFP/+ and MacGreenGFP). CD63+ MHCII- and CD63- MHCII- 
Ly6CLo MDMs were the predominant subsets in the liver during peak 
regeneration. The main functional difference between CD63+ MHCII- and 
CD63- MHCII- Ly6CLo MDMs was phagocytic ability. Tissue staining revealed 
CD63+ macrophages are localized to areas of repair within the liver, where 
they may be exposed to necrotic debris. In vivo and ex vivo phagocytic assays 
confirmed CD63+ macrophages exhibit increased phagocytic capacity and 
phagosome maturation in comparison to their CD63- Ly6CLo counterparts and 
KCs. Experiments in a CCR2 deficient system suggests the four subsets of 
Ly6CLo MDMs are a progeny of BM-derived CCR2+ circulating monocytes. 
The emergence and expansion of CD63+ MHCII- and CD63- MHCII- Ly6CLo 
MDMs during acute CCl4 injury, but not partial hepatectomy, suggests these 
activation states result from an inflammatory cue in the liver. This body of work 
lays the foundation for future work that will investigate the functional relevance 
of these subsets during AILI.  
 
 
Monocytes and macrophages have a dual role during AILI due to their ability 
to change phenotype based on microenvironmental cues, consequently   
 199 
pinpointing precise therapeutic targets has been challenging.  I used scRNA-
seq, during AILI and homeostasis, to delineate specific injury and repair 
promoting subsets. In order to achieve this a broad characterisation of the AILI 
model was necessary to inform timepoint selection for scRNA-seq.  When I 
began my PhD there were few studies that had extensively characterised 
leucocyte responses following AILI (You et al., 2013; Zigmond et al., 2014; 
Guillot and Tacke, 2019). As liver injury responses in mice can be influenced 
by a number of factors including strain background, APAP dose and route of 
administration (Mossanen and Tacke, 2015), I had to characterise leucocyte 
responses throughout the course of AILI in C57BL/6 mice. As shown in Figure 
3.1 and 3.2 6hrs-24hrs post-APAP represented a necroinflammatory (injury) 
phase, characterised by significant necrosis and elevated serum liver enzyme 
levels. The repair phase was between 48hrs-168hrs, defined by a reduction in 
necrosis and restoration of tissue architecture. Hepatocyte proliferation 
peaked between 48hrs-72hrs post-APAP.  
 
As described in chapter 1, the leucocyte response in the liver during AILI is not 
limited to monocytes and macrophages, with a wide range of innate and 
adaptive immune responses influencing liver injury and repair. Therefore, 
using multi-parametric flow cytometry, I simultaneously numerically 
characterized both innate and adaptive leucocytes in the same panel over the 
course of AILI for the first time (Figure 3.3 and 3.4). This highlighted that 
macrophages are the most dominant subset in the liver during peak 
hepatocyte proliferation (48hrs-72hrs post-APAP). Utilizing CX3CR1GFP/+ mice 
Zigmond et al, (2014) categorized monocytes and macrophages populating 
the liver during AILI into three distinct subsets:  KCs, Ly6CHi monocytes and 
Ly6CLo MDMs. As shown in Figure 3.5-3.7 these subsets were identified and 
characterized via flow cytometry. Further phenotypic characterization of these 
subsets revealed heterogeneity within Ly6CLo MDMs, which was previously 
reported as a homogenous population, emphasizing the need to study these 
cells at higher resolution.  
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In chapter 4, I optimised a digestion protocol which allowed isolation of a high 
percentage of viable cells, which is critical in the generation of high-quality 
scRNA-seq data (Figure 4.1-4.3). Previous gene expression studies in the 
context of AILI has relied heavily on known biology, to pre-define monocytes 
and macrophages prior to sequencing (Zigmond et al., 2014; Mossanen et al., 
2016; Graubardt et al., 2017; Triantafyllou et al., 2017). I do believe this 
strategy can limit the identification of novel subtypes and activation states that 
do not conform to the conventional classifications. Therefore, a broad gating 
strategy (all CD45+ cells) was used in isolating cells for scRNA-seq, avoiding 
any front-end selection bias. One could argue this can result in monocytes and 
macrophages being underrepresented in the sample, however these cells 
represented the pre-dominant leucocytes in the liver at 48hrs-post APAP. 
Additionally, given that the number of cells sequenced via the 10X platform 
ranged in the tens of thousands, underrepresentation was unlikely. Indeed, 
broad clustering of CD45+ cells post-sequencing demonstrated the highest 
number of cells were within the mononuclear phagocyte (MP) lineage, which 
includes monocytes and macrophages.  
 
In addition to developing laboratory skills in a cutting-edge technique, this body 
of work exposed me to computational analysis of large datasets. The in silico 
analysis was performed in collaboration with a post-doctoral bioinformatician, 
Dr. John Wilson Kanamori, who is based in the Henderson group. I was able 
to gain valuable insights into the different stages involved in scRNA-seq data 
analysis.  As a result, I now have a greater understanding of data processing, 
the importance of QC steps and normalization and importantly, interpretation 
of scRNA-seq data.  
 
One of the novel findings from my scRNA-seq data was the identification of an 
APAP-specific subset of Ly6CHi monocytes, characterized by a “granulocytic” 
signature (Figure 4.13). Transcriptional switching of circulating monocytes 
following tissue injury has been reported in several other studies (Yáñez et al., 
2017; Ikeda et al., 2018; Krenkel et al., 2019). Contrary to the transcriptional 
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switching seen during NAFLD injury, where monocytes downregulate 
inflammatory genes such as calprotectin genes S100A8/A9 and RTENLG 
(Krenkel et al., 2019), the observation here is akin to the emergence of distinct 
subset of monocytes seen during LPS-induced inflammation (Yáñez et al., 
2017; Ikeda et al., 2018). Yanez et, (2017). In these instances, monocytes are 
derived from granulocyte myeloid precursors (GMPs) expressing a wide range 
of neutrophil genes such as S100A8/A9, LCN2, which is similar to the changes 
I have observed in my scRNA-Seq data. This finding raises a number of 
questions. What is the origin of these cells? Are they derived from cMoPs 
(common monocyte precursor) and then undergo transcriptional switching 
following AILI or are these cells the progeny of GMPs? What is the functional 
relevance of this transcriptional preprogramming? Ikeda et al, (2018) reported 
transcriptional switiching of Ly6CHi monocytes to an immunoregulatory 
phenotype, defined by YM1 expression, which drove tissue repair in a murine 
model of colitis. In the context of AILI are these “granulotyic” monocytes driving 
the repair process or promoting injury? In order to precisely address these 
questions markers are required which allow discrimination between the various 
Ly6CHi monocyte subsets. As most of the discriminatry markers (LCN, 
S100A8/A9, RTENLG) are intracellular proteins and show wide expression in 
both monocytes and neutrohpils, genetically modified Cre-based murine 
systems may be best suited for the future study of these cells.  
 
As shown in Figure 4.10, 4.12 scRNA-Seq of tissue monocytes and 
macrophages during AILI and homeostasis revealed heterogeneity, within KCs 
(Custer 0, 8 and 12), Ly6CHi (cluster 4 and 7) monocytes and Ly6CLo MDMs 
(cluster 5 and 3). One of the main unanswered questions in the field is the 
precise function of KCs during the repair phase of AILI. Although APAP 
specific KCs formed a distinct cluster compared to homeostatic KCs (Figure 
4.10, 4.12), there were no differentially expressed markers which delineated 
the two clusters (Appendix 6). This might be a true biological observation, 
where any APAP-induced transcriptional changes occurring in KCs are subtle 
at gene level, perhaps with more profound post-transcriptional phenotypic and 
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functional changes. The low-read depth and high dropout rate associated with 
the 10X Genomics Chromium system could also have contributed to the lack 
of transcriptional changes between cluster 0 (homeostatic) and cluster 8 
(APAP specific) (Appendix 6). The other more likely explanation is that the 
tissue digestion protocol did not efficiently liberate the “true” injury specific 
population of KCs. Based on immunofluorescence they migrate to areas of 
injury (Figure 3.6) at 48hrs APAP, however despite this no chemotaxis related 
genes were identified in the scRNA-seq analysis. As discussed in chapter 3, 
developing cell isolation protocols which liberate more KCs, in combination 
with imaging studies, are needed to study these cells during the repair phase 
of AILI.  
 
My work in chapter 5 consisted of phenotypically and functionally validating 
scRNA-seq findings using novel marker genes to delineate the heterogeneity 
within Ly6CHi monocytes and Ly6CLo MDMs. ScRNA-seq data indicated that 
SELL (CD62L) marks cluster 7 but not cluster 4 (Figure 5.7). CD62L, also 
known as L-selectin is a type-I transmembrane glycoprotein which regulates 
monocyte trafficking and transmigration into tissue (Geissmann, Jung and 
Littman, 2003; Xu et al., 2008). It is characteristically expressed by 
inflammatory Ly6CHi CCR2+ monocytes (Geissmann, Jung and Littman, 2003; 
Auffray, Sieweke and Geissmann, 2009), and I found that CD62L expression 
was present on a subset of Ly6CHi monocytes at 48hrs-post AILI (Figure 5.7). 
Gene ontology enrichment analysis in chapter 4 generated distinct terms for 
cluster 4 and cluster 7. The terms for cluster 4 (CD62L-) were associated with 
leucocyte migration and differentiation whereas cluster 7 (CD62L+) had terms 
related to immune complex clearance, neutrophil aggregation and clearance 
(Figure 4.12). Ly6CHi monocytes have a role in regulating neutrophil function 
and apoptosis during AILI (Graubardt et al., 2017), and given the gene 
ontology terms associated with cluster 7, CD62L+ Ly6CHi monocytes may 
mediate this. Alternatively, this might represent a monocyte differentiation 
phenotype, i.e. newly recruited Ly6CHi monocytes express CD62L+ and 
subsequently downregulate CD62L expression, thus CD62L- Ly6CHi 
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monocytes could represent an intermediary subset during their reprogramming 
towards Ly6CLo MDMs (Zigmond et al., 2014).  
 
In the context of AILI, Ly6CLo MDMs are defined as a homogeneous pro-
reparative macrophage subset, which are progeny of BM-derived Ly6CHi 
monocytes (Zigmond et al., 2014; Mossanen et al., 2016; Graubardt et al., 
2017). With the aid of scRNA-seq I have shown that Ly6CLo MDMs are 
heterogenous, and using MHCII expression in combination with CD63, I 
identified four distinct subpopulations of Ly6CLo MDMs populating the liver at 
48hrs-post APAP (Figure 5.8). 
 
• CD63+ MHCII-  
• CD63+ MHCII+ 
• CD63- MHCII+  
• CD63-MHCII- 
 
Identification of these subsets in MacGreenGFP and CX3CR1GFP/+ reporter mice 
confirmed that these cells belong to the mononuclear phagocyte system (MPS) 
(Figure 5.10-5.14). The complexity between dendritic cells (DCs) and 
macrophages was mentioned in chapter 1, MHCII and CD11c expression is 
insufficient to faithfully isolate DCs from macrophages. As cDC1, cDC2 and 
pDCs subsets were removed during front-end analysis based on positive 
expression of XCR1, CD24, SiglecH, and CD11c, and negative expression of 
F4/80, it is unlikely that the MHCII expressing cells are derived from the 
common DC progenitor (cDP) lineage. Experiments in CCR2-/- mice (Figure 
5.20) revealed Ly6CLo MDM subsets were deficient in this system, suggesting 
these cells are a progeny of CCR2+ Ly6CHi monocyte derived from cMoPs in 
the bone marrow (Serbina and Pamer, 2006; Mossanen et al., 2016; Guilliams, 
Mildner and Yona, 2018). Studies have described the capacity of circulating 
monocytes to give rise to dendritic cells referred to as m-DCs (monocyte-
derived DCs) (Serbina, Shi and Pamer, 2012; Menezes et al., 2016; Mildner 
et al., 2017). I cannot be certain that the MHCII expressing Ly6CLo MDM 
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subsets described here are not m-DCs as these cells also show expression 
for the classic macrophage markers CD64 and F4/80 (Guilliams and van de 
Laar, 2015). Currently, it is impossible to distinguish between m-DCs and 
MDMs solely based on marker expression. To definitively do this I would need 
to investigate their relative migration and T-cell interaction potential (Guilliams 
and van de Laar, 2015). Further studies will be required to fully elucidate the 
function of mDCs and MDMs during AILI.  
 
The expansion of CD63+ MHCII- and CD63- MHCII- MDMs during peak 
hepatocyte regeneration suggests these cells may be involved in liver repair 
(Figure 5.15). The mechanism by which Ly6CLo MDMs drives liver repair has 
been attributed to phagocytosis; specifically the clearance of apoptotic 
neutrophils (efferocytosis) (Graubardt et al., 2017; Triantafyllou et al., 2017). 
Indeed, phagocytic capacity was a distinguishing feature between the two 
most dominant Ly6CLo MDM subsets, CD63+ MHCII- MDMs have significantly 
higher phagocytic capacity than CD63- MHCII- MDMs (Figure 5.18). 
Localisation of CD63+ macrophages to areas of repair in the liver would be 
consistent with this function, where they are likely to encounter apoptotic 
neutrophils and necrotic debris which they may phagocytose (Figure 5.10). 
We know that acidification of the phagolysosome is an indicator of phagosome 
maturation and thus successful cargo degradation (Kinchen and 
Ravichandran, 2008). In addition to CD63, which has a role in endosomal 
pathways, cluster 3 cells showed upregulation of GPNMB (Appendix 7), known 
to regulate phagosome maturation in phagocytic cells (Li, Castano, Hudson, 
Nowlin, S. L. Lin, et al., 2010). In concordance, the PhagoGreen assay which 
detects acidified phagolysosomes demonstrated that both CD63+ Ly6CLo 
MDM subsets had increased acidified phagolysosome activity compared to 
CD63- Ly6CLo MDMs and KCs during the repair phase (72hrs-post APAP) 
(Figure 5.18). This lends weight to CD63+ MHCII- MDMs being the principle 
phagocytic subset in the liver during the repair phase of AILI.  
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The link between successful phagosome maturation and tissue repair has 
been demonstrated by several studies utilizing GPNMB deficient mice (Li, 
Castano, Hudson, Nowlin, S.-L. Lin, et al., 2010; Campana et al., 2018). 
GPNMB is a protein that is necessary for recruitment of autophagy protein LC3 
to the phagosome, mediating lysosomal fusion with phagosomes containing 
apoptotic cargo (Li, Castano, Hudson, Nowlin, S. L. Lin, et al., 2010). 
Therefore, GPNMB deficient mice have the ability to engulf but do not degrade 
phagocytosed cargo. Following acute kidney injury, GPNMB was upregulated 
in inflammatory monocytes and GPNMB mutant mice had a 5-fold increase in 
apoptotic cellular debris in comparison to wild type mice, which was also 
accompanied by an 85% increase in mortality (Li, Castano, Hudson, Nowlin, 
S. L. Lin, et al., 2010). In the context of acute and chronic liver injury induced 
by APAP and CCl4 respectively, successful phagocytic cargo degradation 
limited tissue injury, promoted polarization of macrophages and increased 
hepatocyte proliferation (Campana et al., 2018). Here, CD63+ MHCII- Ly6CLo 
MDMs may serve to efficiently carry out phagocytosis to promote liver repair.  
 
To fully understand the mechanism by which CD63+ MHCII- Ly6CLo MDMs 
may promote liver repair, there are number of questions that remain 
unanswered: Is liver regeneration induced by debris removal, where a niche is 
created for hepatocyte proliferation or can macrophage phagocytosis also 
release mitogens to directly induce hepatocyte proliferation? There have been 
reports to suggest that clearance of hepatocyte debris can induce Wnt3a, 
which acts on hepatocytes to promote liver regeneration following biliary liver 
injury (Boulter, Govaere and Bird, 2012). This begs the questions whether 
CD63+ MHCII- macrophages show preferential uptake of necrotic versus 
apoptotic debris? In vitro studies suggest apoptotic versus necrotic uptake by 
macrophages activate distinct signaling events (Reddy et al., 2002). During 
AILI hepatocyte necrosis precedes neutrophil apoptosis. So, are there distinct 
macrophage subsets equipped to mediate necrotic and apoptotic cell 
clearance or are phagocytic macrophages equally capable of carrying out 
efferocytosis regardless of the nature of cellular debris? Data by Triantafyllou 
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et al, (2017) shows that secretory leucocyte protease inhibitor (SLPI), can 
promote MerTK expression on macrophages to induce efferocytosis when 
they are presented with apoptotic neutrophils, but not apoptotic and necrotic 
hepatocytes (Triantafyllou et al., 2017). This supports the notion that there are 
distinct cues and outcomes involved in macrophage-mediated efferocytosis, 
interrogating these mechanisms may go a long way in the identification of 
precise macrophage-based targets to drive liver repair.  
 
The four subsets of Ly6CLo MDMs were also identified during CCl4 induced 
acute liver injury, but not partial hepatectomy (PHx). As with APAP a similar 
expansion was seen in CD63+ MHCII- and CD63- MHCII- macrophages at 
48hrs and 72hrs post-CCl4, but the increase was more profound in CCl4 
compared to APAP-induced liver injury (Figure 5.21). These results indicate 
inflammation is a key driver in dictating macrophage responses and activation 
states. PHx is a relatively non-inflammatory model where the mechanisms by 
which macrophages drive liver repair may be different to that in APAP and 
CCl4-induced liver injury. As shown in chapter 3, there is very minimal 
inflammatory infiltrate such as neutrophils and Ly6CHi monocytes following 
PHx in comparison to APAP (Figure 3.10-3.12). It may be interesting to see if 
similar macrophage phenotypes are observed during chronic liver injury or in 
other models of tissue injury which involve inflammation as a primary stimulus.  
 
One of the gene ontology terms for cluster 3 (CD63+ Ly6cLo MDMs) was IL-7 
signaling and indeed a small population of cells in cluster 3 expressed IL7R. 
Validation via flow cytometry suggested a proportion of CD63+ Ly6CLo MDMs 
express interleukin 7 receptor (IL7R) at protein level as well (Figure 4.12). The 
role for IL7R on monocytes and macrophages in the context of tissue repair is 
unexplored. IL7R+ monocytes have been identified as a pathogenic subset 
during autoinflammatory conditions such as rheumatoid arthritis (Chen et al., 
2013) . A recent study demonstrated that both LPS and TNF-a can induce 
IL7R expression on peripheral blood mononuclear cells (PBMCs) monocytes 
in vitro (Al-mossawi et al., 2018). These IL7R+ monocytes are sensitive to IL-
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7 and this stimulation activates multiple transcriptional pathways including anti-
apoptotic pathways (Al-mossawi et al., 2018). Using scRNA-seq the authors 
identified a distinct population of IL7R+ monocytes from synovial fluid from 
spondyloarthritis patients, however the functional role of this monocyte 
population remains unknown (Al-mossawi et al., 2018). I found that IL7R+ 
macrophages accumulate in areas of repair around the centrilobular veins at 
48hrs-post APAP (Figure 5.11), whether this macrophage subpopulation 
regulates elements of the liver repair process remains to be seen.  
 
Using scRNA-seq I was able to study monocyte and macrophage 
heterogeneity during liver homeostasis and post-AILI in a high throughput and 
unbiased manner. This identified heterogeneity within circulating and hepatic 
Ly6CHi monocytes and Ly6CLo MDMs and has opened up multiple avenues for 
the progression of this project.  
 
6.1 Future Work  
 
In order to validate APAP induced transcriptional switching of Ly6CHi 
monocytes to a granulocytic signature, marked by genes such as S100A8, 
S100A9, RETNLG, LCN2, VCAN, I propose to track these cells using a Cre-
lox genetically modified system. A S100A8-cre mouse was acquired during the 
last few months of my PhD, and we are in the process of crossing this mouse 
to a TdTomato fluorescent reporter mouse line, which will drive TdTomato 
expression in S100A8+ cells. Future studies using this system, in conjuction 
with additonal markers such as Ly6C ad Ly6G (neutrophil marker), will allow 
tracking of S100A8+ Ly6C+ cells, and enable their charactersation and 
isolation via flow cytometry and FACS, giving insights into their function during 
AILI.  
 
Hepatic Ly6CHi monocytes were delineated as CD62L+ and CD62L- Ly6CHi 
monocytes during AILI. Gene ontology enrichment suggests a role for CD62L+ 
Ly6CHi monocytes (cluster 7) in regulating neutrophil activity. In vitro 
experiments in which neutrophils are either cultured with CD62L+ or CD62L- 
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Ly6CHi monocytes from APAP livers and measuring neutrophil apoptosis or 
ROS production could inform their role in neutrophil regulation.  
 
The predominant subsets in the liver during peak hepatocyte regeneration 
were the CD63+ MHCII- and CD63- MHCII- Ly6CLo MDMs, suggesting they 
have a key role during the liver repair process. CD63+ MHCII- Ly6CLo MDMs 
were found to be phagocytic, however the overall functional relevance of 
CD63- MHCII- Ly6CLo MDMs in the context of AILI liver injury is yet to be 
investigated. There are several ways I can address this; isolating these 
subsets via FACS and performing conventional gene expression analysis can 
facilitate identification of pro-mitogenic genes and pathways that are 
upregulated. Co-culturing hepatocytes with either CD63+ MHCII- or CD63- 
MHCII- cells and using EdU incorporation as a readout, will assess whether 
these cells have the capacity to directly induce hepatocyte proliferation. In 
order to investigate the efferocytic role of CD63+ MHCII- macrophages, they 
could be cultured with necrotic hepatocytes and apoptotic neutrophils, 
Subsequent analysis of supernatants from these cells may inform us as to 
whether efferocytosis induces release of pro-mitogenic factors.  
 
One major drawback to in vitro experiments designed to further assess 
function of the macrophage subpopulations identified in my scRNA-Seq data 
is that these populations exhibit considerable plasticity when cultured ex-vivo. 
Nevertheless in vitro experiments are a useful starting point to interrogate 
function in the absence of precise transgenic in vivo tools. Importantly, to 
investigate the therapeutic potential of these newly identified subsets, in vivo 
experiments are necessary. One possible option is to use the CCR2 deficient 
mouse line. Following APAP-induced liver injury these mice show attenuated 
hepatic injury in the early phase (Mossanen et al., 2016), followed by impaired 
hepatocyte proliferation (Yang et al., 2019). Adoptively transferring specific 
subsets of monocytes and macrophages into CRR2-/- mice following APAP-
induced liver injury, followed by assessment of hepatocyte necrosis, serum 
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liver enzyme levels and hepatocyte proliferation should inform whether any of 
these subsets have the capacity to modulate the injury and/or repair response.  
 
Investigating the role of IL7R+ macrophages during liver injury and repair may 
be challenging, secondary to its expression on lymphocytes. For instance, a 
pan-blocking antibody against IL7R would also target T cells and B cells, and 
therefore any phenotype observed cannot be ascribed to IL7R function on 
monocytes and macrophages. An alternative to this would be to use RAG 
deficient mice, lacking T cell and B cells (Collins et al., 1996), and analyze the 
effects of IL7R inhibition during AILI, but again this has many drawbacks. A 
more accurate way to interrogate this would be to specifically delete IL7R on 
macrophages during AILI. This could be achievable using a macrophage Cre 
line crossed to IL7R flox mice (Shi et al., 2018).  
The ultimate goal of therapeutic target identification is application of this within 
the clinical setting. It is imperative to consider the similarities and differences 
between murine models of AILI and the human disease in order to develop 
potent regenerative therapies for ALF. The work conducted here and in other 
studies that uses murine models of liver regeneration focusses mainly on 
understanding how the normal liver regenerates and much less attention is 
given to modelling the human clinical syndrome in completeness (Forbes and 
Newsome, 2016). Early endpoints and/or reduction in the degree of liver injury 
that facilitates spontaneous survival in murine models does not reflect clinically 
important scenarios of severe hepatic injury, impaired regeneration and 
fulminant hepatic failure seen in humans (Mossanen and Tacke, 2015; Guillot 
and Tacke, 2019). Additionally, the temporal dynamics seen in age, sex and 
strain-matched mouse models is incomparable to human AILI. Underlying 
health conditions, differences in age, sex, genetic factors, APAP dose and time 
of hospital admission could all influence the severity of AILI and progression 
of ALF in humans and consequently have an impact on the effectiveness of 
therapeutic interventions (Yoon et al., 2016). That said, regenerative murine 
models do give us an insight into the cellular and molecular mechanisms 
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underpinning successful liver regeneration following AILI. In regard to 
monocytes/macrophages, despite the differences in their surface markers 
between mouse and human, many key aspects of macrophage activation, 
recruitment signals and functional activities following AILI appear to be 
conserved (Heymann and Tacke, 2016; Guillot and Tacke, 2019). Therefore, 
monocyte/macrophage-directed targets identified in this context have a 
tangible translational potential. Promising results from early phase clinical trials 
using macrophage-based therapies such as cenicriviroc; a CCR2/CCR5 
inhibitor (Friedman et al., 2018), and autologous macrophages (Moroni et al., 
2019) in patients with liver disease indicate that macrophage-targeted findings 
in murine models have the potential to be translated into the clinical setting 
(Ramachandran et al., 2012; Lefebvre et al., 2016).  
 
The relevance of the findings in my doctoral work to human ALF has not been 
elucidated as yet. Assessment of explant livers from ALF patients could 
identify analogous subsets of monocytes/macrophages to those I have 
described here in murine models. Combining conventional techniques such as 
flow cytometry with immunohistochemistry would facilitate phenotypic, 
morphological and topographical characterization of cells. Applying novel 
techniques like scRNA-seq in the setting of human ALF could be powerful. For 
example, scRNA-seq of circulating leucocytes from ALF patients and heathy 
donors could be an excellent way to investigate the systemic inflammatory 
response (SIRS). Identifying key characteristics of monocyte and neutrophil 
phenotype in ALF could help with patient prognostication, as well as facilitating 
the identification of therapeutic targets. ScRNA-seq of explant livers is also 
possible, however the low frequency of viable cells in AILI ALF explant livers 
represents a significant technical challenge.  
 
In summary, future studies in this area are likely to take a multimodal approach, 
combining conventional and cutting-edge techniques to enable in-depth study 
of monocyte and macrophage biology in the context of ALF, thereby 
accelerating the development of effective therapies.  
 211 









































Appendix 1 Comparison of histology stains to visualize liver architecture. 
Mouse liver sections post-6hrs APAP overdose were stained with different types 
of histology stains to visualize liver architecture and hepatocyte necrosis. The red 
dotted line represents necrosis, the stain which gave the biggest contrast 
between necrotic and non-necrotic area was chosen (Periodic acid-Schiff) for the 


































Appendix 2 Gating strategy for the identification of hepatic leucocytes 
following acute liver injury. Based on their expression of lineage specific, cell 
surface markers different types of hepatic leucocytes were isolated (black dotted 








Appendix 3 Gating strategy for the identification of systemic leucocytes 
following acute liver injury. Based on their expression of lineage specific, cell 
surface markers different types of systemic leucocytes were isolated (black 
dotted line, red font), using the gating strategy shown above. The “others” group 


























Appendix 4 Gene signature analysis. Lineage marker genes used for 
annotation of different clusters. 
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gene avg_logFC pct.1 pct.2 cluster 
Cd5l 2.45655475 1 0.271 0 
Clec4f 2.44001988 1 0.214 0 
Apoc1 2.35842084 0.998 0.384 0 
Vsig4 2.31330119 0.999 0.158 0 
Fcna 2.21426212 0.994 0.172 0 
Sdc3 2.17032632 0.997 0.553 0 
Slc40a1 2.1099609 0.998 0.309 0 
C1qa 1.98206211 1 0.466 0 
AW112010 1.88106832 0.995 0.588 0 
Folr2 1.87658307 0.971 0.211 0 
Ly6c2 1.49168613 0.963 0.468 1 
Plac8 1.28304401 0.998 0.935 1 
Ms4a4c 1.24404742 0.948 0.488 1 
Lyz2 1.20028056 1 1 1 
Hp 1.19192389 0.971 0.389 1 
Tmsb10 1.15431215 0.999 0.838 1 
Vim 1.11985885 0.988 0.734 1 
Emb 1.11950286 0.934 0.398 1 
Hbb-bs 1.07984256 0.673 0.15 1 
Mgst1 1.0780224 0.938 0.46 1 
Pglyrp1 2.06991488 0.9 0.263 2 
Ace 1.74616363 0.865 0.117 2 
Eno3 1.7126095 0.768 0.109 2 
Ear2 1.53588727 0.94 0.552 2 
Spn 1.46618967 0.767 0.141 2 
Hbb-bs 1.26948186 0.694 0.151 2 
Agpat4 1.24053454 0.715 0.243 2 
Cd9 1.22596158 0.729 0.317 2 
Pou2f2 1.21903661 0.925 0.587 2 
Ceacam1 1.19451535 0.716 0.207 2 
Spp1 2.60976962 0.874 0.197 3 
Fabp5 2.17162858 0.914 0.338 3 
Gpnmb 2.14200509 0.971 0.207 3 
Ccl7 1.83696357 0.815 0.178 3 
Cd63 1.81711603 0.935 0.201 3 
Ccl2 1.73188847 0.915 0.266 3 
Plin2 1.67909828 0.998 0.694 3 
Lgals1 1.6421731 1 0.659 3 
Lgals3 1.49834252 1 0.958 3 
Cdkn1a 1.35544856 0.901 0.319 3 
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Ccr2 0.91454342 0.96 0.499 4 
Tpt1 0.55080549 1 0.999 4 
Rps16 0.47452663 1 0.998 4 
Rpl7 0.46100621 0.999 0.99 4 
Rps15a 0.45029681 1 0.994 4 
Eef1a1 0.44024885 1 1 4 
Rpl23 0.42287958 1 0.999 4 
Rpl26 0.40738651 1 0.997 4 
Rps23 0.37408262 1 0.999 4 
Rpl36 -0.64181209 0.99 0.993 4 
Pf4 1.47919441 0.893 0.341 5 
Trem2 1.00115622 0.979 0.47 5 
Cd93 0.98308861 0.944 0.297 5 
Lgals1 0.95588087 0.998 0.664 5 
Stab1 0.65364869 0.807 0.281 5 
Rps2 0.65103902 1 0.987 5 
Rnase4 0.61091007 0.678 0.195 5 
Gpnmb 0.56700306 0.789 0.23 5 
Rps29 -0.86794746 1 1 5 
Gpx1 -0.76444994 0.999 0.998 5 
S100a8 2.15535183 0.996 0.65 6 
Chil3 2.10426684 0.994 0.545 6 
Lcn2 1.95927349 0.892 0.132 6 
Fn1 1.72190821 0.988 0.343 6 
Hp 1.70686082 0.996 0.425 6 
Ly6c2 1.65590409 0.995 0.498 6 
Tmsb10 1.58047511 1 0.848 6 
Slpi 1.5130568 0.957 0.321 6 
Wfdc21 1.51044666 0.638 0.101 6 
Mgst1 1.42689164 0.99 0.487 6 
Cxcl2 1.65467849 0.751 0.142 7 
Ccl2 1.2736 0.867 0.282 7 
Slpi 1.14862695 0.912 0.326 7 
Clec4e 1.09903957 0.865 0.188 7 
Ccl3 1.00313324 0.874 0.306 7 
Fos 0.95871314 0.986 0.791 7 
Atf3 0.87302482 0.933 0.379 7 
Ptafr 0.8571625 0.844 0.283 7 
Clec4d 0.84175274 0.9 0.252 7 
F10 0.80243655 0.854 0.29 7 
Marco 1.60388433 0.926 0.297 8 
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Ccdc148 0.46357102 0.488 0.069 8 
Fabp7 1.12335081 0.971 0.411 8 
Vcam1 0.92494878 0.885 0.289 8 
Clec1b 0.80773018 0.952 0.332 8 
Tk1 0.65210537 0.485 0.096 8 
Lyz2 -1.56445465 1 0.999 8 
Epb41l3 0.48407053 0.609 0.139 8 
Hbegf 0.46248235 0.419 0.072 8 
Ccl24 0.99126903 0.875 0.337 8 
Cd24a 1.56578493 0.905 0.181 9 
Xcr1 1.19222166 0.59 0.012 9 
Tnni2 1.10868585 0.811 0.142 9 
Sept_6 0.99576958 0.872 0.126 9 
H2-Oa 0.94541111 0.703 0.04 9 
Amica1 0.8578624 0.74 0.085 9 
Flt3 0.85357772 0.746 0.039 9 
Gpr171 0.85116606 0.581 0.03 9 
H2-DMb2 0.7961426 0.672 0.089 9 
Olfm1 0.74129343 0.688 0.099 9 
Cd74 1.95243731 1 0.893 10 
H2-Aa 1.9845549 0.99 0.72 10 
H2-Eb1 2.1508667 0.99 0.631 10 
H2-Ab1 1.98153361 0.998 0.762 10 
H2-DMb1 1.14454725 0.959 0.567 10 
Ciita 0.36698387 0.35 0.053 10 
Mgl2 0.40404887 0.144 0.01 10 
Ccnd2 0.653666 0.559 0.171 10 
Tmem176a 0.96520949 0.755 0.325 10 
H2-DMa 0.89037145 0.952 0.709 10 
2810417H13Rik 1.82086736 0.982 0.064 11 
Stmn1 1.78679578 1 0.18 11 
Birc5 1.30693407 0.885 0.059 11 
Top2a 1.21478972 0.845 0.064 11 
Mki67 1.21327674 0.903 0.067 11 
Cks1b 1.13976866 0.989 0.182 11 
Smc2 1.12866165 0.968 0.142 11 
Cdca3 1.05068616 0.835 0.043 11 
Ube2c 0.98119494 0.683 0.051 11 
Cdca8 0.79116517 0.813 0.051 11 
Malat1 -2.30405907 0.869 1 12 
Folr2 1.44452758 0.973 0.422 12 
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Vsig4 1.36021675 0.986 0.391 12 
C1qb 1.34067447 1 0.67 12 
C1qa 1.36483044 1 0.614 12 
AW112010 1.40751751 0.991 0.701 12 
C1qc 1.22409951 1 0.639 12 
Cd5l 1.28871347 0.995 0.473 12 
Clec4f 1.27367078 0.991 0.432 12 











Appendix 5 Top 10 differentially expressed genes identified for MP clusters 
0-12. (genes) name of the gene identified. (avg_log_FC) Fold-change of the 
average expression between the two groups, positive values indicate a gene is 
highly expressed in the first group. (pct.1) The percentage of cells where the gene 
is detected in the first group. (pct.2) The percentage of cells where the gene is 
detected in the second group. (cluster) MP cluster which the gene corresponds 










Appendix 6 t-SNE visualization of top markers genes identified for Kupffer 
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